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chapter 1 chapter 
General introduction 

1. Genera! introduction 
1.1 Asthma and childhood 
At present, astluna is regarded as a chronic inflammatory disorder of the airways, In susceptible 
individuals, asthma causes symptoms, that are usually associated with variable, but often 
reversible airflow obstmction I, Astlulla is the most conunon lung disease in childhood, with a 
symptom-based asthma prevalence of approximately 11% in The Netherlands2• \Vorldwide, 
asthma prevalence appears to be on the increase3• Although 1ll0liaiity rates are low, asthma 
causes significant morbidity and school absenteism in children4• 
The clinical expression of asthma varies from patient to patient and from time to time within 
each patient. Anamnestic features suggestive of a diagnosis of asthma are intermittent episodes 
of wheezing, chest tightness and shortness of breath, as well as recurrent or persistent cough. 
Symptoms may worsen at night or in the early morning, and are precipitated by viral infections, 
allergen exposure, exercise, chemical irritants, tobacco smoke and strong emotional expressi-
onsS•7. 
Diagnosis may be especially difficult in infancy. \Vheezing in infancy as a reflection of 
early-onset asthma appears to be associated with increased sensitization to allergens and a 
deterioration of lung function in the first 6 years of lifes. Risk factors for development of 
asthma in older children and adolescents also include atopic sensitization as well as the occu-
rence of bronchial hyperresponsiveness (BHR)9,IO, The BHR in children decreases with age, 
but the tendency to retain BHR is closely related to markers of atopy, such as selUl11 IgE levels 
and positive skin prick tests II. These epidemiological data underline the close association 
between atopy, BHR and asthma. Supportive evidence for a genetic basis of this association 
has now been provided by the identification of a gene cluster on chromosome 5, linked to both 
elevated IgE levels and BHR". 
1.2 Pathophysiology of asthma 
Prominent infiltration of the airway wall with inflanunatory cells, such as mast cells, eosinop-
hils and lymphocytes, together with hyperplasia and hypertrophy of the muscular layer and 
extensive damage to the epithelium was identified in lung tissue of patients who had died from 
stahls asthmaticus13, In vivo ftberoptic bronchoscopy studies in adults asthmatics have subse-
quently shown that these inflammatory changes in the airways are also present in mild, stable 
asthm.atics I4 .16. The chronicity of the inflammatory responses is reflected by the thickening of 
the lamina reticularis beneath the basement membrane l4 . Consequently, the consensus has 
emerged that airway inflammation is a consistent feature of astlm131 • 
Mast cells are recognized as key cells of type I hypersensitivity reactions 17. Experimental 
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allergen challenge leads to the production and release of mast cell derived mediators such as 
histamine, tryptase, prostanoids and leukotrienes, which are involved in the cady asthmatic 
reaction's, In addition, mast cells are capable of generating an array ofcytokines, among which 
ILM4 and ILM13, involved in switching the B·lymphocyte to IgE production, as well as ILM5, and 
granuiocyteMlllacrophage colony stimulating factor (GMMCSF), known to promote eosinophil 
priming and activation 17, Thus, mast cells may be important for initiating allergenMinduced 
airway inflammation'9, 
Activated T Mlymphocytes seem to regulate the chronic inilammatOlY response in atopic 
asthma through the production of cytokines pertinent to allergy20, The TMhelper cell population 
can be divided into two subsets: the Thl cells, that predominantly produce ILM2 and interferonM 
gamma, and are associated with delayed hypersensitivity reactions, The second subset consists 
of the Th2 cells, and is predominant in allergic asthma21 ,22, Th2 cells synthesize various 
cytokines, including 11-3, IL-4, IL-5, and IL-IO, and GMCSI', These cytokines enhance allergic 
responses by activating mast cells and eosinophils, as well as prolonging the sun'ivai of the 
latter granuloc)1e23, 
The eosinophil leucocyte appears to be the predominant effector cell in asthma, and is seen 
to infiltrate the full thickness of the airway wa1l24,25, Eosinophils are capable of producing a 
wide range of vasoM and bronchoactive mediators, including cysteinylMleukotrienes, PAF, 
prostanoids and neuropeptides, as well as cytotoxic proteins, such as eosinophil cationic 
protein, eosinophil-protein X and eosinophil peroxidase26, These latter products may cause 
epithelial injury and denudation resulting in an increased permeability to irritant stimuli for 
sensory nerves, while repeated denudation~restitution processes may lead to thickening of the 
reticular basement membrane27, In asthmatic adults, an association between the inflammatory 
cellular infiltrate, especially cosinophils, and the degree of bronchial hyperresponsiveness has 
been observed28,29, Likewise, a correlation between airway responsiveness and cellular activa-
tion was documented in children with asthma3o, 
1.3 Bronchial hyperresponsivcIlcSS 
Bronchial hyperresponsiveness (BHR) refers to the exaggerated response to bronchoconstrictor 
stimuli of physical, chemical or pharmacological origin3', Bronchial responsiveness is expresM 
sed as the provocative dose or concentration of an agent which induces a predefined fall in air 
flow, commonly a 20% decrease in forced expiratory volume in 1 second (FEV ,)32, In a 
random popUlation sample of children, bronchial responsiveness to histamine was shown to 
16 
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have a conlllluous, unimodal, log~normal distribution, with astlunatic subjects at the more 
responsive end of the distribution33. The degree of BHR correlates with respiratory symptoms. 
However, there is a wide overlap between symptomatic and asymptomatic individuals, redu-
cing the predictive value of a positive test for the presence of asthma in the general 
population34,35. 
The various bronchoconstrictor stimuli used to assess the degree of BHR act either directly 
through stimulations of the bronchial smooth muscle in the airway wall, or indirectly through 
infiltrative or resident pulmonary cells or neural pathways36. For example, methacholine has a 
direct bronchoconstricting effect on the ainvay smooth muscle32, while cysteinyl-Ieukotricncs 
mediate their bronchoconstrictor effects via stimulation of various cell types, and possibly 
through the secondary release of neuropeptides37. Therefore, it can be postulated that difteren-
ces in responsiveness to directly and indirectly acting bronchoconstricor stimuli may reflcct 
differences in the underlying pathophysiology of asthma29,38 and may be hclpful in the evalua-
tion of dmg treatment for asthma. 
Exercise, especially in childhood, is a COllllllon trigger of acute, usually short~lived asthma 
attacks, referred to as exercise-induced bronchocollstriction (EIB)39. The current knowledge on 
its mechanism suggests that inflalllmatory mediators arc released in response to airway cooling 
and/or drying due to the hyperventilation of exercise40. The main goal of this thesis is to 
broaden our understanding of the pathophysiologic mechanisms underlying the manifestations 
of EIB and its significance as an expression of BHR. In addition, treatment strategies for the 
prevention of EIB in childhood asthma are evaluated. 
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2. Exercise-induced bronclioconstriclion and childhood asthma 
2.1 Introduction 
Currently, asthma is viewed as a chronic inflammatory disease of the airways, characterized by 
variable airways obstruction over time l . Fluctuations in airway patency can occur either 
spontaneously or in response to bronchoconstrictor stimuli2• The degree of response to such 
stimuli is a measure for the severity of the underlying bronchial hyperresponsiveness, currently 
thought to be a hallmark of asthma3. Exercise is a very common, physiologic trigger of acute, 
usually short-lived asthma attacks in daily life. And although three hundcrd years have passsed 
since Sir Floyer in 1698, observed that HAll violent exercise makes the asthmatic to breathe 
short,,4, it has only been for the past thirty years that substantial progress has been made 
regarding the understanding of asthma and its relationship with exercise5. 
In this chapter, the current knowledge on EIB with respect to clinical characteristics in 
asthma, bronchial hyperresponsiveness, pathophysiologic mechanisms, diagnosis and dmg 
trcatment will be reviewed, with special emphasis on its occurence in childhood. 
2.2 Clinical characteristics 
2.2.1 Symptomatology 
In the daily life of many astlunatic children, exercise is a common cause of short-lasting 
astluna-attacks, usually referred to as "exercise-induced asthma" (EIA) or Hexercise-induced 
bronchoconstriction" (EIB)5,6. It refers to the airway narrowing that occurs minutes after the 
onset of vigorous exercise. A history of cough, wheezing, or shortness of breath during or after 
moderately severe exercise, is suggestive of EIB. In addition, chest pain in otherwise healthy 
children is often overlooked as its symptom 7. Likewise, endurance problems with exercise are 
more readily but wrongly associated with poor physical fitness than with EIB8. Finally, it is not 
unusual that EIB goes unnoticed by the patient itself 9 
In the typical response, the bronchoconstrictioll after exercise reaches its maximum within 
the first 10 minutes after exercise, and is most marked at 5 minutes post-exercisc6,JO,II. Gene-
rally, the recovery of EIB occurs spontaneously within 30 minutes, but may occasionally last 
more than 60 minutes in individual astlunatic childrcn lO,l2. It has been suggested in the earlier 
studies on EIB that children reach their maximum level of airway obstruction sooner, and 
subsequently recover more quickly to baseline levels than adults6. 
2.2.2 Exercise refractoriness 
\Vhen exercise is repeated at intervals of two hours or less, there is a diminishing broncho-
constrictor response to successive exercise, known as refractoriness 13 • The time period during 
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which this is present, is called the refractory period. Allthough the refractory period can extend 
up to 4 hours after exercise, it is strongest during the first hour postMexercise13 ,14,15. Refractori-
ness to subsequent exercise can be induced in many asthmatic children suffering from RIB, 
allthough in some it will not occur I5,16. The extent of refractoriness is variable, and not depenM 
dent on the degree of bronchoconstriction in the first exercise17. In fact, refractoriness to 
repeated exercise can occur without prior bronchoconstriction in the initial exerciseI6,18, 
suggesting that exercise itself is an important factor for its occurence. 
2.2.3 Late asthmatic response 
The potential development of a late asthmatic response (LAR) to exercise in asthmatic 
children and adults is a subject of considcrable controversy. Several studies have bcen publis-
hed describing the occurence ofa LAR three or four, or up to ten hours after exercise lO,19-23. In 
these studies, a late astlm13tic response was prevalent in 10% to 89% of the population 
studied lO,19-23. However, other investigators have not succeeded in documenting such a late 
response post-exercise24-27 . \Vhen evaluating the results of these studies, the design of many 
can be critisized for absence of appropriate control days28, on which to shIdy the normal 
variation in lung function. Contributing to the confusion concerning the existence of a LAR, is 
the lack of agreement on its definition I9.27. Thus far, the controversy around the LAR has not 
been solved29. 
2.3 Exercise-induced bronchoconstriction and bronchial hYPCl"rcSPOIlSiYCIlCSS 
2.3.1 Definition and epidemiology 
The bronchial response to exercise in the general population is represented by a unimodal 
normal distribution, with the asthmatic subjects at the more responsive end of the 
distribution30-33. By definition, the response to exercise testing is considered abnormal, when 
the decline in lung function from the pre-exercise value, expressed as the percentage fall in 
forced expiratory volume in I second (FEY,) or peak expiratory flow rate (PEFR) (%fall), 
exceeds twice the standard deviation of the mean %fall obtained in normal childrcn6, I 1,34. 
Applying this definiton, a %fall in FEY, of 10% or more is indicative ofEIB (figure I). The 
response to PEFR is more variable, the upper limit ofllormal varying from 10%6 to l2.5% 35 to 
17.5% 11 fall. Hence, in epidemiological studies, a fall in PEFR exceeding 15% is considered to 
be abnormal36. 
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Figure I: example of the bronchoconstrictor response after exercise (pre = baseline pre·exercise) 
The prevalence of EIB in a random sample of children and adults has been reported to vary 
between 4% to 16%31,32,35,370 39, with the prevalence of EIB in the general population being 
lowest in Africa35,37. As was previously observed for BHR to pharmacological stimuli30,40 , an 
age-dependent decrease in BHR to exercise has been described in non-asthmatic subjects30,31. 
A positive response to exercise testing is significantly associated with history of respiratory 
symptoms41 , the frequency of wheeze attacks 32, atopy 42, as well as to symptomatic asthma 43. 
However, EIB is not limited to children diagnosed with asthma, an abnormal response also 
occurring more frequently in atopic non-astluuatics (approximately 14%44 to 23%42), as well as 
in nOll-asthmatic relatives of asthmatic children45, In addition, an increased occurence of an 
excessive bronchoconstrictor response to exercise can be observed competitive ice rink 
skaters46, possibly as a consequence of performing exercise in extreme conditions of tempera-
ture and humidity47. 
Allthough in one study the occurence of EIB in asymptomatic children and adolescents was 
shown to be a risk fhctor for the subsequent development of asthma33, this could not be confir-
med in another study43. Hence, despite the strong association between EIB, atopy and asthma, 
EIB is not equivalent with asthma. Therefore, exercise-induced bronchoconstriction is a more 
appropriate term in describing the phenomenon than the often used term exercise-induced 
asthma. 
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2.3.2 Relationship of EIB with bronchial hyperrespoJ1siveness in clinical asthma 
Several studies have looked at the prevalence of EIB in children diagnosed with asthma. 
When defining EIB as at least 10% fall in FEY I after a standardized exercise test, the prevalen-
ce of documented EIB averages around 74%34,48,49 to nearly 90% II in untreated asthmatic 
children. The severity ofEIB is generally related to the severity of clinical asthma50. Conside-
rable overlap has been shown to exist between the response to exercise and other non-specific 
bronchoconstrictor stimuli, such as histamine32,48,51,52 and methacholind3,54 . The relationship 
between the response to exercise challenge and the response to histamine challenge is generally 
good, with a correlation coefficient of approx. 0.78 in the asthmatic population52 . The relati-
onship with methacholine challenge seems to be less strong53,54. This implicates that some 
ehildren are more responsive to histamine than to exercise52, or vice versa32. In addition, it was 
shown that exercise is better than methacholine in discriminating asthma from chronic lung 
diseases in children·19. These data support the view that although exercise (a physiologic 
stimulus), and histamine or methacholine (a pharmacological stimulus), both reflect the severi-
ty of the underlying bronchial hyperresponsiveness in asthma, they measure different compo-
nents of the ainvays dysfunetion55. 
The precise mechanism by which airway inflammation results in bronchial hypelTesponsive-
ness is not known, yet the two are closely related l ,56. Therefore, factors inducing (transient) 
changes in airway inflammation most likely will influence the degree of EIB. h has been 
shown that allergen exposure aggrevates the severity of EIB, in laboratory challenges57,58 as 
well as in natural cireumstances59, while allergen avoidance leads to a decrease in the degree of 
EIB in asthmatic children6o. Viral infections me known to exacerbate asthma in children 61 , 
suggesting a worsening of EIB during an upper respiratory tract infection. Thus far, studies 
investigating the effect of experimentally administered viral infections on EIB in asthmatic 
adults, have been unable to confirm this62 . Lastly, regular treatment with inhaled steroids, 
drugs that exert their inhibiting effects on many aspects of airway inflammation63 , attenuate the 
bronchoconstrictor response in asthmatic ehildren64 and adults65 . 
2.4 Pathophysiology of Em 
2.4.1 The initiating stimulus 
One of the earliest observations on the pathophysiology of EIB was made when it was shown 
that the bronchoconstriction post-exercise was dependent upon the type of exercise66, its 
intensity and durationl4. As it is known that one of the physiological effects of exercise is, to 
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increase the minute ventilation67, it was poshtiated and subsequently shown that the severity of 
EIB was related to the level of ventilation reached during exercise68,69. In addition, it was 
observed that the bronchoconstrictor response to exercise could be modified by varying the 
temperahlre and the humidity of the inspired air7o, the largest bronchoconstrictor response 
induced while breathing dry air during exercise, whereas warm, fully saturated air completely 
inhibited EIB 71. 
During normal breathing, heat and water are transferred from the mucosa of the upper 
airways, including the nose, to the incoming air to warm and humidify inspired air to alveolar 
conditions72. During the high ventilatory drive of exercise, this mechanism is not sufticient, 
and consequently, the lower respiratory mucosa compensates to complete the conditioning 
process. Tllis results in both evaporative and conductive cooling of the airways. Based on 
measurements of ventilation, temperature, and humidity of the inspired air, the total heat flux 
from the airways could be quantified during an exercise task7o, the ensuing bronchocollstrictioll 
proportional to the respiratory heat exchanged. Similar observations were made with 
hyperventilation-induced bronchoconstriction73 , leading to the conclusion that the severity of 
EIB was determined by the hyperpnoea of exercise, as well as the temperahlre and the humidity 
of the inspired air during exercise73. Thus it was proposed that the prime stimulus for EIB was 
airway cooling secondary to respiratory heat loss during hyperpnoea of exercise, and not 
exercise itself74. Ainvay cooling was later confirmed by direct temperature recordings from the 
pharynx up to the subsegmental bronchi75. 
The total heat loss during exercise however, is caused by a combination of heat loss due to 
differences in the in- and expiratory air temperature as well as heat loss due to the evaporation 
of water. And since some of the observations on EIB were difficult to explain by heat loss 
alone, for example the breathing of hot dry air also inducing bronchoconstriction71 , it was 
postulated that respiratory water loss during hyperpnoea of exercise was more important than 
heat loss in EIB. This was sUPP0l1ed by studies showing that the severity of EIB was not 
altered with increasing temperature when the water content was kept constant 76. Further 
evidence was put forward when experiments, using gasses with similar water contents but 
different volume heat capacities, showed that the bronchoconstriction post~exercise correlated 
closely with evaporative water loss, but poorly with the temperature gradient77 . Lastly, signifi-
cant EIB was found to be provoked, without significant heat loss or airway cooling, but mainly 
determined by amount of water loss78. The mechanisms by which water loss from the bronchial 
mucosa induces bronchoconstriction was not known, but increasing evidence suggested that it 
might be due to hypertonicity of the airway lining fluid79. 
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The debate on the initiating stimulus remained inconclusive, and yet an alternative hypothe-
sis on the reaction sequence was forwarded. Since airway cooling occurred both in normal and 
asthmatic subjects, the effects of breathing air at different temperatures immediately after 
exercise were studied, to investigate whether post-exertional thermal events might explain the 
difference in response between asthmatics and normais80. Immediately post-exercise, the 
airways of asthmatic adults rewarm twice as rapidly as those ofnonnal sUbjects81 . Attenuation 
of the bronchoconstrictor response occured when rewarming was slowed down by breathing 
cold air8o. It was then postulated that the thermal gradient during and after exercise and the rate 
of airway rewarming provided the initiating stimulus for EIB82 , 
To date, it is agreed upon that the ainvay microvasulature has the potential for contributing 
to the pathophysiology of EIB. However, discussion remains to whether the increased blood 
flow during airway rewarming may be the consequence of mediator release in response to 
osmolarity changes rather than the initiating stimulus itselfD , Evidence in favor of this view 
comes from studies showing that EIB can occur in the absence of a thermal gradieneo. ErB 
can already occur during exercise, that is before rewarming occurs84 , Lastly, breathing of dry 
air increases ainvay blood flow in animals85 , Although one should be cautious when extrapola-
ting data from animal studies to man, if asthmatic subjects would respond to breathing of dry 
air in similar fashion as other mammals, reactive hyperaemia is unlikely to occur after 
exercise85 , In contrast, an increased blood flow following exercise in asthmatics could well be 
explained as a consequence of mediator release due to changes in osmolarity induced by the 
hyperpnoea of exercise, with mediators either directly relaxing precapillary sphincters of blood 
vessels, or indirectly causing leakage of the microvasculature through one or more of the 
sensory neuropeptides83. Consistent with the hypertonicity-mediator-release-hypothesis is that 
hyperosmolar stimuli induce pulmonary mast cell degranulation in vilr086, and that hypertonic 
solutions induce bronchoconstriction in asthmatic subjects87,88. However, conclusive evidence 
of the hypertonicity theory based on direct measurement of osmolarity during hyperpnoea of 
exercise is still lacking. 
2.4.2 Mediator release ill EIB 
Many investigators have tried to elucidate the relative contribution of different mediators to the 
severity of EIB, either by direct measurements of their concentrations in biological fluids, or 
indirectly by determining the effect of specific mediator antagonists or synthesis inhibitors. 
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Histamine. Most histamine is stored preformed in c)1oplasmic granules of mast cells and 
basophils89, Its bronchoconstrictor effect is mediated through HI-receptors 90, Exercise-induced 
release of histamine has been observed in asthmatic children91 , however, measurements were 
not compared to a control group of normal children. In adults, histamine in serum post-exercise 
was increased for both normal and astlmlatic subjects, with the difference between groups not 
significant92, Direct measurements of the level of histamine pre- and post exercise in broncho-
alveolar lavage fluid did not succeed in implicating histamine in the reaction sequence93,94. In 
contrast, pretreatment with the highly potent and selective HI-receptor antagonist, terfenadine, 
almost completely blocked the response to exercise in asthmatic children95 , while in asthmatic 
adults96,97 the largest inhibition occurred during the first 5 minutes of the bronchoconstrictor 
response. 
Cysteillyiieukoh"ielles (LTC" LTD" alld LTE,). Cysteillylleukotrielles (Cys-LT) are metaboli-
tes of arachidonic acid, and represent a heterogeneous group of biologically active mediators9S• 
They are preferentially generated by mast celis, eosinophils and basophils89. In addition to 
being potent spasmogens of airway smooth muscle, they also induce increased micro vascular 
permeability and mucus hypersecretion99 , In asthmatic children, but not adultdoo, a significant 
rise in urinary excretion of Cys-LT after exercise was found compared to normal children 101, it 
being most evident in those children with the most severe EIB 102. In adults, direct measure-
ments of increased levels of Cys-LT in BALfluid post-exercise could not be observed93 . Yet, 
following pre-treatment with potent leukotriene receptor antagonists lO3- 106 and synthesis 
inhibitors 107. involvement of Cys-LT in the reaction sequence was demonstrated. Studies 
investigating the involvement ofCys~LT in EIB in pediatric asthma are cUlTentiy under way, 
with preliminary reports confirming their role in EIB in childhood asthma 108,109. 
Prostaglandins. Prostaglandins are metabolites of arachidonic acid via the cyclo-oxygenase 
pathway I 10. Prostaglandin D2, its principal metabolite POF 2 ct, and thromboxane (TX) A 2 are 
potent bronchoconstrictors, while PGE2 is a major bronchodilator prostanoid, able to antagoni-
ze PGF2ct-induced bronchoconstriction. Again, direct measurements of prostaglandins before 
and after exercise did not show differences in the level of prostanoids in BALfluid in adult 
asthmatics93 , Neither did pretreatment with a potent thromboxane receptor antagonist attenuate 
EIB III, Evidence for involvement of prostanoids comes from studies showing inhibition of 
EIB following pretreatment "with the cyclo~oxygenase inhibitor fiurbiprofen97 . Indomethacin, 
another less potent eyclo-oxygenase inhibitor, did not inhibit EIB in asthmatic adults 112 and 
adolescents'8 when given orally. However, pre-treatment with inhaled indomethacin did show 
attenuation of the bronchoconstrictor response in asthmatic children 113. Since exercise refracto~ 
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riness was significantly reduced after treatment with indomethacin, inhibitory or bronchodila~ 
ting prostaglandins, such as PGE2, and PGI1 , are currently thought to be involved in its 
mechanism 18, 114. 
2.4.3 Neural mechanisms ill EIB 
The role of an increase in vagal discharge has been investigated by determining the effect of 
anticholinergic drugs such as atropine or ipratropiumbromide in protecting against EIB. 
Ipratropiumbromide attenuates the bronchoconstrictor response to exercise in asthmatic chil-
dren, however, its protective effect is weak and illconsistentIl5,116. This suggests that the 
importance of the vagal reflex in EIB may vary in different patients, and also in time. 
Recently, it has been suggested from studies using animals models ofEIB85 , that neurogenic 
mechanisms are involved in its mechanism, These neural mechanisms paliicularly refer to 
nonadrenerge, noncholinerge pathways, which can either be excitatory, or inhibitory II?, There 
is growing evidence that after hyperventilation with dry air, the release of tachykinins may 
contribute to the subsequent airway obstmction in guinea pigs Il8,II9, possibly through the 
release of cysteinylleukotrienes I2O, However, it has been suggested that in humans, neuropep-
tides are released secondary to leukotrienes l21 . Thus far, in mild to moderate astlunatic adults, 
pre~treatment with thiorphan, an inhibitor of the neuropeptide degrading enzym neutral endo~ 
peptidase (NEP), significantly attenuated the bronchoconstrictor response to exercise, specifi-
cally during the recovery periodl22 . However, NEP~inhibition with thiorphan could equally 
well have resulted in a prolonged action of the bronchorelaxing peptide atrial natriuretic 
peptide (ANP), known to protect against histamine-induced bronchoconstriction l23 . Fm1her 
studies are needed to elucidate the role of neuropcptide release in asthma and EIB. 
2.4.4 Cellular involvement 
The mast cell has always been regarded as an important effector cell for EIB 124. Because a 
difference in mast cell mediators post~exercise as compared to pre~exercise values could not be 
measured in brollchoalveolar lavage fluid, it was thought that EIB was not associated with mast 
cell activation93,94. However, after using mediator antagonists or synthesis inhibitor to unequi-
vocally implicate histamine95-97 , cysteinyl leukotrienes lO3-109 and prostaglandinsI8,97,113 in 
ErB, the mast cell, being an important source for these mediators 110, is currently thought to be 
an important effector cell3. Fm1her supportive evidence for its role in EIB is forwarded by the 
inhibitory effect of heparin on EIB I25,126 most likely through an inhibitory modulation of mast 
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cell activation l27 . Secondly, a greater percentage of degranulated mast ceIJs in bronchial 
biopsies is observed after exercise- as compared to methacholine-induced bronchocon-
striction 128. 
On the other hand, eosinophils are nowadays put at the forefront of the effector leucocytes in 
chronic asthma I29,130, Numerous studies have shown a relationship between bronchial eosinop-
hil activation, airway inflammation and bronchial hypcrresponsiveness in adult 131 ,132 and 
pediatric asthma I33,134, Indeed, eosinophils are potent generators of leukotrienes98 . In adults 
asthmatics, a good relationship was found between the level of senUl1 eosinophil cationic 
protein (sECP) and the severity ofEIB 135, However, to date, no studies adressing the relations-
hip between sECP and EIB have been adressed in childhood asthma. 
Other pulmonwJI cells. It is known that the number of basophils increases after exercise, and 
thereby may account for some of the histamine released post-exercise92.136. In addition, bron-
chial epithelial cells may play an important role in asthma, not only tluough their role of ainvay 
protectors against noxious agents, but also as cells that can synthesize and release a wide array 
of mediators, including prostanoids and leukotrienes, either spontaneously or after stimu-
lation 137, Given their close contact with the airway microvasculature, they may potentially be 
influential in EIB 138. 
Conclusion, Studies aimed at directly measuring mediators in biological fluids, have not 
unequivocally implicated their release in EIB. This might be relatcd to methodological issues, 
such as the timing of measurements after challenge93,94, (in)sensitivity of assay techniqud 36 , 
or the relatively small contribution of locally released mediators to the total body content 100. 
Notwithstanding, the available evidence provided from studies using mediator antagonists, 
sUPPol1s a strong case for mediator release as the mechanism ofEIB 139, 
2.5 Diagnosis of EIB 
EIB should be suspected in any child who presents with wheezing, cough, chest tightness or 
dyspnoea during or shortly after exercise6. Epidemiological studies have shown that these 
symptoms, as well as sleep disturbance due to wheeze, are risk factors for the prevalence of 
bronchial responsiveness to exereise39,41. In addition, chest pain 7 or exercise intolerance8 in 
otherwise healthy children or adolescents can be symptoms of EIB. Due to the inherent variabi-
lity of asthma with intermittent exacerbations and remissions, the percentage of patients 
reporting exercise-induced symptoms is expected to be higher than the percentage of patients in 
1· 1 EIB b d d 'fi' " , ,3941 '4014' W llC 1 can e ocumente at a speCI IC tune pomt uSing exerCIse tcstlllg , , , . 
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\Vhen evaluating EIB, changes in spirometry after exercise are used to assess the degree of 
bronchusobstructionI4,36. As mentioned previously, various factors, such as humidity and 
temperature of the air inspired during exercising l42, exercise intensity, duration of the test, and 
time since last exercise period will influence the bronchoconstrictor response to exerci~eI4. 
Therefore, it is a prerequisite that the method of exercise testing is standardized, leading to 
adequately reproducible results36. A duration of the test of6 to 8 minutes at a workload at 60% 
to 85% of the predicted maximum oxygen consumption l4 or at 90% of predicted maximum 
heart rate l43 has been recommended earlier. As the level of hyperventilation reached during 
exercise is an important determinant of the bronchoconstrictor response, it is nowadays recolll-
mended to measure ventilation, and to select a subject's workload between 40% to 60% of the 
predicted maximum voluntary ventilation during the last 4 minutes of the test36. In addition, it 
is strongly recommended that air inspired during exercise has a water content less than 10 mg 
per litre (equivalent to relative humidity less than 50% between 20-25°C). The nose must be 
clipped during running to ensure mouth breathing. Repeated exercise tests should be separated 
by at least 2, but preferably 4 hours to avoid influence of the refractory period13. 
Lung fUllction measurements (FEV I , PEFR) are performed before exercise, and should be 
at least within 80% of the subjects' usual value, and preferably better than 75% of their predic-
ted value. Post-exercise, measurements of lung function are repeated at regular intervals up to 
30 minutes after exercise, or until lung function has recovered to within 10% of pre~exercise 
value. The severity ofEIB is usually reflected in the %fall index (%[all), which is calculated by 
subtracting the lowest value of FEV I or PEFR recorded after exercise and expressing it as a 
percentage of the value recorded immediately before exercise. In formula: 
%fall ~ [(FEV I pre-exercise - lowest FEV I post-exercise) I FEV I pre-exercise] * 100%. 
In addition, calculating the area under the time-response cUn'c post-exercise may provide 
valuable information on the recovery phase ofEIB97,103,122. 
Reproducibility of the response to exercise testing has been shown to vary with the time 
interval between tests, the coefficient of variation (CV = [standard deviation/mean] * 100%) 
varying from 12 to 35% with repeated challengcs at different time intervals I4,143,144. However, 
the CV will vary with the mean value of EIB in a study group, making comparisons between 
studies difficult to interpret 143. Nowadays, it is recommended to use the intra-class correlation 
coefficient as an indcx of repeatability l45. Despite the inherent variability in EIBI46 ,exercise 
testing has proven very useful for evaluating drug treatment in asthma. 
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2.6 Tl'eatment of EIB 
One of the aims of asthma treatment, as summarized in the latest guidelines, is the participation 
of children in play and sports without Iimitations I47,148. This can be achieved through nOI1-
phannacological interventions, as well as the prescibing of dmg therapy shown to provide 
adequate protection against EIB 149. 
2. 6.1 NOI1-phw·macological illterventiOJl 
Since wann, humified air blocks EIB, exercising in a warm, humidified environment might be 
beneficial in inhibiting its occurence l7. Local hyperthermia by breating hot and fully humidi-
fied air 30 minutes prior to exercise has been shown to attenuate EIBI50. Breathing through the 
nose, or wearing a scarf over the nose and mouth in cold weather are effective ways of increa-
sing the temperature and humidity of the inspired air. 
Effectively treating nasal blockage is capable of attenuating EIB 151. This is in accordance 
with earlier observations on the beneficial effect of nose breathing as compared to oral breating 
in reducing EIBI52. However, it is not easy for many subjects to keep up nose breathing while 
performing strenuous exercise. 
In some asthmatic patients, inducing refractoriness to submaximal exercise by a preceding 
bout of repetitive exercise of short duration might be helpful to prevent exercise-induced 
complaints 153. The ability to induce refractoriness to subsequent exercise is maintained despite 
an initial exercise being performed in wann, humidified air'8. It has been suggested that 
patients not protected by cromolyn sodium will not be rendered refractoryl54. Unfoliunately, 
no formal studies have been performed on what clinical or spirometric paramcters accurately 
predict which patients are likely to benefit from refractoriness. Empirical induction for all 
patients with EIB is therefore recommended. 
The role of physical training in the prevention of EIB in astlullatic children has been subject 
to investigation. Normal cardiovascular fitness does not prevent the occurence of EIB 155. Some 
studies have described amelioration of EIB after a training programme I56,157, whilst others 
could not observe such an effect I58,159. These inconsistencies may be related to methodological 
issues. Physical training improves cardiovascular fitness as assessed by the maximal oxygen 
uptake, and the workload performedl60 . Thus, when assessing the effect of training on the 
severity of EIE, the workload during the exercise test post-training should not be similar to the 
workload during the test before training, lest the apparent beneficial effect be the consequence 
of a significantly lower ventilation rate post-training. However, regardless of the effects of 
training on EIB, it is clear that psychological benefits are gained by increasing physical fitness, 
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since children become more self-confident and may better participate in group activities l59 . 
Lastly, allergen avoidance has been shown to improve the severity of EIB6o. Therefore, 
interventions aimed at reducing or removing relevant altergen exposure, such as bed covers or 
removal of pets, should be strongly supported when treating EIB in paediatric asthma 147. 
2.6.2 Pharmacological intervention 
The actions of dmgs known to protect against the occurence of EIB can be divided into two 
categories: quick-relief actions, working acutely to prevent or reverse exercise-induced airway 
narrowing, and long-term preventive actions, preventing symptoms and attacks by treating the 
underlying bronchial hyperresponsiveness l48 . The institution of prophylactic treatment is 
warranted if symptoms occur more than once a week, but less than once a day I47,I48. 
In an earlier study, it was proposed to assess the protective effect of a drug against EIB by 
either of three methods l49 : 
1. By determining the statistical significance of the difference in protective effect between an 
active dmg and its placebo using appropriate statistical tests. 
2. By determining the percentage of subjects who experience a fall in lung function post-
exercise within the normal range for either placebo or active dmg (= complete protection). 
3. By determining the protection index of a drug, i.e. the ability to reduce the severity of EIB 
as compared to placebo (= clinical protection). In formula: 
%protection = ([EIB p!accbo - EIB active drug] / EIB placeoo) * 100%. 
As a test for statistical significance does not provide an estimate of the effect size that is 
clinically relevant l61 , the protection index has now become most accepted for assessing the 
preventive effects of drugs. Based on previous studies on the repreducibility of EIB in astlulla-
tic subjects I4,143,I44, a protection index of at least 50% on the maximal %fall was found to be 
clinically relevant 15. Although the %fall does not take into account the effect of a drug on the 
recovery phase of EIB, the protection index for assessing drug efiects on %fall will be used in 
this thesis to facilitate comparison between studies. 
Beta-2-agonists. Used as quick-relief medications, inhaled short-acting Pragonists are highly 
effective in preventing execise-induced bronchoconstriction when given shortly before 
exerciseI62·t66. The protection index (PI) of a dose of 200 meg, usually prescribed in these 
studies, varied from 50% to 80%. Protection may be increased using higher doses, as dose-
response effects for protection against EIB have been shown in adults I67. The duration of 
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protection with short-acting i3ragonists is usually less than two hours I63 ,IM,168. In contrast, 
single doses of long-acting i3ragonists offer prolonged protection, varying from 8 1M,169 up to 
12 hours after dosingI68,170,!7!. The protection index at these time points ranges from 30% up 
to 80%. 
However, clu·onic dosing with both short- and long-acting i3ragonists in adults asthmatics 
resulted in a decreased protective effect against EIB I72 ,173. Although no such studies investiga-
ting the efTect of chronic dosing on the protection against EIB, have been performed in asthma-
tic children, a decreased protection against methacholine-induced bronchoconstriction with 
regular salmeterol has been described in this age groupI74. Therefore, one should be cautious 
when prescribing regular mono-therapy with i3ragonists in children as treatment for EIE. 
Allticholillergics. These drugs are mainly used for their quick-relief actions. The few studies 
that have been performed on the effectiveness of anticholinergic drugs in preventing EIB in 
children, have shown only weak protective effects115,116,I75-177. The protection index on the 
maximal %fall varies from 25% to 50% at the most. The protection is not dependent upon the 
dose, higher doses being no more protective than lower doses I 16. Notwithstanding these results 
for asthmatic children in general, individual subjects have been shown to derive substantial 
benefit from inhalation of ipratropiumbromide before exercising 175, underlining the heteroge-
neity ofElB in childhood ll '. 
eromo/yn sodium. Over the years, cromolyn has been extensively studied with respect to its 
protective effect on EIB in paediatric and adolescent asthma I54,I62,163,165,I76-183. The protective 
effect of a single dose of cromolyn sodium in these studies, given less than 20 minutes before 
exercise, varies from 26% 163 to nearly 80% 183. Some of this variability in the inhibiting effect 
on EIB is explained by the dose used, with the higher dose range (20 mg or above) giving at 
least 50% protectionI65,177,182,183, while the protection of a lower dose (less than 20 mg) 
usually does not exceed 50%163,180,181. In general, the duration of protection of a single dose 
lasts less than 2 hours I63,165,181. 
Surpdsingly, while many studies have looked at the quick relief actions of cromolyn sodi-
um, only few studies have investigated the long term preventive properties of cromolyn sodium 
on EIB in astluna65,184. Regular use did not reduce the bronchial responsiveness to exercise in 
children 184 or adults65. 
Corticosteroids. Inhaled corticosteroids are currently the most effective long-term preventive 
medications I48, most likely through their inhibitory effects all many aspects of the airway 
inflanmlatio1163. Single doses of inhaled corticosteroids are not helpful in preventing EIBl85 
And although the first reports of the protective effects on EIB during short term treatment were 
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not very encouragingI86, later studies documented reductions in EIB of at least 50% within 3 to 
8 weeks after starting drug therapy64,I87,188. Inllloderate to severe asthmatic children, a dose 
response effect for the degree of protection \vas observed l88. In part of the asthmatic populati-
on, EIB can still occur despite the use oflllaintenance treatment with EIB64. To date, it is not 
known whether increasing the dose of inhaled steroids might be beneficial in these patiens. 
Anli-leukolriene therapy. Cysteinylleukotriene receptor antagonists or synthesis inhibitors are 
a new class of dmgs, targeted at inhibiting specific mediators in asthma98 ,99. Although they 
have shown promising results in pre-clinical studies, their place in anti-asthma therapy is not 
yet ciearI89,190. Single doses of Cys-LTI receptor antagonists as well as synthesis inhibitors 
have shown to provide good protection against EIB in adult asthmatics103·107 as soon as 20 
minutes after dosinglO3. The protection index on the maximal %fall in these studies varied from 
40% to 63%103,1O.f,106,107, with the protection afforded up to 8 hours after dosing106 . Time to 
recovery from EIB was significantly reduced, the protection index for the area under the time-
response curve ranging from 60%104 to 86% 107 . Preliminary reports on pre-treatment with 
single doses of anti-Ieukotriene therapy against EIB in paediatric asthma seem to suggest 
similar efficayl08,109, the protection extending up to 24 hours after dosing 109. 
To date, one study has investigated the long-term preventive effects on EIB aner chronic 
dosing during one week. It was found that the degree of protection was sustained for the higher 
doses, but not the low dose107. However, fmiher studies are needed to confinn or refute these 
findings. Likewise, the role of antileukotriene therapy as regular mono therapy or as adjuvans to 
maintenance treatment with inhaled steroids needs to be investigated. 
2.7 Conclusions 
Exercise-induced bronchoconstriction in childhood asthma, as assessed by > 10% fall in FEV 1 
from baseline after standardized exercise testing, is an exaggeration of the bronchial response 
to exercise in normal children. EIB is related to the clinical severity of asthma, as measured by 
the severity of the underlying bronchial hyperresponsiveness. The postulated pathophysiology 
of EIB fits in well with the concept of asthma being an inflammatory disorder of the airways. 
The cardinal issue at hand is, whether EIB is merely a reflection of that airway inflammation, 
or whether exercise itself is capable of maintaining or contributing to the underlying airway 
disease in astlm13. Obviously, the answer to that question will determine the significance of 
EIB in the management of childhood asthma. 
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chapter 3 chapter 
Aims of the studies 
In tlus thesis, we aimed to clarify some of the questions pertaining to the symptom of exercise-
induced bronchoconstriction in childhood asthma. The primalY objective of the studies was to 
gain more insight in the pathofysiologic mechanisms underlying EIB in childhood asthma. The 
second, equally important objective was to evaluate treatment strategies in the prevention of 
EIB. To that end, we raised the following questions: 
* Is the bronchoconstrictor response to exercise testing for diagnosis of EIB using a standardi-
zed protocol adequately reproducible to allow the set-up of research studies in a limited 
number of subjects with sufficient power? Hence, we determined the index of repeatability 
of two repeated exercise challenges on two separate days, using a standardized treadmill 
exercise protocol, and applied the data to construct power curves that allowed estimations 
on sample size requirements for studies ofEIB in children (Chapter 4). 
* Is the clinical expression of EIB the same throughout the years of childhood? Based partly 
on clinical observation, and partly on comparison with literature in adults, we hypothesized 
that the recovery from exercise-induced bronchoconstriction is prolonged with increasing 
age. This would reflect the underlying mechmusm to change with rising age. To verify this 
hypothesis, we measured the rate of recovery ofEIB in two different age groups of children, 
and compared tIus to their rate of recovery from histamine-induced bronchoconstriction 
(Chapter 5). 
* Does exercise challenge result in a late asthmatic reaction (LAR) in all or part of the asthma-
tic children with EIB? The occurrence of a LAR could have important consequences for 
understanding the pathophysiologic mechanisms of EIB, as the late asthmatic reaction after 
allergen challenge is shown to be associated with influx of inflammatory cells and the 
development of bronchial hyperresponsiveness. To mlswer this question, we repeatedly 
measured lung function up to eight hours after exercise challenge, and compared this to lung 
function measurements on a control day without exercise, as well as to lung function measu-
red on a control day after histamine challenge inducing a matched level of bronchoconstric-
tion to that observed after exercise (Chapter 6). 
* Does seasonal allergen exposure result in increased bronchial responsiveness to exercise and 
to methacholine, and arc these effects mediated through changes in the eosinophil-induced 
arway inflammation? Secondly, are inhaled steroids beneficial in modifying these effects? 
\Ve postulated that the effects of the pollen season on airway inflammation and bronchial 
responsiveness would be dependent upon the cumulative pollen counts, as well as the 
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patients' sensitization to grass pollen. \Ve assumed the serum level of eosinophil cationic 
protein (sEep) to reflect the allergen-induced eosinophilic inflammation. To test this 
hypothesis, we concomitantly measured bronchial responsiveness to exercise m~d methacho-
line, and sECP before and during the grass pollen season in non-steroid and steroid treated 
grass pollen allergic asthmatic children and their controls, and related these to the severity of 
the allergen exposure (C!zapter 7). 
* Is the inhibiting effect of inhaled steroids against exercise-induced bronchoconstriction 
time- and dose-dependent during long-term treatment? Does a similar time- and dose-
dependency exist for the improvement in methacholine-induced bronchoconstriction during 
treatment with inhaled steroids? We postulated that the protection afforded by inhaled 
steroids against directly (methacholine) and indirectly (exercise) acting bronchoconstrictor 
stimuli would be mediated through different mechanisms. Therefore, we repeatedly measu-
red the severity of EIB, and bronchial responsiveness to methacholine during 24 weeks of 
treatment using two dose levels of fluticasone propionate in a placebo-controlled, parallel 
group study (C!zapler 8). 
* Do leukotrienes play a role in the early astlunatic reaction of EIB in childhood asthma? 
Cysteinyl leukotrienes were hypothesized to be predominantly active in prolonging the 
bronchoconstriction reaction, as based on studies descibed in chapter 5. To test this hypo-
thesis, the efficacy of zafirlukast, a cysteinyl leukotriene receptor antagonist, in inhibiting 
EIB in asthmatic adolescents was evaluated, using a randomised, double-blind, placebo-
controlled cross-over study design (Chapter 9). 
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4. Sample size estimation ill EIB 
4.1 Summary 
The repeatability of the response to standardized treadmill exercise testing using dl)1 air and 
monitoring of heart rate in asthmatic children suffering from exercise-induced brol1chocoll-
stl'iction (EIB) has not been well established. Therefore, twentyseven asthmatic children with 
dOClimente EIB pelf armed standardized exercise testing hi'ice within a period of three weeks. 
The tests were pel/armed all a treadmill while breathing dry ail'. During both tests heart rate 
had to reach 90% of the predicted maximum. Response to exercise was expressed as %fall in 
FEV1!rom baseline (%fall) and as area under the curve (AUe) of the time-response Curve. The 
repeatability was assessed bycalculating the intra-class correlation coefficients (ICC) for %fall 
and AUe (logtransformed), which were 0.57 and 0.67, respectively. From these data pml'er 
curves were constructed allowing sample size estimations for studies monitoring EIB in 
children, indicating that if a drug is expected to reduce EIB by 50%, as few as 12 patients in 
lotal suffice to demonstrate this effect (90% powe/~, using a parallel design study. Thus, 
standardized exercise testing for EIB using d,y air and monitoring of heart rate is adequately 
repeatable for use ;11 research and clinical practice in children with asthma. 
4.2 Introduction 
At present, exercise-induced bronchoconstrictioll (EIB) is regarded as an expression of airway 
hyperresponsiveness to non-sensitizing bronchoconstrictor stimuli, which is a common charac-
teristic of current symptomatic astlnua I . One of the goals of asthma treatment is to enable the 
patients to participate in activities and exercise without limitations2• Exercise testing for 
determining the severity of EIB can therefore be a helpful tool in asthma diagnosis and mana-
gement, and in research studies investigating dntg therapy, provided the method of exercise 
testing is standardized, and reproducible. It is recommended to use inspired dry air and to 
adjust the work intensity of the subject achieving 40-50% of predicted maximal voluntary 
ventilation3 or, alternatively, a heart rate L 90% of maximum predicted during the last minutes 
of the test'. Allthough data are available on the reproducibility of the response to standardized 
exercise testing4-7, data for dry air exercise testing in children are lacking. Therefore, we 
investigated the repeatability of EIB induced by standardized treadmill exercise testing with 
breathing of dry air in asthmatic children with documented EIB, and used the data for sample 
size estimations for studies ofEIB. 
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4.3 Matedals and methods 
4.3.1. Patiellts 
Twentyseven astlunatic children (12 malc, 11 female; age 6-14), with a current history ofEIB, 
were recruited from the clinic of the Juliana Childrens' Hospital, The Hague, and 't Lange Land 
Hospital in Zoetenllcer. Pre-exercise, forced expiratory volume in 1 second (FEV I) was above 
70% of predicted for all children, while post-exercise testing, all showed a ;:0; 15% fall in FEV I 
compared to baseline. Four children used continuous treatment with inhaled corticosteroids, but 
not in the week before, nor during the study period. All children used short-acting inhaled 
bronchodilators on demand only, which were withheld for 8 hours before exercise testing. 
4.3.2 Study desigll 
After the screening exercise, the children attended twice at approximately the same time of day 
on separate days (interval range: 6 - 24 days), At both visits, a standardized treadmill exercise 
challenge was performed. The two tests were considered to be acceptable for analysis if the 
child had reached the target heart rate in both tests, regardless of the speed of the treadmill 
used, and ifthe duration of the two tests did not differ by more than 30 seconds. 
4.3.3 Exercise challenge 
Before exercise, baseline FEV I was measured in triplicate, with the largest FEY I used for 
analysis. Exercise testing was performed by running on a treadmill4 (LE 2000, Jaeger, Genna-
ny or Tunturi J880, Finland), while breathing dry air3 (relative humidity <10%) during numing. 
Dry air was obtained by pressurized medical air, collected in a Douglas bag (contents 150 
litre), and inhaled by the child through a face mask (Hans-Rudolph) with an in-and expiratory 
port. Heart rate was monitored by a radiographic device (Polar Sport Tester). The incline of the 
treadmill was set at 5 to 10%, depending on the physical condition of the child. During the first 
minute of the test, the children walked at slow speed to familiarize themselves again with the 
procedure. Subsequently, the speed of the treadmill was increased during the first three minutes 
of the test to induce a heart rate> 90% of the predicted maximum (approx. 2I0-age4) by the 
third minute of the test. Thereafter, the children ran for another three minutes, unless dyspnoea 
made further running impossible. FEV! was measured in duplicate at 1,3,5,7.5, 10, 15,20 
and 30 minutes after running, with the largest FEV I at each time point retained for analysis. 
54 
4. Sample size estimation in EIB 
4.4 Statistical analysis 
The severity of EIB was expressed as maximal percent decrease in FEV 1 post-exercise as 
compared to baseline FEV! (%&111), and as area under the time-response curve (AVe) between 
° and 30 min post-exercise. The values of the test days for heart rate during the last minute of 
the test, %fall and AUe, respectively, were compared using Students! t-test (paired samples), 
with p-values <0.05 (two-sided) considered as statistically significant. Analysis of the repeata-
bility was perfonlled according to published guidelines8 by calculating the intra-class correlati-
on coefficient (=between subject variance/within+between subject variance). 
Curves for estimation of sample size were constructed using within-subject variability 
measurements and published power functions (one-sided) for predicting sample size9. For 
comparison of active versus placebo treatment, the change over time in the outcome variable 
was chosen as the main efficacy parameter, the treatment-induced change over time being a 
more sensitive indicator of dmg effect than the absolute values of the outcome variable at each 
time point of measurement. Assuming absence of period or carry-over effects, the approximate 
number of subjects required in a cross-over design study was subsequently calculated using the 
fonllula: 
N (number of subjects) ~ [(Sdd * {Z. - Z~}) / D J'. 
with: Sdd = standard deviation of the change in outcome variable; 
Z« = standard normal deviate corresponding to a right-hand tail area of a; 
Z~ = standard normal deviate corresponding to a left-hand tail area of~; 
D = expected mean change in EIB produced by treatment (i.e. 40%, 50% etc) 
For a parallel group design study, comparing the change over time of the outcome variable for 
the two groups, the number of subjects was calculated according to: 
N (number of subjects) ~ 2* [(Sdd * {Z. - Z~}) / D)' in each group. 
\Vith estimated sample sizes $; 30, Z-values should be replaced by Student's t values for the 
same a and p, but based on n-I degrees of freedom [with n~estimated sample size). 
4.5 Results 
All children completed the study according to the protocol. Between children, the duration of 
the exercise tests varied from 3.5 to 6 minutes. Heart rate during the last minute of the test did 
not differ significantly between the test days (mean (SD»: 188 (9) min'!, and 189 (8) min'! 
respectively, p~0.44). Mean (SD) %fall for the first test was 32.1 (10.5)%, and for the repeat 
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test it was 31.7 (10.3)%. Mean AUC was 582 (307) %min for test 1, and 596 (297) %min for 
test 2, respectively. The severity of EIB did not differ significantly between the two tests 
(%fall:p~0.87; AUC:p~0.80). Because the differences in %fall and AUC between the two tests 
were proportional to their mean, both parameters were log-transformed, thereby achieving 
normality of the differences (figure la, Ib). 
The ICC (based on these log-transformed data) for %fall was 0.57 and 0.67 for AUC. Curves 
for estimation of sample sizes at given power levels were constructed for parallel group studies 
(figure 2: %faU in FEV 1) and for cross-over studies (not shown). The standard deviation of the 
difference in EIB for the two tests (=Sdd) used in the formulae to calculate sample size, was 
0.296 for the log-transformed data of%fall, and 0.416 for the Iog-transfonned data of AUC. In 
table I, estimated sample sizes needed at different power levels to discriminate statistically 
significant reductions in EIB of 40% and 50% respectively, are presented, the required number 
of subjects dependent on the choice of design (cross-over or parallel) and outcome variable 
(%fall or AUC). For example, if a drug-induced reduction of 50% is considered to be clinically 
effective, only 5 (%fall) to 6 (AUC) patients are needed to achieve statistical significance 
(u~0.05, two-sided, p~0.90, one-sided) using a cross-over design, whilc a parallel group design 
requires a total of 12 (%fall) to 20 (AUC) patients only. 
Table 1: Sample size estimations (n) at given power levels required in cross-over and parallel group studies to 
discriminate the expected protective effect ofa drug and placebo against EIB with statistical significance (<<=0.05, 
two-sided). 
CROSS-OVER PARALLEL§ 
PI (%) power(%) %fall AUC %fall 
40 80 5 8 16 
90 6 10 20 
95 7 \I 24 
50 80 4 6 12 
90 4 6 12 
95 5 8 16 
Pi= protection index= f(EIBpo>!'PbC,*O - EIB,.,>!.Jrug)f EIBpost.r!~~}* 100%; 
§ : n for drug and placebo group together, hence 'lin per treatment amI. 
AUC 
26 
32 
40 
16 
20 
24 
57 
4.6 Discussion 
This study has shown that in astlullatic children the response to standardized exercisc testing is 
adequately repeatable using inspiration of dry air and monitoring of heart rate. Sample sizes 
needed to detect significant differences in EIB are relatively smail, supporting the feasibility of 
research studies monitoring EIB in childhood asthma. 
Two methodological points need to be adressed when comparing our results to those in the 
Iiterature'-7 Firstly, the repeatability is influenced by the degree ofEIB of the selected patients. 
This is illustrated by an epidemiological study of Haby et al7, in which the reproducibility of 
the %fall to a standardized free range miming exercise test was assessed by the calculation of 
the single determination 95% range. Taking into account all children in that study, a 95% range 
of ± 12 % was calculated, meaning that there is a 95% chance of the true value for a subject to 
be found within the range of 12% fall in FEV 1 around the single measurement value. However, 
when re-analysing the published data in children with at least 20% fall in FEV 1 post-exercise 
(comparable to our study population), we have estimated the single determination 95% range to 
be±18.5%7. 
95 
power (%) 
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20 25 30 35 50 55 6Q 
least detectable attenuation in %fall from baseline FEV1 
Figure 2: Curves, based on log-transfomled data, for estimation of sample size needed in a parallel group 
study to show variable attenuations in Em at certain power levels for %fall in FEYI, with N = required 
subjects per treatment amI 
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Secondly, in the studies published, different indexes of repeatability arc used, such as coeffi-
cient of variation (CV = standard deviation divided by mean)4,5, the intra-class correlation 
coefficient6, or the 95% CI of a single measuremenr . The CV is only to be used when the 
standard deviation is prop0l1ional to the mean 10, otherwise the CV will vary with the mean 
value of EIB, as was elegantly shown for %fall by Eggleston et a14. In our shldy, we choose to 
use ICC as an index of repeatability, as has recently been advised, because in all circumstances 
the ICC relates the size of the elTor variation to the size of the variation of interest 10 . However, 
a low ICC does not necessarily implicate a larger sample size, as the sample size estimation is 
dependent on the standard deviation of the difference between two tests, and not the ICC 
itself". 
'Vhat are the implications of these data? The short-term repeatability of the response to 
standardized dry air exercise testing is adequate enough to allow dmg evaluation for EIB in 
limited numbers of children, with the required shldy sample sizes influenced by the choice of 
design (cross-over or parallel) and outcome variable (%fall or AUC). Thus, standardized dry air 
exercise testing can be an important tool in management of childhood asthma. "'llether repea-
tability can be improved by measuring ventilation instead of heart rate during testing, remains 
to be investigated. 
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5. Reco\'eryji'om EtB 
5.1 Summary 
It has been suggested that children recover more quickly from bronc/wconstriction after 
exercise than adults. Based on clinical observation we hypothesized that recove,y rate from 
exercise-induced asthma (EIA) in childhood decreases with age. In 14 children aged 7 to i2 
year, with a histOJ)1 of EIA we measured spontaneous recave,y ji'om brollchocol1striction 
induced by two d(fferent stimuli: exercise and histamine. The children attended the lahora/DlY 
011 three visits. After a screening exercise test all the first visit, standardized bronclwprovo-
cation tests witlz either exercise or histamine were pe,formed all the following visits in random 
order. The degree of bronclwcollstriction induced by histamine was matclled for that observed 
after exercise. During recove,y forced e.\piratoJ'Y volume in 1 second (FEVj) was measured 
repeatedly up to 2 hours postchallenge. The recovery rate (%increase in FEV/mill) was 
calculated from the linear slope of the lime-response curve. Differences in recovel}' rate 
between the hl'o stimuli were analysed by paired t-test, while age reiated differences were 
analysed using multiple regression analysis, For the group as a whole, recove,y rate was 110t 
differenl belween Ihe 111'0 slilllllli (lIIean±SD: 1.22±O.91 for exercise and 1.46±O.65 for his-
tamine, p=O, 31), However, the recove,)! rate for exercise-induced bronchocollctrictiall de-
creased significantly with age (1'=-0,74, p=0.003), in cOlltrast to the reCOVel)1 rate for hista-
mine (1'=-0,15, p=0.60). Consequently, in the oldest age group (11-12 yr, 11=5) recovelY rate 
for exercise was significantly lower as compared fa the younger age group (7-10 year, 11=9): 
0,54±0.17 and 1.60±0.93, respectively, p=0.009, and also as compared to recove,y rate for 
histamine: 0,54±0.17 and 1,33±0.54, respectively, p=O,03. In the younger age group the 
recove,)} rates for exercise and histamine were not dtfferent: 1,60±0.93 and 1.54±O. 73, respec-
tively, p=0.83. We conclude that recovel)! ji'Oln EJA ill childhood decreases with increasing 
age, These data suggest that the mechanism of exercise-induced asthma in childhood changes 
with age. This might be due to changes ill mediator productio11. 
5.2 Introduction 
Since long it has been recognized that exercise can induce acute bronchoconstriction in patients 
with asthma I (exercise-induced asthma: EIA). Symptoms of ErA may include any of the 
following: wheezing, cough, shortness of breath, chest pain or discomfort after strenuous 
exercise. Symptoms arc most intense 5 to 10 minutes folJowing exercise cessation and usuaIJy 
resolve spontaneously within one hour2. In childhood asthma the prevalence of EIA varies 
from 70% to 90%3,4. The most important trigger for EIA to occur is thought to be the hyper-
pnoea which results in an increase in ainvay osmolarity and in airway cooling, due to evapo-
63 
rative water loss5. These changes lead to release of mediators that directly or indirectly induce 
bronchoconstriction. 
Direct measurements of mediators in blood or bronchoalveolar lavage after EIA has led to 
inconclusive results about the mediators involved6,7. Using receptor antagonists it has been 
shown that histamine8 and also leukotrienes 9 are important components in EIA. However, the 
protective effect of antagonists of these mediators in individual adult astlunatic subjects differs 
from complete protection against EIA to no protection at all, suggesting heterogeneity of 
mcchanisms involved in the bronchoconstrictive response lO• 
It has been suggested that there are differences in the clinical expression of EIA between 
adults and children, with children recovering more quickly from bronchoconstriction after 
exercise! I and having fewer late asthmatic reactionP . However, no published data are availa-
ble on the recovery phase of EIA in childhood asthma. Since it is known that bronchoconstric-
tion to leukotriencs is more prolonged than to histamine I3,!4, different time courses of EIA 
between various age groups could implicate different mechanisms of EIA. This could have 
important clinical consequences, particularly regarding the choice of therapeutic interventions. 
Based on clinical experience with exercise testing in asthmatic children, we hypothesized 
that recovery from EIA is prolonged with increasing age in childhood asthma. To that end we 
measured the rate of recovery from the acute bronchoconstriction to exercise in asthmatic 
children of different ages, and compared this to the rate of recovery from a matched level of 
brollchoconstriction to histamine. 
5.3 Materials and methods 
5.3.1 Patiellts 
Fourteen children (6 male, 8 female) clinically diagnosed as having asthma, were recruited 
from the outpatient clinic of the Department of Paediatric Pulmonology of the Juliana Chil-
dreus' Hospital in The Hague. All children had a history of exercise-induced astlilna and all 
showed a fall in forced expiratory volume in I second (FEVj) >10% after a standardized 
screening exercise challenge. Patient characteristics are summarized in table 1. Mean age of the 
children was 9.7 years (range 7 - 12 years). All children but one were atopic (RAST class, 2 
for at least one inhalant allergen). All children were clinically stable (Le. such as 110 history of 
viral infections in the two weeks before entry into the study). During a run-in period mainte-
nance treatment was reduced according to a standardized protocol. Sodium cromoglycate (3 out 
of 14) was stopped two weeks before the first study day. The dose of inhaled corticosteroids (5 
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out of 14) was halved for the first week and thereafter tapered down with 100 mcg each week 
until no inhaled corticosteroids had been used in the week before the fust study visit. Inhaled 
short-acting bronchodilators were used as rescue medication during the study period. TIllS 
bronchodilatory therapy was witWleld for at least 8 hours before each visit. 
Informed consent was obtained in all cases. The study was approved by the Local Medical 
Ethics Committee. 
Table 1. Patient characteristics. 
Ilr sex age FEVI EIA at screening therapy 
(yr) (%predieted) (%[a11 ill FEV I) 
1 m 7 94 14 sal 
2 [ 7 103 55 dseg 
3 m 8 108 16 dseg 
4 [ 9 82 34 bdp 
5 III 9 85 58 sal 
6 m 10 98 28 sal 
7 [ 10 99 40 bdp 
8 f 10 83 54 eet 
9 m 10 87 61 dseg 
10 f 11 105 25 bdp 
11 f 11 93 53 sal 
12 m 11 102 58 bdp 
13 [ 12 91 24 bdp 
14 f 12 113 41 sal 
mean 9.7 96.2 40.0 
SD 1.6 9.3 16.6 
ElA at screening %fall in FEVI rrom baseline after the screening exercise; therapy: sal salbutamol; cet 
cetirizine; dscg = sodium cromoglycate; bdp = beclomethasone dipropionate; 
5.3.2 Study design 
The children attended the lung function laboratory for three visits within a study period of two 
weeks. On the first visit baseline FEV 1 was measured in triplicate followed by standardized 
exercise challenge. During the recovery period lung function measurements were made repetiti-
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vely up to two hours aftcr challenge. On the subsequent visits in random order either a second 
exercise challenge was done or a histamine inhalation challenge matching the degree of bron-
choconstriction measured after the ftrst exercise. All three study visits started at the same time 
of day for each child. 
5.3.3 Lung/unction measurements 
Lung function measurements were made using a dry rolling seal spirometer (Vicatest 5, ~1ijn­
hardt the Netherlands) or a pneumotachograph (Flowscreen, Jaeger Germany), using the same 
calibrated device for each child. The highest FEV I obtained from three forced expiratory 
manoeuvres was retained for analysis 15. 
5.3.4 Exercise challenge 
Exercise challenge was performed by nmning on a treadmill (LE 2000, Jaeger Germany) for 6 
minutes l6. As it is known that temperature and humidity of the inspired air modulate the 
response to exercise17, dry air was used to minimize the influence of changes in environmental 
factors between visits. It also increases the osmotic stress to the ainvays in a standardized way. 
Dry air (relative humidity .s; 15%) was inspired from a reservoir bag through a face mask with 
an in- and expiratory POlt (Speak Easy II) during the test. Heart rate was measured using a 
heart rate monitor (Polar Sporttester). The children stmted at walking pace on the treadmill for 
one minute. During the test the speed of the treadmill was increased to induce a heart rate of at 
least 90% of the child's maximum predicted heart· rate (maximal heart rate = 210-age). Lung 
function measurements were made in triplicate 1,3,5,7, 10, 15,20,25, and 30 minutes after 
running, thereafter every 10 to 15 minutes, with the last measurement being made two hours 
after the start of the challenge. 
5.3.5 Histamine challenge 
Histamine challenge was done by a standardized dosimetric technique l8. Histamine was 
delivered to the mouth by a Rosenthal-French dosimeter which was connected to a DeVillbiss 
nebulizer type 646. The dosimeter was triggered by slow inhalation from functional residual 
capacity (FRC) to total lung capacity (TLC). Doubling doses (5 - 640 mcg) of histamine 
diphosphate in physiologic saline were inhaled. Each provocation challenge stalied with the 
lowest dose of histamine. Three minutes after inhaling each dose of histamine FEV I was 
measured in triplicate, the highest FEV I being used in the analysis. The histamine challenge 
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ended if the %fall in FEV 1 from baseline did not differ by more than 10% from the %fall in 
FEV I as induced by the first (screening) exercise test for each individual child. During sponta-
neous recovery from the bronchoconstriction to histamine FEV I measurements were repeated 
in triplicate at 3,5,10,15,20 and 30 minutes after the last dose of histamine given, thereafter 
every 15 minutes with the last FEV I measurement taken two hours after the start of the chal-
lenge. To assess bronchial responsiveness to histamine, PD20histamine was determined by 
linear interpolation between two data points on the non-cumulative log dose-response eurve I8. 
5.4 Statistical analysis 
5.4.1 Bronchoconstrictiol1 to exercise and histamine 
Acute bronchoconstriction to exercise or histamine was expressed as maximal %fall in FEV I 
from baseline during the first hour. The responses to exercise and histamine were compared 
using Students' t-test of paired samples. 
5.4.2 Recovery from bl'onc/toconstl'ictioll 
The recovery phase of the bronchoconstrictive response was defined as the duration between 
the time point at which FEV 1 had reached its maximal %fall from baseline and the time point 
at which FEV I had returned to at least 90% of baseline. The recovery rate of bronchocon-
striction was calculated by measuring the linear slope of the time-response curve during the 
recovery phase and was expressed as %increase in FEV, per minute (%incr FEV,/min). Diffe-
rences in recovery rate between exercise and histamine challenge were analysed by paired t-
test. Age-related differences in recovery rate for the two stimuli were analysed by using mul-
tiple regression analysis, with recovery rate as dependent variable and age and maximal %fall 
in FEV I as independent variables. In order to investigate whether differences in recovery rate 
between children were related to age, the analysis was repeated in two age groups. The children 
in group I were 7 to 10 years of age (n~9); the children in group 2 were II and 12 years of age 
(n=5). P-valucs less than 0.05 were considered statistically significant. Results are expressed in 
mean±SD. 
5.5 Results 
Baseline FEV I was >80% of predicted in all children and did not differ by more than 10% 
between visits in each individual. There was no significant difference in baseline FEV, be-
tween the exercise and histamine day (mean difference± SD: 0.93 ± 4.11, p~O.4I). Ten out of 
14 children did not run for the full 6 minutes because of discomfort associated with wheezing 
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already during running. The duration of the exercise test for these children ranged from 3.5 to 
5.5 minutes. In one child bronchodilatory treatment was given immediately after the first 
exercise because of dyspnea. 
5.5.1 Acute bronchocollstriction after exercise or histamine 
Examples of the time~response curves to exercise and histamine challenge are given in figure 
1a and I b. Maximal %fall in FEV I from baseline after each challenge is shown in table 2. 
Differences in mean %fall in FEV I between the challenges were not significant (mean %fall in 
FEY, after exercise: 37.2 ± 15, and after histamine: 40.1 ± II, p~0.39) 
Table 2: Acute bronchoconstriction to exercise or histamine and the recovery rate for both challenges. 
exercise histamine 
nr %fa11 FEYI recovery rate* %fa11 FEYI recovery rate* 
14 3.50 25 1.70 
2 30 2.08 41 2.17 
3 34 1.45 35 0.74 
4 37 1.23 38 0.70 
5 54 1.05 53 1.60 
6 20 0.30 35 1.00 
7 48 2.20 39 3.00 
8 53 0.84 39 1.45 
9 57 1.74 54 1.47 
10 35 0.51 28 2.10 
II 62 0.48 49 1.64 
12 32 0.31 60 0.73 
13 18 0.61 25 1.00 
14 27 0.78 40 1.20 
mean 37 1.22 40 1.46 
SD 15 0.91 II 0.65 
*: recovery rate in %increase in FEV J/minute; 
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5.5.2 RecovelJlfrom broncllOCOl1sll'iclioll 
Individual recovery rates for each patient are shown in table 2. Mean recovery rate for exercise 
was 1.22 ± 0.91 %incr. FEV,imin, and for histamine 1.46 ± 0.65 %incr. FEV, imin. For the 
group as a whole there was no difference in recovery rate between exercise and histamine 
(p~0.31). 
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Figure la:Example of the bronchoconstrictive response to exercise in 2 children of different ages 
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Figure Ib: Example of the bronchoconstrictive response to histamine in 2 children of different ages 
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There was a significant relationship between recovery rate for exercise and age (r= -0.74, 
p=0.003; figure 2). No such relationship was found between recovery rate for histamine and 
age (1= -0.15, p~0.60; figure 3). Recovery rate was not dependent on the severity of the acute 
bronchoconstriction (p=0.83 and p=O.93 for exercise and histamine, respectively), nor upon the 
level of bronchial responsiveness as measured by 'logPD,o (~0.26 and ~0.40), baseline 
FEV I (p~0.43 and p~0.77) or on the highest dosis of histamine used (p~0.54). 
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Figure 2: The relationship between the age of the child and the recovery rate from bronchoconstriction after 
exercise challenge 
The children were then divided into two age groups: 7-10 year old and 11-12 year old children 
(table 3). Baseline FEV I before histamine challenge was not different between the two groups 
(p~0.06). Baseline FEV I before exercise challenge was slightly but significantly different 
(p~0.02), with the younger age group having the lowest baseline FEV I' The two groups were 
not different with respect to severity of the acute bronchoconstrietion to exercise (1'=0.69) or to 
histamine (p~0.9S), level of bronchial responsiveness as measured by 'logPD20 (p~0.89), or 
highest dose of histamine given (p=0.29). The recovery rate for exercise was significantlylower 
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in the older age group as compared to the younger age group: 0.54 ± 0.17 and 1.60 ± 0.93, 
respectively, p=O.009. Recovery rate for exercise in the older age group (11-12 years) was also 
significantly lower as compared to the recovery ratc to histamine in the same age group: 0.54 ± 
0.17 and 1.33 ± 0.54, respectively, p~0.03. On the contrary in the younger age group the 
rccovery rate for exercise was not significantly different from the recovery rate for histamine: 
1.60 ± 0.93 and 1.54 ± 0.73, respectively, p~0.83. 
Table 3. Patient characteristics and differences in recovery rate (mean ±SD) for exercise and histamine challenge 
for the two age groups. 
group I 
number 9 
age (years) 7 - 10 
FEV I (%predicted) 
before exercise 91.3 ±6.8 
before histamine 91.7 ±8.7 
exercise rcspollset 38.6 ±15.5 
histamine responset 39.9 ±9.0 
PD,o (mcg)t 33.4 ±1.0 
dose histamine (mcg)* 73 ±56 
recovery~ exercise 1.60 ±0.93 
group 2 
5 
II - 12 
t-test 
p-value 
103.2 ±7.3 0.02 
100.0 ±6.2 0.06 
34.8 ± 16.5 0.69 
40.4 ±14.6 0.95 
31.5 ±1.l 0.89 
136 ±III 0.29 
0.54 ±0.17+ 0.009 
recovery~ histamine 1.54 ±0.73 1.33 ±0.54 0.57 
t: in %fall in FEV1; t: geom. mean±doubling doses; *: highest dose given; 'If: recovery rate in %increase in 
FEV j/minute; +: p=O.03 as compared to recovery rale for histamine in the same age group; 
5.6 Discussion 
This study describes differences in the clinical expression of EIA within a population of 7 - 12 
year old asthmatic children. \Ve have shown that the recovery rate from the acute bronchocon-
striction to exercise decreases with age in contrast to recovery from a matched level of bron-
choconstriction to histamine. Recovery rate is not dependent on the severity of the response, 
nor on baseline FEV1, the level of bronchial hyperresponsiveness to histamine, or the dose of 
histamine used to induce bronchoconstrictioll. These data may implicate that the mechanism of 
exercise-induced asthma is changing when children grow older. 
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Figure 3: The relationship between the age of the child and the recovery rate from bronchoconstriction 
after histamine challenge 
This is the first study on the relationship between age and recovery from EIA in childhood 
asthma. Even though it had been suggested by Anderson2 that the recovery of EIA in children 
is faster than in adults, to the best of our knowledge no data were available on age-related 
differences in tills respect. OUf results indicate that EIA is associated with more prolonged 
brollchoconstriction with increasing age. When interpreting our findings, a number of metho-
dological points need to be addressed. Firstly, the data presented here are cross-sectional and 
might be due to a selection bias, because it cannot be excluded that relatively slow recovery 
from EIA can be one of the reasons for referal to a specialist clinic as ours. However, it seems 
very unlikely that such bias would be related to age. Secondly, we do not think that exercise 
per se would account for the differences between the two groups. All children were exercised 
with heartrate being :::: 90% of their predicted maximum heartrate and thus close to their 
predicted maximum ventilation, as these two indices are related to each other l9 . In addition no 
difference was observed in the maximal %fall in FEV I to exercise in the two age groups. 
Thirdly, although we tried to match the two stimuli for level of acute bronchoconstriction 
within a 10% range, this was not achieved for all individual children. However, we do not think 
our data were influenced by this as there was no significant difference between the mean levels 
of acute bronchoconstriction for the two stimuli. Fourthly, there was a slight but significant 
72 
5. Recovery' from EIB 
difference between baseline FEV, before exercise challenge in the two subgroups. It is very 
unlikely that this has had an influence 011 the results described because analysis showed that the 
recovery rate was not dependent on baseline level of FEV,. Finally, our results might have 
been influenced by the analysis of the timeHresponse curves. Other investigators looking at 
recovery from induced bronchoconstriction have used the time to complete recovery as a varia-
ble lO,20. However, it Ill.ay be that the time to complete recovery is at least partly dependent 
upon the maximal %£111 in FEV,. Because the acute bronchoconstrictive response to exercise 
or histamine ranged from 14% to 62% fall in FEV, in our study, we choose to measure the 
slope of the recovery phase as an index of recovery. This index seems to be also preferable to 
analysis of the area under the time-response curve (AVC), because the latter is not suitable for 
the comparison of single dose challenge (exercise) with a multiple dose (histamine) challenge. 
How can the present results be explained? It is not unlikely that the observed differences in 
recovery rate from exercise-induced bronchoconstriction are due to a changing mediator profile 
ofElA with age. It has been suggested that heterogeneity ofElA in adult asthma may be due to 
the fact that some asthmatics are predominantly histamine producers, whilst others preferen-
tially generate Icukotrienes lO. It is known that recovery fromleukotriene challenge is prolonged 
as compared to histamine challenge I3,I4. Barnes et a1. found the average recovery time of the 
specific ainvay conductance (sGaw) to return to 90% of baseline value after a histamine 
challenge to be 9.9 minutes, with the average recovery time after L TD4 and LTC 4 challenges 
being 25.3 and 32.2 minutes, respectively l3, \Veiss et a1. showed that recovery ofV3o to 90% of 
baseline after histamine challenge required 10 to 14 minutes, whereas the recovery after LTD4 
challenge rcquired 18 to 30 minutes l4. Hence, recovery aftcr leukotriene challenge takes 2-3 
times as long as recovery after histamine challenge. Applying this to our data, the similar 
recovery rates for exercise and histamine in the young age group would be indicative of pre dOH 
minant histamine release, whereas the 2-3 times prolonged recovery phase after excrcise in 
older children would be in keeping with predominant lcukotriene release. This may have 
pathophysiological consequences. Due to the proHinflammatory activity of leukotrienes21 -23 , 
this could be indicative of ongoing inflammation in the airways in relatively older children 
with asthma. The relative contribution of these mediators to ElA in various age groups of 
childhood astluna should now be examined, using potent histamine and/or leukotriene receptor 
antagonists24 as pretreatment to exercise challenge. 
Pretreatment with an anticholinergic drug has shown a protective effect to ElA in some pa-
tients, thus implicating the autonomic nervous system in the response to exercise in at least part 
of the asthmatic population25,26, The role of the sympathic regulation of the airways in EIA is 
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not entirely clear. Both in normal and asthmatic subjects circulating plasma levels of adrenaline 
and noradrenaline increase during exercise27 . Allthough bronchial hyperreactivity to histamine 
can be modified by circulating physiologic levels of adrenaline28, blocking the sympathic 
system with propanolol does not effect the bronchotone during exercise in normal human 
sUbjects29• An attractive altemative explanation for the observed differences in recovery time 
from EIA is a changing role of circulating protective mediators, such as atrial natriuretic factor 
(ANF)3o. It could be postulated that the release of ANF, as observed during exercise 3! , may be 
elevated in young children as compared to older children and adults. As it is known that ANF 
decreases bronchial reactivity in astlul1atic subjects in a dose-dependent manner32, higher levels 
of ANF during exercise could result in a stronger relaxing effect during the ensuing broncho-
constriction. 
\Vhat is the clinical significance of these data? Firstly, our results strongly suggest that it is not 
only impOliant to measure the maximal %fall in FEV I after exercise challenge, but that it is 
equally important to record the recovery phase. It can be postulated that a prolonged recovery 
phase is associated with the subjective severity of ETA in children. Tlus requires further investi-
gation. Secondly, if it can be confirmed that an increase in the duration of the response to ETA 
is a reflection of the release of (pro-inflammatory) leukotrienes this will have therapeutical 
consequences in choosing symptomatic or prophylactic therapy. 
In conclusion, we have shown a relationship between age and the duration of the acute 
bronchoconstrictive response to exercise in asthmatic children. It appears that the recovery 
phase after ETA is more prolonged in older children. \Vhether dus is due to a changing media-
tor profile with age in ErA during childhood needs to be further investigated. 
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6. The late asthmatic response 
6.1 Summary 
At this moment, there is still controvers), on the presence of a late asthmatic response (LAR) to 
exercise challenge in asthma. Therefore, we 'l(n~e investigated the occlirence of a LAR after 
exercise in asthmatic children visiting an out-patient clinic, using lime-matched baseline and 
histamine control days, and a statistical analysis according to recently published recommenda-
tions. After a screening exercise day, seventeen children (aged 7 to J 4 ye(f1~ randomly pelfor-
med, 011 three following study days, either a second standardized exercise challenge, or a 
histamine challenge whilst matching the brollchocOllstriction after exercise, or only measure-
ment of baseline lung fUllction without allY challenge. l\1easurements of forced e.'piratOl)' 
volume in one second (FEVd were repeatedly made during 8 hours. Analysis was done using 
mUltiple regressioll analysis per patient, with FEVj as the dependent, and test day (exercise 01' 
control) and clocktime as independent variables during the period between 2 and 8 hours after 
exercise. A sign~ficmlt interaction (p<O.05) between test day and clock time was considered to 
be indicative of a LAR. Fifteen children completed the study. All children showed an early 
asthmatic reaction to exercise (range 14 - 62% Jedl in FEVI). In two children a significant 
interaction (p<O. 05) was found between test day and clock lime. However, the d(fference ill 
FEVj between exercise and control days for each clocktime did not exceed the 99.6% cOlzfi-
dence limits of normal diurnal variation in any Q/ the children. We conclude that il1 children 
with mild to moderate asthma, a LAR to exercise does not occur. This suggests that exercise is 
a symptomatic trigger a/asthma. Whether exercise is capable o/inducing inflammation, Jleeds 
to be further investigated. 
6.2 Introduction 
Since long it has been recognized that exercise can induce acute bronchoconstriction in patients 
with asthma 1, the so~called exercise-induced bronchoconstriction EIB. In childhood astlmla the 
prevalence of EIB varies from 70% to 90%2,3. Children suffering from EIB may complain 
about any of the following symptoms during or after strenuolls exercise: wheezing, shortness of 
breath, cough or chest pain4,5. The bronchoconstrictor response to exercise is determined by the 
level of ventilation reached during exercise as well as the temperature and water content of the 
inspired air6. The precise mechanism by which EIB occurs is still a maHer of debate. However, 
studies with mediator antagonists and synthesis inhibitors have provided supportive evidence 
for the release of mediators such as histamine, prostaglandins and leukotrienes during the early 
asthmatic response (EAR) after exercise7,8. 
Ever since its first description in 19809, there is considerable controversy in the literature on 
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the potential development of a late asthmatic response (LAR) to exercise in astlun8. It is known 
that the occurence of a LAR after allergen challenge is associated with an influx of inflammato-
ry cells and the development of bronchial hypcrresponsiveness lO. Therefore, if a LAR after 
exercise does exist, it could have important consequences for our understanding of the patho-
physiological mechanisms ofEIB, and consequently for the therapy of asthma. 
A number of studies have been published describing the occurence of a LAR, with its 
prevalence ranging from 10% to 89%"-17. However, nearly as many studies have been unable 
to document a LARI8-23. The experimental design of some of the studies showing a LAR has 
been criticized because of the lack of 'appropriate' control days24, during which lung fUllction is 
being documented without exercise or following bronchoconstriction induced by inhaled 
histamine. FUl1hermore, when evaluating the results of these studies, there seems to be conside-
rable lack of agreement among the various investigators on the definition of the LAR after 
exercise. The LAR has been defined as either a 10%12,15, or a 15%14,20,23 or a 20%16,17,19,21 fall 
in lung function (e.g. the forced expiratory volume in one second: FEY.) during different time 
periods after exercise challenge. However, the definition according to a fixed %fall in fEY 1 
carries the risk of a false-negative or a false-positive diagnosis, because it does not take into 
account normal diurnal variation in lung function in the asthmatic subjects. 
Recently, a paper has been published in this journal describing statistical methods for the 
identification of a LAR in individu~l subjects25 , using serial hourly measurements of lung 
function on several control days. The aim of tltis analysis has been to interpret challenges with 
allergens or occupational sensitizers more sensitively25, by taking into account individual day-
to-day variability in pulmonary function on control days. Therefore, in the present study we 
have applied an analogous approach, using multiple lineair regression analysis per patient, to 
evaluate the occurence of LAR after exercise in a group of asthmatic children. To that end we 
repeatedly measured lung function up to 8 hours after exercise challenge. \Ve also measured 
lung function during a control day without exercise (negative control), and on a day after 
histamine challenge inducing a matched level of bronchoconstriction as obsenfed after exercise 
(positive control). 
6.3 Materials and methods 
6.3.1 Patiellts 
Seventeen children (8 male, 9 female) were recruited from the outpatient clinic of the Depart-
ment of Paediatric Pulmonology of the Juliana Childrens' Hospital in The Hague (table I). 
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They were all known at the clinic with a diagnosis of asthma26• All had a history of excrcise-
induced bronchoconstriction and showed a fall in FEV 1 > 1 0% as compared to pre-exercise 
FEV 1 after a standardized screening exercise challenge. Mean age of the children was 9.7 years 
(range 7 - 14 years) and at screening their baseline FEV! was> 75% of predicted value2'. All 
children except two were atopic (RAST class z 2 for at least one inhalant allergen). 
All children were clinically stable (i.e no history of exacerbation andlor respiratory viral 
infection during the two weeks before entry into the study). Anti-inflammatory maintenance 
Table 1: Patient characteristics 
pat sex age atopy BASELINE VALUE PD20t therapy~ 
nr FEVI (%pred)# (mcg) 
EXI EX2 H C 
I m 7 + 94 92 92 96 120 sal 
2 m 8 + 108 102 104 102 30 dscg 
3 f 12 + 91 95 97 90 36 bdp 
4 f 11 + 105 107 107 112 55 bdp 
5 m 10 + 98 91 94 93 55 sal 
6 f 9 + 82 91 89 85 20 bdp 
7 m 14 + 83 80 79 89 4 bud 
8 f 10 + 99 98 101 101 23 bdp 
9 f 12 113 113 103 112 31 sal 
10 f II + 93 98 91 97 40 sal 
II f 10 + 85 85 86 86 9.2 cet 
12 f 7 + 103 97 99 99 II dscg 
13 m 11 + 102 103 102 101 90 bdp 
14 m 9 + 85 84 79 79 28 sal 
15 f 7 85 94 7.6 sal 
16 m 7 + 97 95 5.5 cet,bdp 
17 III 10 + 87 82 81 77 28 dscg 
mean 9.7 95 95 94 95 24t 
±SD 2.0 10 9 9 11 l.4t 
# FEV I at start of study day expressed as % of predicted FEVl; t dose of histamine to provoke a 20% fall in 
FEVI from baseline; t = geometric mean value ± SD in doubting doses; ~ = therapy before standardized cessation 
of regular treatment: sal=salbutamol; eet = cetirizine; dscg = sodiumdicromoglycate; bdp = becJontethasone 
dipropionate; bud = budesonide; 
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treatment was reduced according to a standardized protocol. Sodium cromogiycate (3 out of 
17) and the antiwhistamine cetirizine (2 out of 17) were stopped two weeks before the first study 
day. The dose of inhaled c0l1icosteroids (7 out of 17) was halved for the first week and thereaf-
ter tapered down with 100 mcg each week, until no inhaled steroids had been used in the week 
before the first study day. Inhaled short-acting bronchodilators were used as rescue medication 
during the study period. No bronchodilatory therapy was used for at least 8 hours before each 
study day. 
Informed consent was obtained in all cases. The study was approved by the Local Hospital 
IVledical Ethics Committee. 
6.3.2 Study desigll 
All practical work has been performed at the Juliana Childrens' Hospital in The Hague. The 
children attended the lung function laboratory on 4 consecutive days at intervals of at least 24 
hours and within a study period of 3 weeks. On the first day (exercise screening day = EXl-
day) baseline FEV I was measured in triplicate followed by standardized exercise challenge. 
Lung function measurements (FEV I) were made repeatedly during the recovery period, and 
thereafter half-hourly up to eight hours after challenge. On the subsequent three study days, in 
random order, either a second exercise challenge (EX2-day) was performed, or a histamine 
inhalation challenge (II-day) matching the degree of bronchoconstriction after the screening 
exercise, or only lung function measurements were performed in the absence of challenge (C-
day), again during thc same 8 hour period. At each of the 4 study days individual children 
started at the same time of day, usuaHy 9.00 a.m. During the study days the children stayed in 
one of the rooms of the lung function laboratory abstaining from strenuous exercise. 
6.3.3 Lung/unction measurements 
For each individual child, lung function measurements were made either using a dry rolling 
seal spirometer (Vicatest 5, Mijnhardt the Netherlands) or a pneumotachograph (Flowscreen, 
Jaeger Gennany). Only one device was used per child. The highest FEV 1 obtained from three 
forced expiratory manoeuvres at each time point was retained for analysis28 . 
On the control day without any challenge, the FEV 1 measurements were performed in triplicate 
every 15 minutes during the first two hours, thereafter repeated every 30 minutes until lung 
function measurements had been recorded during a time period of 8 hours. 
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6.3.4 Exercise chal/ellge (EX-days) 
Exercise challenge was performed by running on a treadmill (LE 2000, Jacger Germany) for 6 
minutes29 . During the test, heart rate was checked using a heart rate monitor (Polar Sporttester). 
The children started at walking pace on the treadmill for one minute. Thereafter, the speed of 
the trendmill was increased to induce a hemt rate of at least 90% of the maximum predicted 
heart rate for each individual child (maximum heart rate = 210 ~ age in years). Knowing that 
the occurence of a tAR may be dependent upon the severity of the early asthmatic response 
(EAR) to exercise l3, and knowing that the severity of the EAR to exercise is aggrcvated when 
humidity of the inspired air during exercise is decreased30, dry air was used to increase the 
osmotic stress to the airways in order to augment the EAR. This dry air (relative humidity 
<15%) was inspired from a reservoir bag through a face mask with an in- and expiratory port 
(Speak Easy II) during l1uming. Using this protocol in our laboratory, the intra~class correlati-
on coefficient for repeatability of the bronchoconstrictor response (expressed as %fall in 
FEV 1), is 0.5731 . Dry air was not used when a preliminary exercise challenge had shown severe 
obstruction (%fall in FEV 1 >45%) already when breathing room air (n=3) or in case of fear of 
the mask (n= 1). Lung function measurements were made in triplicate before exercise as well as 
1,3,5,7, 10, 15,20,25, and 30 minutes afterwards, and then every 10 to 15 minutes, until two 
hours after challenge. Thereafter, lung function measurements were made every 30 minutes up 
to 8 hours after exercise, allowing the calculation of the EAR and the LAR to exercise. 
6.3.5 Histamine challenge (H-day) 
A standardiscd dosimetric technique was used to perform the histaminc chailenge32. A 
Rosenthal-French dosimeter was cOlmected to a DeViHbiss nebulizer type 646. By slow 
inhalation from functional residual capacity (FRC) to total lung capacity (TLC), the dosimeter 
was triggered to deliver a dose of histamine to the mouth. Starting with the lowest dose of 
histamine diphosphate in physiologic saline, doubling doses (5 - 640 mcg) were then inhaled. 
Three minutes after inhaling each dose of histamine FEY 1 was measured in triplicate, the 
highest FEV 1 being used in the analysis. The histamine challenge ended if the %f.111 in FEV 1 
from baseline did not differ by more than 10% from the %fall in FEY 1 as induced by the first 
exercise test on EXI-day for each individual child. 
During spontaneous recovery from the bronchoconstriction to histamine FEV 1 measurements 
were repeated in triplicate at the same time intervals as used after exercise challenge up to 8 
hours. This allowed the calculation of the EAR to histamine in the same way as used for 
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exercise. To assess bronchial responsiveness to histamine, PD20histamine was determined by 
linear interpolation between two data points on the non-cumulative log dose-response curve32. 
6.4 Statistical allalysis 
For analysis, EX2-day was taken as the active challenge day, while FEY, measurements of 
both C-day and H-day served as control values. The lise of histamine as a positive control 
challenge was based on the assumption that a LAR does not occur after histamine challenge in 
the time period studied33 . Study days were only used for analysis if FEY I (expressed as %pre-
dieted) at the start of the challenge days and the control days did not differ by more than 10%. 
6.4.1 Early asthmatic re~pOl1se to exercise and histamine 
The EAR to exercise or histamine was expressed as maximal %fall in FEV, from pre-challenge 
baseline value during the first hour, according to: 
EAR ~ [(pre-challenge FEV I - lowest FEV I in first hour)! pre-challenge FEV tl * 100%. 
The EAR to exercise and histamine were compared using Students' t-test of paired samples. 
6.4.2 Late asthmatic response to exercise 
To identify a LAR after exercise, multiple regression analysis34 per patient was applied based 
on the half-hourly FEV, measurements in the time period 2 to 8 hours post-exercise. FEV, was 
taken as the dependent variable, with day (exercise or control) and clock time (of FEV I measu-
rement) as independent variables. In a first fitted ~egression model, only the main effects of day 
and clock time were evaluated, the effect of day for each patient being the difference in lung 
function between exercise day and control days, at each clock time. Multiple linear regression 
analysis automatically provides the proper t-test for this effect within each patient. However, in 
the presence of a LAR, a difference in lung function should vary with time of day. Therefore, 
in a second step, the regression model was extended with the interaction variable of day and 
clock time. Again, multiple linear regression analysis automatically provides the proper F-test. 
If a statistically significant (p<O.05) interaction was found in an individual patient, the standard 
error of the difference between exercise day and control days as estimated in the second 
regression model, was used to calculate a JOO*(O.95 1f13) = 99.6% confidence interval for this 
difference (Bollferroni correction). To verify the occurence of a LAR, a graphical representa-
tion of the difference in lung function between the exercise day and the control days for each 
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clocktime was drawn, together with its 99.6% confidence interval. For a LAR to be present, at 
least two consecutive time points had to lie outside the confidence interval. 
The analysis was performed using the absolute val ue (liter) of the FEY I measurements at each 
time point as well as the values expressed as % of baseline FEY I at the start of the study day. 
6.5 Results 
Thirteen children completed all 4 study days, and in an additional 2 children data were availa-
ble on at least one exercise day and both control days. Two children completed two study days 
only, due to clinical deterioration of their asthma requiring therapeutic intervention, and they 
were excluded from analysis. There was no significant difference in baseline FEY I between the 
exercise and the control days (mean difference ± SD between EX2 day and II-day: 1.07 ± 4.3 
%predicted, p~0.29; between EX2-day and C-day: 0.07 ± 4.3 %predicted, p~0.95). Twelve 
out of 17 children did not mn for the full 6 minutes because of discomfort associated with 
wheezing already during running. The duration of the exercise test for these children ranged 
from 3.5 to 5.5 minutes. Room temperature varied from 19°C to 25°C depending on the season. 
Within the study period of an individual child, room temperature did not vary more than 2°C. 
Relative humidity of the dry air varied from 4.5% to 9%. 
6.5.1 Early astlullatic response 
Maximal %fall in FEY 1 during the first hour after exercise or after histamine challenge is 
shown in table 2. Differences in mean %fall in FEV I between the challenges were not statisti-
cally significant (mean EAR ± SD: after EXI: 39.7 ± 16 %fall, after EX2: 37.9 ± IS %fall, and 
after histamine: 40.9 ± II %fall, p>0.05; figure I). 
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Figure 1: Mean (±SD) %fall in FEVl from baseline during the first hour for each of the 
four study days (EX I-day: first exercise day; EX2-da>': repeat exercise day; H-day: 
histamine day; Coday: control day) 
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6.5.2 The late asthmatic rejpOllse 
Table 2 also shows the individual results of the multiple regression analysis over the period 
between 2 and 8 hours post~exercise. The effect of day on FEV 1 in this analysis as estimated 
from the first step (main effects only) is shown for each child. In 10 out of 15 children the 
difference in FEV 1 between EX2~day and control days, although small, was statistically 
significant, with FEV, either being lower (n~6) or higher (IF4) on the active challenge day as 
Table 2: Early asthmatic response (EAR) after exercise and histamine challenge and the occurence of a LAR. TIle 
results of the analysis is represented in two parts, with the effect of day only (nrst step), and the interaction eftcct 
of day and time shown separately. 
EAR effect of dayt p-value~ effect of dayt p-value1r 
nr %fall ill FEV, all FEV, interaction all FEV, interaction ef~ 
EXI EX2 H (liter) effect (% baseline) feet 
14 14 25 -0.084§ 0.94 -3.54§ 0.42 
2 16 34 35 -0.077§ 0.072 -3.12§ 0.017 
3 24 18 25 +0.126§ 0.99 +5.35§ 0.99 
4 25 35 28 -0.052§ 0.58 -0.35 0.99 
5 28 20 35 -0.020 1.0 +1.62 1.0 
6 34 37 38 +0.029 0.12 -2.65§ 0.10 
7 35 48 53 -0.229§ 0.84 -3.79 0.87 
8 40 48 39 +0.027 0.56 +1.38 0.96 
9 41 27 40 +0.009 0.60 -5.08§ 0.84 
10 53 62 49 -0.1l8§ 0.88 -8.70§ 0.10 
II 54 53 39 +0.087§ 0.80 +6.27§ 0.76 
12 55 30 41 -0.009 0.68 +1.04 0.56 
13 58 32 60 -0.089§ 0.049 -5.40§ 0.040 
14 58 54 53 +0.104§ 0.92 +1.10 0.94 
17 61 57 54 +0.223§ 0.38 +8.83§ 0.55 
mean 40 38 41 
±SD 16 15 II 
t - effect of day: difference in FEV I between EX2·day and mean of control days, for given time of the day, as 
evaluated in the first step of the analysis; § = p<O.05 for main effect of day only; 'J = p·value of the interaction 
effect between day and time in the second step of the analysis; 
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compared to control days, for given time of the day. The next column in table 2 shows the 
results of the second step in the analysis, in which the interaction effect between day and clock 
time is evaluated. When this analysis was performed using absolute values of FEV b a statisti-
cally significant interaction effect indicative of a potential LAR was found only in I child (11f. 
13). Repeating the analysis using FEV I expressed as % of baseline resulted in one additional 
child (nr. 2) showing a potential LAR. In figure 2A and 3A, respectively, the lung function of 
these two children during the 4 study days is represented, while in figure 2B and 3B, respecti-
vely, a graphical representation ofthe difference in FEV I measurements between EX2-day and 
control days for these two children is given together with its 99.6% confidence interval. As can 
be seen from this figures, for hath children, all differences in FEV I measurements beween 
EX2-day and control days arc within the confidence interval. 
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Figure 2a: Lung function measurements (FEVl) during the four study days in child nr. 13 
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Figure 2b: Difference in FEV I between EX2-day and control days for each time of the day, with the 
99.6% confidence interval, in child nr. 13 
6.6 Discussion 
In tIus study we have shown the absence of a late asthmatic response to exercise in children 
with mild to moderate asthma visiting an Qut-patient clituc. An children suffered an early asth~ 
matic response to exercise. To identify a LAR accurately, and to take into account individual 
variability of diurnal variation in lung function, a statistical method was applied using multiple 
regression analysis per patient, based on serial lung function measurements after exercise 
challenge and during a positive and negative control day. These data implicate that exercise, 
unlike allergens, is merely a symptomatic, and not a causative trigger of asthma35 leading to 
obstruction but not to inflammation itlduction. 
This is not the first study on the occurence of a LAR after exercise in asthmatic subjects. 
The results presented are in agreement with those of Rubinstein et al19 and of Boner et a1 23 • In 
contrast, other investigators did describe the existence of a LAR after exercise in asthmatic 
children ll ,I3,16. \Vhen comparing the results of our shldy with those published, a number of 
methodological points need to be addressed. 
Firstly, the selection of the population studied may be important. In our study the children 
were treated for their asthma at an outpatient clinic. Other investigators have used a study 
group of asthmatic children, resident at special asthma clinicsI6,23. It could be argued that the 
latter population may have suffered from more severe and uncontrollable asthma, which is 
often the reason for referral to specialized clinics. Secondly, the exercise provocation method 
may have influenced the results. In our study, as opposed to others, most children (13 out of 
17) breathed dry air during running. Even though inspired dry air is cUlTentiy the method of 
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choice36, we did not use this potentially strong stimulus in 3 children who already showed 
severe bronchoconstriction when inhaling room air. One could argue that this could mean a 
difference in the exercise stimulus applied. However, as the fall ill FEV I postexercise is pro~ 
portional to the total amount of water lost from the airways37, we do not think that this has 
influenced our results, as long as the stimulus remains constant within subjects. 
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Figure 3a: Lung function measurements (FEVl) during the four study days in child ilL 2 
Thirdly, and perhaps more importantly, the designs of the different studies on the LAR after 
exercise merit special consideration. Among the 13 studies cited ll -23, only 4 have been using 
randomized study daysI6,20-22. The choice of Ifadequate rt control days to establish normal 
diurnal variation in lung function can be considered to be of vital importance24. Measurements 
of spontaneous variations in lung function have to be made both after another non-specific 
challenge, e.g. histamine or methacholine, and during a day without any bronchial challenge. 
The importance of using adequate control days is illustrated by two studies of Boner el aI14,23. 
In the first study l4, only one negative control day was used and prevalence of a LAR after 
exercise was found to he 26%. However, when the study was repeated using multiple control 
days to account for normal diurnal variation in lung fUIlction, the occurence of a LAR after 
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exercise could no longer be confirmed23. Even though in the latter study lung function measu-
rements were performed on hoth a negative and a positive control day, the present study is the 
only one in which the bronchoconstriction induced by histamine was carefully matched for 
degree of bronc hoc on stricti on after exercise. 
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Figure 3b: Difference in FEVI between EX2-day and control days for each time of the day. with the 
99.6% confidence interval. in child nr. 2 
Finally, there is considerable lack of agreement among the various investigators about the 
analysis of a potential LAR. For instance, it has not been clarified during which time period a 
LAR after exercise might occur. In addition, most authors define the LAR according to a pre-
determined %fall in lung function, either from pre-challenge value I2,14,15,19-21, or as compared 
to lung function measured at an identical time point on a control day I6,17,23. However, these 
methods are somewhat arbitrarily. They carry the risk of a false positive diagnosis in a subject 
with considerable spontaneous variability of ventilatory function, or similarly, the risk of a 
false negative diagnosis if spontaneous variability is low. To eliminate the potential confounR 
ding effect of day-to-day variability in pulmonary function when identifYing a LAR, it has 
recently been advocated to use statistical tests to quantify normal diurnal variation25 • thereby 
allowing recognition of a LAR after challenge with greater precision. Therefore, we have used 
multiple regression analysis within each patient, taking into account normal diurnal variation 
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on a positive and a negative control day, to optimise the identification of a LAR after exercise 
in the patient group studied. 
How can the present results be interpreted? Our results show that in out-patients with 
childhood asthma, in stable conditions, avoiding anti-asthma dmgs, a LAR after exercise 
challenge is absent. Tllis contrasts to allergen provocation, after which a LAR occurs in 50% -
75% of asthmatics challenged38. During the allergen-induced late phase reactions, an influx of 
eosinophils into the bronchial system has been observed39, also reflected in an increase in 
serum eosinophil cationic protein (sECP)40. The occurence of a post-allergen LAR has also 
been associated with an increase in bronchial hyperresponsiveness to histamine, while the 
absence has not4!. During the early asthmatic reaction after exercise, the different mediators 
released, such as histamine, prostaglandins and leukotrienes7,8, resemble those released during 
the EAR after allergen challenge42. However, the absence of a post-exercise LAR implicates 
that apparently exercise does not induce an inflammatory process, wllich is indirectly sUPP0l1ed 
by the observation that bronchial hypen'esponsiveness to histamine is not increased after 
exercise provocation23, as opposed to allergen challenge43. 
\Vhat is the clinical significance of these data? Firstly, in the absence of aLAR aftcr exercise, 
one could argue that it would suffice to treat patients with asthma symptoms occurring only 
after exercise symptomatically, e.g. with a sh0l1-acting bronchodilator'"''"', disodium cromogly-
catc or nedocromil45. However, it should be reminded that the symptom of EIB in astiuna 
should be interpreted as a sign of bronchial hyperrcsponsiveness35. It has been known for many 
years that the severity of EIB is moderately correlated to the severity of methacholine-induced 
hyperresponsiveness46. In the CutTent concept of astluna as an inflammatory disease, there are 
many studies linking bronchial hypenesponsiveness to inflammatory changes in the ainvays. 
Therefore, we think it valid to consider regular anti-inflammatolY therapy in those patients with 
moderate to severe EIB47. 
In conclusion, we have shown the absence of a late astlunatic response after exercise in child-
hood asthma. This supports the concept of exercise being a symptomatic trigger, and thus a 
reflection of bronchial hypenesponsiveness, instead of a causative factor in asthma. However, 
more studies are needed in asthmatic children to investigate the relationship between bronchial 
hyperresponsiveness, EIB and inflammatory changes in the airways. 
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7. Seasonal variation in sECP and EIB 
7.1 Summary 
Bronchial hyperresponsiveness (BHR) and its changes after allergen challenge are associated 
with eosinophilic activity ill the airways of asthmatic patients. This study was therefore desig-
ned to e.\plore the relationship between serum eosinophilic cationic protein (sEC.T), and BHR 
to exercise and methacholine in asthmatic children, as well as changes over time ill these 
parameters due to natural grass pollen exposure. A possible modifying effect of inhaled 
steroids was evaluated concurrently. To that end, measllrements of lung fUl1ctioll, symptoms, 
sECP, and BHR to exercise and methacholine were pelf armed in non-steroid and steroid 
treated grass pollen allergic asthmatic children and their controls, and were repeated during 
the grass pollen season The results showed that before the season, the BHR to exercise, but 
/lOtlllelhachalille, was weakly related 10 Ihe level a/sEeP (r~-0.043, p~0.076) illlloll-steroid 
treated children only. In the grass-pollen allergic patients of this group, the rise in sECP in 
season was associated mainly with the grass pollen RAST class (p=O.076), while the change in 
BHR to exercise and methacholine was also significantly related (p<0.05) to the cumulative 
pollen cOllllls during season. No such associations were found in steroid treated children 
Notwithstanding these results, the change in sECP over time for all participating children 
sigllificalltly (r~ -0.35, p~0.025) correlaled with Ihe challge ill BHR 10 exercise, bllt 1I0t 
methacholine, irrespective of allergy or treatment llsed. It is concluded that these data indicate 
thaI sensitization alld allergen 'load are both important factors ill aggravating BHR in 11011-
steroid treated asthmatic children. Treatment with inhaled steroids protects against allergen-
induced injlammalOlJI changes. BHR to indirectly acting stimuli is better related /0 cellular 
activity than directly acting stimuli, rendering sECP a potential role in monitoring disease 
severity in seasonal allergen exposure. 
7.2 Introduction 
Asthma is a chronic disease characterized by the episodic occurence of cough, dyspnea, wheeze 
and chest tightness, alone or in combination '. One of the key features of asthma is the increa-
sed bronchial responsiveness to sensitizing (Le. allergic) and non-sensitizing (i.e. physical or 
chemical) stimuli, leading to variable airways obstruction2. Although the underlying mecha-
nisms of bronchial hyperresponsiveness in astlulla are not fully elucidated yet, its association 
with eosinophilic airway inflammation is now well established3.4. 
One of the non-sensitizing stimuli to cause episodic symptoms and bronchoconstriction in 
daily life, is physical activity5. The precise pathophysiologic mechanism of such exercise-
induced bronchoconstriction (EIB) is still a matter of debate, the major pathways being prima-
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rill' thermal (ainvay cooHng and/or rewarming) or osmolar (airway hypertonicity) stimulation 
to the airways6. The involvement of different mediators in the reaction sequence has been 
convincingly established, by direct measurements in serum 7, by inhibiting mediator produc-
tions or by receptor antagonism8,9 . The relative contribution of the various cells within the 
airways to EIB is less clear. Mast cells have not been unequivocally implicated in EIB IO,1l , 
whilst the association between sennll eosinophil cationic protein (sECP) and the severity of 
EIB favours the involvement of eosinophilic airway inflanlluation J2. 
It is known from previous studies, that the bronchial response to exercise is aggrevated after 
allergen exposure, either in nahlfal 13, or laboratory conditionsI4 . Likewise, bronchial hyperres-
ponsiveness to histamine is increased post allergen challenge, which is associated with an 
increase in circulating eosinophilsI 5, and in levels ofsECpl6. In view of these fllldings, it can 
be postulated that the severity of ErB, as well as its changes over time, are a reflection of the 
eosinophilic inflammation within the airways of patients with asthma. From a clinical point of 
view, it would be very useful if such disease activity would be reflected in the level of sECP. 
Hence, we investigated the relationship between the severity of EIB and the level of sECP, as 
well as the changes in these variables after natural allergen exposure in astlunatic children 
before and during the grass pollen season. To that end, we measured the bronchial response to 
exercise and methacholine, as well as peakflow variability and symptoms, before and during 
the grasspollen season. Subsequently, we related those clinical characteristics to concomitant 
measurements of sECP. In order to evaluate the potential interaction of regular treatment with 
inhaled steroids, the same measurements were performed in astlunatic children with and 
without such maintenance treatment. 
7.3 Materials and methods 
7.3.1 Patients 
Fortyseven children (30 male, 17 female) were recruited from the outpatient clinic of the 
Department of Paediatric Pulmonology of the Juliana Childrens! Hospital in The Hague. Mean 
age of the children was 10.8 year (range 7 - 16 yr), and their baseline FEV 1 was > 70 % 
predicted (range 70% - 116%)17. All children had a history o[wheezing or cough with exercise, 
either longstanding or particularly during the pollen season. They were clinically stable, i.e. no 
history of viral infections during the two weeks before the challenges, and no hospital admissi-
ons or use of oral steroids during the 4 weeks before entry into the study. 
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The children were subdivided into groups based upon the presence (index group) Of absence 
(control group) of grasspollen allergy (specific RAST class L 2), as well as the presence or 
absence of maintenance treatment with inhaled steroids. Inhaled steroids had to have been used 
for at least 6 months before entry into the steroid group, whereas a 3 month period without 
steroids was an inclusion criterium for the non-steroid group. In this way, four groups were 
fanned. Sodium cromoglycate and nedocromil sodium were stopped two weeks before the first 
study visit. Rescue medication consisted of inhaled short-acting bronchodilators on demand. 
Rhinitis symptoms were relieved by local treatment with anti-histamines or steroids only. 
\Vritten informed consent was obtained from all children and their parents. The study was 
approved by the Medical Ethics Committee of the Juliana Children's Hospital. 
7.3.2 SllIdy design 
The study had a prospective, two-period design, including pre- and in-season measurements. 
In the first period, before the start of the local pollen season (February through April I8), the 
children attended the lung function laboratory on two visits within one week. On the one visit, 
bronchial hyperresponsiveness to methacholine was determined by standardized dosimetric 
technique, while on the other visit a standardized exercise challenge was performed for measu-
rement of EIB. Blood was drawn by vena punction for determination of sE~P before bronchial 
provocation was started. Afterwards the children kept a diary to measure peak flow variability, 
use of rescue medication and asthma symptom score for two weeks. Furthermore, the children 
already on maintenance treatment with inhaled steroids, were now prescribed a standardized 
dosage of 600 meg of beclometasone daily. 
In the second shldy period, during the second half of the pollen season (mid-June through 
JulyI8), the two study visits were repeated in an identical way. Diary cards were now kept 
during the two weeks prior to the study visits. 
7.3.3 LWlgfimction meaSUreme11ts 
Spirometric measurements were made using a pneumotachograph (Masterscreen, Jaeger 
Germany). The highest FEV I obtained from three forced expiratory manoeuvres at each time 
point was retained for analysis 19. 
7.3.4 Exercise challenge 
Exercise challenge was perfonned by rulUling on a treadmill (LE 2000, Jaeger Germany) for 4 
to 6 minutes20. During running. heart rate was continously assessed using a heart rate monitor 
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(Polar Sporttester), while dry air (at room temperature, relative humidity <15%) was inspired 
from a reservoir bag through a face mask with an in- and expiratory pOIi (Hans Rudolf Mask). 
After the first minute at walking pace on the treadmill in order to let the children familiarize 
themselves with the test, the speed of the treadmill was increased to induce a he3l1 rate of at 
least 90% of the maximum predicted heart rate for each individual child (maximum heart rate = 
210 - age21 ). The children ran for 6 minutes, unless dyspnea made further running impossible. 
FEV, measurements were perfollned in duplicate before as well as 1, 3, 5, 7, 10 and 15 minutes 
after the end of exercise. The severity of EIB was expressed as maximal %fall in FEV 1 from 
baseline (%fall), and as area-under-the-curve (AUC) of the time-response curve (0 - 15 min). 
7.3.5 iWethacholine challenge 
A standardised dosimetric technique was used to perform the methacholine chaUenge22. 
Methacholine was delivered to the mouth with a Rosenthal-French dosimeter, connected to a 
De Villbiss nebulizer type 646. The nebulizer was operated by compressed air at 140 kPa and 
the timing adjustment of the dosimeter was 0.6 seconds. The dosimeter was triggered to deliver 
a dose of methacholine to the mouth by slow inhalation (3 - 4 sec) from functional residual 
capacity to total lung capacity. Each provocation dose was given in 4 inhalations of 5 microli-
ter. Doubling doses of methacholine bromide in 0.9% saline were inhaled, at 5 minute intervals 
(dose range 3-3200 mcg). Three minutes after inhaling each dose of methacholine, FEV, was 
measured in triplicate, the highest FEV 1 being used in the analysis. When FEV 1 had fallen by 
more than 20% from baseline value, the induced bronchoconstriction was reversed by the 
inhalation of 400 to 800 mcg of salbutamol by metered-dose inhaler comlected to a spacer. 
Bronchial responsiveness to methacholine was expressed as PD2omethacholine, which was 
determined by linear interpolation between two data points on the non-cumulative log dose-
response curve22 . 
7.3.6 Measurement a/sECP 
Before methacholine challenge, 4 Illl of blood was drawn by vena punction, with dripping of 
blood into the glass tube. Thereafter, it was allowed to clot for 60 ±10 minutes at room tempe-
rature. After centrifugation, serum samples were stored by -20°C until further analysis by 
radio-immuno assay, according to the manufachuer's instructions (Phannacia Uppjohn23). 
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7.3.7 Diary cards 
Symptom scores were recorded on the diary cards for daytime cough, daytime wheeze, and 
llocturnal awakenings due to asthma over a two week period24. Each item could be graded for 
severity using a 0 to 3 scale (O=nolle; l=mild; 2=moderate; 3=severe). Mean symptoms score 
was calculated by the cumulative sum of scores averaged for the number of recorded days. 
Peak flow measurements were made using a mini\Vright peak flow meter. Measurements were 
performed in triplicate without using a bronchodilator after rising in the morning, and were 
repeated in the evening. Mean peak flow varibility (PEFvariability) was calculated as the ratio: 
[(highest daily PEF - lowest daily PEF) / highest daily PEF], and averaged for the number of 
recorded days 1 • 
7.3.8 Recording of pollen exposure during season 
The study was performed during the grass pollen seasons of 1992,1993, and 1995. During the 
grasspollen seaSOll, observations of airborne pollen concentrations were made with the volume-
tric Burkard® (Riclunansworth, U.K.) pollen trap, at the roof of the Leiden University Hospi-
tal, about 20 kIll from The Hague l8• As it was shown that the airborne allergen fractions of the 
grass pollens are well correlated to the daily grass pollen counts, the cumulative pollen counts 
were used as an estimate of the amount of airborne allergen during the season. For each child, 
the daily pollen counts between the visits of the first and second study period were added to 
fonn this cumulative pollen counts. 
7.4 Statistical analysis 
Values ofPD2omethacholine were logtransformed before analysis (base 2). sEep was analysed 
non-parametrically, and logtransformed before use in regression analysis. Differences between 
groups regarding baseline variables were compared by ANOVA (FEV J%predicted, POzome-
thacholine, severity of EIB, PEFvariability), or, non-parametrically by using Kmskal-\Vallis 
analysis (sEep and mean symptom score). 
The influence of allergen exposure on eosinophil activity, lung function parameters as well 
as symptoms was examined by comparing pre- and in-season measurements. In each of the 
four distinct groups, the values of %fall, AVe, PD2omethacholine, sEep, FEY 1 %predicted, 
PEFvariability and symptom score obtained pre- and in-season, were tested pairwise using 
Wilcoxon signed rank sum test. In this analysis, the children not allergic to grass pollen served 
as control subjects. 
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Subsequently, the effect of grass polien exposure was studied in sensitized individuals. In 
analogy to allergen challenges performed in the laboratory2S, it was hypothesized that the 
effects of natural allergen exposure would be a function of the quantity of antigen (i.e. cumula~ 
tive pollen counts) as well as the degree of sensitization to that allergen (i.e. grass~pollen 
RAST-class). To study these effects on sEep, and on bronchial responsiveness to exercise and 
methacholine, a multiple regression analysis was applied on the data of the grass pollen allergic 
children. To that end, the level of the outcome variable (i.e. In(ECP), AUC or PD2omethacholi-
ne) during season was taken as the dependent variable, with both the (log-transformed) cumula-
tive pollen counts, and the grass pollen RAST class as independent variables, and the pre-
season level of the outcome variable as covariate. The simultaneous effects of cumulative 
pollen counts and RAST class were studied by testing the significance of both variables 
together, the llullhypothesis being that the effects of these two parameters will be simultane-
ously equal to zero. The analyses were performed separately for the non-steroid and steroid 
treated grass pollen allergic children to explore the possibility of effect-modification by inhaled 
steroids. 
To evaluate the potential of sECP as a clinical marker of disease activity, the cross-sectional 
relationship between the level of sECP and the severity of EIB pre-season and in-season, was 
investigated using multiple linear regression analysis. The AVe was taken as the dependent 
variable, with the concomitant level of sECI' (log-transformed), the type of treatment used 
(steroid or nonsteroid), and their interaction term, as independent variables. A possible relati-
onship between EIB and sECP was also studied longitudinally, by relating the change in 
In(ECP) during season to the observed change in EIB. Again using a multiple regression 
model, the severity of EIB in-season was now the variable to be explained, with change in 
In(ECP) as explanatory variable, as well as treatment used and their interaction term, while the 
pre-season level of EIB was considered as covariate. 
Likewise, the existence of associations between (changes in) In(ECP) and (changes in) 
bronchial responsiveness to methacholine was studied. 
For all analyses, P-values < 0.05 were considered statistically significant. 
7.5 Results 
The characteristics of the 4 study groups are presented in table la (nonwsteroid treated children) 
and table Ib (steroid treated children). Between groups, 110 significant differences were found 
with respect to baseline variables. 
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Table la: Pre-season and in-season measurement values (mean ±SD) of lung function parameters, sECP and 
symptom score of the non-steroid treated children. 
grass pollen allergy POSITIVE 
time point of season PRE 
number 10 
age (years) 10.2±2.9 
FEV I (%predicted) 95.0±1O.2 
PD,ometacholine(mcg)t 40.7 ±1.7 
EIB (%fall, %) 22.4 ±14.1 
EIB (AVC, %.min) 1298 ±143 
ECP (mcg/l)tt 9.7 (4.4-20) 
symptom scorett 0.18 (0- 2.4) 
PEFvariability (%) 12.2 ±5.6 
t geom. Illean ±doubling doses; tt median (range); 
,: p<O.05 when compared to pre-season value; 
IN 
10 
94.8 ±10.8 
36.6±1.6 
21.5 ±11.3 
1272 ±157 
17.9 (2.7-62)~ 
0.75 (0.1-3.3)~ 
12.1 ±4.0 
NEGATIVE 
PRE IN 
12 8 
10.9 ±2.7 
91.6 ±9.9 88.3 ±1O.7 
58.7 ±1.2 56.4 ±1.4 
22.6 ±8.1 22.8 ±6.5 
1273 ±139 1308 ±126 
8.8 (2.9-14.9) 8.4 (4.3-26.5) 
1.21 (0- 4.4) 1.32 (0- 2.6) 
16.3 ±5.4 15.4 ±3.9 
Table lb: Pre-season and in-season measurement values (mean ±SD) of lung function parameters, sECP and 
symptom score of the steroid treated children. 
grass pollen allergy POSITIVE NEGATIVE 
time point of season PRE IN PRE IN 
number 10 9 15 15 
age (years) 10.6±3.2 II.3±\.8 
FEV I (%predicted) 95.5±1l.l 95.3±10.5 90.3±8.2 92.4±7.8 
PDzometacholine(mcg)t 35.2±1.1 42.5±1.8 42.6±1.1 29.6±\'2 
EIB (%fall, %) 19.7±13.0 17.8±10.0 28.1±8.3 30.9±14.7 
EIB (AVC, %.min) 1315±172 1331±117 1184±128 1214±144 
ECP (mcgll)tt 9.4 (2.2-18.6) 12.9 (\.9-40) I\,4 (5-18.3) 13.3 (3-133) 
symptom scorett \.0 (0- 4.4) 1.43 (0- 3.6) 0.5 (0- 1.7) 0.54 (0- 1.8) 
PEFvariabiIity (%) 14.2±4.8 15.0±5.1 12.8±3.9 14.7±8.5 
t- geom. mean ±doubling doses; tt- median (range); 
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Five children were unable to attend for the repeat tests in-season due to intercurrent respiratory 
tract infections, while one child attained other commitments during the second study period. 
After allergen exposure, in the non-steroid-using, grass pollen allergic children, a statistical-
ly significant increase in symptoms (p~0.028) as well as in sECP (p~0.037) was found in-
season as compared to pre-season, whereas such an increase was not found in the other threc 
groups. \Vhen further comparing pre- and in-season measuremcnts of EIB (%fall and AUC), 
PD2omethacholine, FEV\ %predicted and PEFvariability, no significant changes were found in 
any group (table la, Ib). 
The potential associations between the severity of allergen exposure and changes in lung 
function parameters as well as sECP, were examined in grass pollen allergic children only. The 
cumulative pollen counts the children were exposed to, ranged from 3143 up to 8960 (grains/-
m3), while the childrens' RAST-class ranged from 2 to 5. The effects (P) of the cumulative 
pollen counts and RAST on the outcome variable (in(ECP), PD2omethacholine and AVC), as 
estimated from the m.ultiple lineair regression analyses, are shown in table 2. 
Table 2: Estimated effects of the cumulative pollen counts and the RAST class on eosinophilic inflammation and 
bronchial responsiveness to exercise and methacholine 
NON-STEROID estimated effect (P) of: 
outcome variable pre-season In(pollen) RAST class R 
level 
In(ECP) +0.50 +0.19 +0.75t 0.72 
'logPD20 +O.73t - 1.67t - 0.78t 0.97 
AVC(n~IO) 
- 0.03 - 180 - 94 0.57 
AVC (n~9) +0.31 - 236t - 142t 0.83 
R: multiple correlation coefficient; 
§: test for the effects ofln(pollen) and RAST to be simultaneously equal to zero (see text); 
t: p~O.069; t: p<O.05; 
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p-value 
test§ 
0.165 
0.012 
0.054 
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From these analyses it appeared that the in-season level of In(EeP) was related mainly to the 
RAST class (P~+0.74, p~0.069), meaning that if the RAST class is increased by I, the serum 
Eep level will increase with a factor expO.74. However, the in-season level of PD20methacholi-
ne was not only related to the RAST class (p<0.05), but also to the cumulative pollen counts 
during season (p<O.05), the multiple correlation coefficient R being 0.97. Hence, the 
21ogPD20methacholine in season decreases with approximately 1.67 points if In(pollcn) increa-
ses with I (equal to a trebling of the cumulative pollen counts), while an increase in RAST 
class by 1 will result in a decrease in the 210gPD20l11ethacholine in season by 0.78 points. 
The in-season severity of EIB was studied next, but no relationship was found with any of 
the three independent variables. This was most likely due to the results of one patient, who did 
not show EIB in season, despite an increased bronchial responsiveness to methacholine and a 
rise in sEep. \Vhen excluding this patient from the analysis, the bronchial responsiveness to 
exercise in season was again significantly related to both the RAST class and the cumulative 
pollen counts (table 2). The magnitude of effect was such that if In(pollcn) should increase by 
I, the AUC will decrease with 236 %.111in (95%CI 56-416), while an increase in RAST class of 
I will consequently decrease the AUC with 142 %.min (95% CI32-252). 
\Vhen the analyses of the above relationships were performed in the steroid-treated grass 
pollen allergic children, only the association between RAST and Ave in-season was borderli-
ne significant (P~ -79 [95% CI 18-139]; p~0.063). No other associations were found between 
in-season measurements of sEep or bronchial responsiveness to methacholine and RAST 
respectively In(pollen) in this group of children. 
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Figure 1: Relationship bcn'r'een the pre-season level ofsECP and the severity of exercise-
induced bronchoconstriction in non-steroid treated eh ildren 105 
Subsequently, sECP was explored as a clinical marker of disease severity. Cross-sectional 
analysis of the pre-seasonal data of the total study population showed a weak, borderline 
significant correlation between the severity of EIB expressed as AUC, and the level of sECP in 
the non-steroid treated children (F-0.43, p~0.076; figure I), but not the steroid-treated c1lil-
dren. In-season, this association was no longer evident. However, when relating the change in 
InECP during season to the change in AUC, a small, but statistically significant (p~0.025) 
effect was found, irrespective of the treatment used. For example, if the sECP in-season had 
risen to three times the pre-season level, the AUC was found to decrease with 70 %.min (95% 
CI: 11-130; figure 2). 
The level of sECP was not related to the PD2omethacholine, neither cross-sectionally, nor 
longitudinally, nor when evaluating the two treatment groups separately. 
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Figure 2: Individual change over time (in-season minus pre-season level) in exercise-induced 
bronchocosntriction (expressed as AUC), plotted against the change in the log-transformed level of 
sECP (a difference of (x) denotes that the pre-season level ofsECP should be multiplied with e(~) to 
obtain the in-season level, i.e. (x) > 0: increase in sECP, (x) < 0: decrease in sECP; III = non-steroid 
trealed children; .A = steroid treated children) 
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7.6 Discussion 
In this study, we have shown that in stable, non-steroid treated, mild to moderate asthmatic 
children with perellllial symptoms, bronchial responsiveness to exercise but not methacholine, 
is weakly related to the eosinophilic inflammation as measured by sECP in the blood. During 
natural allergen exposure, both symptoms and serum level of ECP increase significantly in-
season in non-steroid, grass pollen allergic children. Individual changes in sECP appear to be 
related mainly to the degree of sensitization to grass pollen, whereas changes in bronchial 
responsiveness to exercise and methacholine during the grass pollen season are also influenced 
by the total amount of grass pollen allergens. Similar results can not be found in steroid-treated 
children, suggesting a modifying effect of these drugs against inflammatory changes induced 
by natural allergen exposure. \Vhen evaluating sECP as a clinical marker of disease activity, 
only the change in EIB is related to the change in eosinophil activity as measured by sEep. 
These results suggest that in asthmatic children, bronchial responsiveness to indirectly acting 
stimuli is better related to cellular activity than bronchial responsiveness to directly acting 
stimuli. 
Ours is a prospective study, investigating the effect of environmental allergen exposure on 
inflatmnatory mediators and bronchial hyperresponsiveness in asthmatic children with perenni-
al and seasonal allergies. The rise in symptoms and sECP after exposure to grass pollen in non-
steroid treated, grass pollen allergic children, is in agreement with results described in adults26• 
In our study, this individual seasonal change in eosinophil activity was associated mainly with 
the sensitization to grass pollen antigen. In contrast, it was shown that the extent of change in 
bronchial hyperresponsiveness to exercise and methacholine is influenced not only by the 
degree of sensitization, but also by the cumulative dose of allergen one is exposed to during 
season. \Vhile in keeping with studies showing a reduction in bronchial hyperresponsiveness 
when asthmatic children are transferred to environments with little or no allergen exposure27, 
our results are more elaborative in describing dose-effect relationships between antigen exposu-
re, sensitization level and subsequent changes in bronchial hyperresponsiveness. 
One of the consequences of eosinophilic activity is likely to be bronchial hyperresponsive-
ness to exercise, as the degree of (pre-season) EIB was related, albeit weakly, to the (pre-seaon) 
level of sECP. In addition to this cross-sectional relationship, which is in keeping with results 
described for adults 12, it was subsequently shown that the changes over time for sECP and EIB 
are also related, irrespective of the treatment used. Like others28 , we failed to demonstrate such 
relationships for sECP and bronchial hyperresponsiveness to methacholine. 
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\Vhen comparing our results with those published, a number of methodological issues need 
to be adressed. Firstly, in order to reduce the number of visits for the children, measurements 
were made only once before and once during season. Consequently, it is not known whether 
sEep, EIB and PD2omethacholine were measured at the time-point of maximal change in 
season. Although a relationship was found between the cumulative dose of allergen during the 
season and changes in the afore mentioned variables, it cannot be excluded that these changes 
are mainly due to the degree of allergen exposure in the last two or three weeks before the 
measurements. 
Secondly, blood for measurement of sEep was drawn at the first visit before bronchial 
provocation took place. However, in order to prevent the occurence of excessive bronchocon-
striction post-exercise (Le. >50% fall in FEV I), methacholine challenge was performed first, as 
its result allowed us to "predicC' the degree of EIB for each child, because the responses to the 
two tests are related29. Consequently, it could be that the observed, relative weak relationship 
between sECP and EIB, when compared to adultsl2, may have been influenced by the greater 
time interval between sECP measurements and exercise testing. 
Thirdly, some children used intranasal beclomethasone (nBDP) for treatment of rhinitis 
symptoms before and during the study. We do not feel this has influenced our results, nBDP 
being used already prior to entry. Also, the use of nBDP does not block the increase in me-
thacholine responsiveness during seasonal allergen exposure30. 
P' II I' , 'I I'd' I I' f Eep'628]I]' lila y, t lere IS no conSIstency 111 t le Iterature regar 111g t le ana YSIS 0 s.., "'. 
Because our data tended to be non-Gaussian distributed, just as in other studies28,33, either 11011-
parametrical tests were used or naturallogtransformation applied34. When exploring sEep as a 
marker of disease activity, many studies have analysed the relationship between sEep and 
airway function cross_sectionallyI2,16,28,31, with few studies attempting to relate their longitudi-
nal changes to each otherJ2 , 
How can the present results be interpreted? The rise in sECP in season, in keeping with 
observations in adults l6, very likely reflects the post-allergen increase in eosinophilic activity, 
as described for laboratory allergen chaUenges J5. In the latter condition, an increased number 
and/or activity of eosinophils post-allergen was shown in the ainvays, followed by an increased 
bronchial hyperresponsiveness. Our data suggest that, allthough being sensitized to allergen 
suffizes to activate eosinophils, exposure to increased amounts of allergen is equally important 
in aggravating bronchial hypelTesponsiveness in sensitive asthmatic children. Hence, it appears 
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that sEep is more a reflection of allergen sensitization, and allergen-induced eosinophilic 
infianmlation, than of bronchial responsiveness. 
Notwithstanding, when using sEep for monitoring the eosinophilic activity in relation to 
disease severity, our data show that its change over time is more clearly related to changes in 
airway responsiveness to exercise than to methacholine. This underlines the concept that 
cellular driven, indirectly acting stimuli of bronchial hypen·esponsiveness35 are more suitable 
to monitor seasonal variations in disease severity than directly acting stimuli, which may better 
reflect the long-term course of the disease36 and the airway remodelling in chronic disease37. 
What is the clinical significance of these data? Firstly, in asthmatic children, treated with 
inhaled symptomatic therapy only, a high level of sEep is a risk factor for the existence of 
exercise-induced bronchoconstriction. However, a nomlallevel of sEep does not exclude EIB. 
Secondly, cumulative exposure to natural grass pollen leads to increases in symptoms and 
sEep in children allergic to grass pollen. The change in hyperresponsiveness is detennined by 
the total pollen counts during a season as well as the degree of sensitization to grass pollen, 
whereas the change in the level of sEep is mainly related to the grass pollen RAST class. 
Although the change in sEep is only partially related to increases in bronchial responsiveness, 
monitoring sEep as a parameter of disease activity during (natural) allergen exposure, could be 
potentially useful. Steep increases in sEep during season reveal patients at risk for developing 
increased bronchial reactivity. Our results indicate that the use of maintenance treatment with 
inhaled steroids is effective in preventing seasonal exacerbations due to grass pollen exposure 
in perennial asthmatic children. Despite steroid treatment, a changing sEep as a reflection of 
eosinophil activity is still associated with subsequent changes in bronchial responsiveness to 
exercise. However, effects are small, and further studies are needed to establish the clinical 
significance of sEep as a potential marker of disease severity. 
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8. Dose-response effects of inhaled steroids 
8.1 Summal1' 
III adult asthmatic patients, short-term treatment with high dose inhaled steroids induced 
similar reductions ill the severity of histamil1e-, and exercise-induced bronchocollstrictioll 
(EIB). In the present study, we investigated ill children with asthma, whether the il1hibitOlY 
~ffect ojjluticasolle propiollate (FP, 100 alld 250 mcg b.d.) 011 exercise- alld methacholille-
induced bronc/wconstriction is time- (lnd dose-dependent. 37 asthmatic children, aged 6 to 14 
years, and with a forced expiratOJ)' volume ill one second (FEV/) greater than 70% of predic-
ted, participated in a double-blbul, placebo-controlled parallel group study. At entry, none of 
the children had llsed inhaled steroids ill the past 4 months, alld all showed at least 20%fall in 
FEVj from baseline ajier a standardized treadmill exercise test using dl)1 inspired air. During 
the study, children receiving placebo were re-randomized to active treatment ajier 6 weeks. 
Standardized d,y air exercise testing and methacholine challenge lIsing a standardized dosime-
tric technique were performed repeatedly during the 24 weeks of treatment. Concomitant 
measurements of serum eosinophil cationic protein (.'jECP) were pelf armed, to evaluate ;,S 
potential role il1 monitoring treatment efficacy. The severity of EIB significantly (p<0.05) 
decreased compared to placebo within 3 weeks, the geom. mean %fall being reduced }i'om 34.1 
(%) to 9.9 (%) jor 100 FP, alldfi'om 35.9("/0) to 7.6 (%) jor 250 FP. Reductiolls ill EIB were 
sustained throughout the study period Bronchial responsiveness to methacholine significantly 
improved withill the first 6 weeks as compared to placebo (p<O.04). Thereafter, the PD20me-
thacholine steadily increased with time il1 both treatment limbs (p=O.04), the difference in 
improvement (100 FP: 1.6 dose steps; 250 FP: 3.3 dose steps) approaching significance ajier 
24 weeks of treatment (p=O.06). In contrast, the level of sECP did not change significantly 
during treatment. We conclude that the protection of inhaled jluticasolle propionate against 
methacholille- and exercise-induced broncllOcol1slrictiofl in childhood asthma, is time- and 
dose-dependent, supporting a hypothesis of different modes of action of steroids in protecting 
against directly and indirectly acting stimuli. 
8.2 Introduction 
Asthma is a chronic inflammatory disorder of the airways, characterised by variable airways 
obstruction over timet. Fluctuations in airway patency can occur either spontaneously or in 
reaction to bronchoconstrictor stimuli. The degree of response to such stimuli is a measure for 
the severity of the underlying bronchial hyperresponsiveness, currently thought to be a hall-
mark of asthma2. The bronchoconstrictor stimuli can either directly trigger the bronchial 
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smooth muscle in the airway wall, or act indirectly through infiltrative or resident pulmonary 
cells or neural pathways3. 
Exercise, a physiologic trigger of acute, usually short-lived asthma attacks in daily life, is an 
example of a very common, indirectly acting bronchoconstrictor stimulus4• Prevalence of 
exercise-induced bronchoconstriction (EIB) among atopic children with astluna rates very high, 
ranging to almost 90%5, thereby limiting daily life activities of many patients. The precise 
mechanisms underlying EIB have not been fully clarified yet, the stimulus to the airways 
potentially being thermal (airway cooling and/or rewarming) or osmolar (drying of the 
ainvays)6. The bronchoconstrictor response itself is most likely due to the release of me-
diators7,8, although neural activity is also involvecf' . A strong association was found between 
the level of serum eosinophil cationic protein (sEep) and the severity of EIB in adults lO, 
suggesting a role for the eosinophil in EIB. 
One of the aims of asthma treatment is to enable the patient to participate in daily activities 
without limitations'. Current guidelines advocate the use of anti-inflammatory treatment, as 
soon as symptoms occur more than once a week'. Inhaled glucocorticosteroids are currently the 
most effective drugs for treatment of asthma 11. They suppress airway inflammation 12 , protect 
against allergen-induced inflammatory changes 13, and reduce bronchial hyperresponsiveness to 
the different bronchoconstrictor stimuli II. In adult asthmatic patients, short-term treatment with 
inhaled steroid induced similar reductions in severity of histamine-, exercise- and eucapnic 
hyperventilation-induced bronchoconstriction 14. However, only one, relatively high dose of 
inhaled steroids was studied, so that dose-response effects of steroids on histamine-IS and 
exercise-induced bronchoconstriction 16 remain unknown. In asthmatic children using mainte-
nance treatment with inhaled steroids, an ongoing improvement in bronchial hypenesponsive-
ness to histamine over a 22 month period was seen17, while in that same study population, 
maximal inhibition ofEIB already reached a plateau within 2 months'8. This suggests that the 
effects of inhaled steroids on bronchial responsiveness to directly and indirectly acting stimuli 
are time- and dose-related, potentially due to the involvement of different modes of action. 
In the present study, we investigated in children with asthma, whether the inhibitory effect 
of inhaled steroids on exercise- and methacholine-induced bronchoconstriction is time- and 
dose-dependent. To that end, we measured the efficacy offluticasone 100 meg b.d. and flutica-
sane 250 mcg b.d. in reducing EIB and bronchial hypenesponsiveness to methacholine during 
24 weeks of treatment using a placebo-controlled parallel group study design. In addition, the 
association between the severity of EIB and concomitant measurements of serum eosinophil 
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cationic protein (sECP) was investigated, to evaluate a potential role of sECP in monitoring 
treatment efficacyl9. 
8.3 Materials and methods 
8.3.1 Patiellts 
Thirtyscven children (23 male, 14 female) clinically diagnosed as having asthmal, were rccmi-
ted through the Department of Community Youth Health Care in The Hague as well as from 
general practitioners and hospital out-patients clinics in The Hague and Zoetenneer. Mean age 
of the children was 10.3 years (range 6 - 14 year), and their baseline forced expiratory volume 
in I second (FEV,) was >70% of predicted (table 1)20. All children suffered from exercise-
induced bronchoconstrictiol1, as shown by a falJ in FEV I of at least 20% from baseline after a 
standardized screening exercise test. They were clinicalJy stable, i.e. no history of viral infecti-
ons during the two weeks before screening, and no hospital admissions or use of oral steroids 
during the 4 weeks before entry into the study. Thirtytwo children were atopic to at least one 
inhalant allergen, as shown by a positive RAST class ~2. Nineteen children had never been 
treated with inhaled steroids before, while thirteen children had used inhaled steroids previous-
ly, but not in the four months prior to entry into the study. Five children used sodium cromo-
glycate or nedocromil as maintentance treatment, which was stopped at the screening visit. Use 
of intranasal and dermatological steroids, as well as ophthalmological cromolynes was allowed 
providing dose and frequency were not changed during the study period. 
The shldy was approved by the Medical Ethics Conullittees of the two participating hospi-
tals, and written informed consent was obtained from all children and their parents. 
8.3.2 Stlldy design 
The study had a double-blind, placebo-controlled design with a treatment period of 24 weeks. 
After a run-in period of two weeks using inhaled salbutamol only, the children were randomly 
allocated into three treatment groups to receive either fluticasone propionate FP 100 meg b.d., 
or fluticasone propionate FP 250 meg h.d. or a matched placebo, using a metered-dose inhaler 
attached to a Volumatic™ spacer. Six weeks after randomization, the placebo group was re-
allocated in random order, to receive active treatment for the remaining 18 weeks of the study. 
The children attended the lung function laboratory at screening and at entry, as well as 3 and 6 
weeks after randomisation, and thereafter every 6 weeks until 24 weeks had elapsed. At each 
visit at approximately the same time of day, a standardized exercise challenge test was perfor-
med by running on a treadmill while breathing dry air. At entry, as well as 6, 18 and 24 weeks 
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after randomization, bronchial hyperresponsiveness to methacholine was measured. Exercise 
and methacholine challenge were separated by no more than 7 days. Venous blood for measu-
rement of sEep was drawn before each exercise provocation, except at screening and at 12 
weeks after randomisation. During the whole study period, noctumal and day time symptoms 
(cough, wheeze, shortness of breath and exercise-related symptoms), rescue bronchodilator 
medication as well as peak flow measurements were recorded. Rescue therapy tor relief of 
acute asthma symptoms consisted of inhaled salbutamol on demand (max, 1600 ~tg per day). 
In addition, at each clinic visit height, body weight, heart rate, systolic and diastolic blood 
pressure were measured. Furthermore, the patients were asked for adverse events. Treatment 
compliance was checked after the study without the subjects knowledge, by dividing the actual 
weight loss of the canisters by the expected weight loss. 
Table 1: Baseline characteristics of the treatment groups at entry 
placebo 100 FP 250 FP 
number 12 II 14 
age (years) 9.8±2.4 9.9±1.6 11.1±2.4 
duration of asthma (yr) 5.2±4.3 5.8±3.6 7.5±3.9 
FEVI%prcdictcd (%) 92.1±12.5 96.6±6.9 93.2±13.3 
reversibility (%)~ 8.0 (3-23) 7.0 (0-29) 9.0 (-3-27) 
EIB: %fall (%)t 33.2*e±O_32 34.1 *e±O.37 35.9*e*O.35 
: AVCo.3o (%.min))' 764*e±O.39 764*e±O·3--1 855*e*O,49 
PD2omethacholine (~Ig)t 26.4±1.5 26.6±1.0 24.7±1.5 
ECP (!lg/I)t 12.5*e!o.96 17.1*ei.O.53 17.7*e±o-95 
(mean±SD); 'if median (range);t geom. mcan*e±so; t gcom. mean ±doubling doses; 
8.3.3 Lungfimction measurements 
Salbutamol was withheld for at least 8 hours before lung function measurements or bronchial 
provocation tests were performed. Spirometric measurements were made using a pneumotacho-
graph (lvlasterscrecn, Jaeger Germany). At each visit, baseline lung function was detennined as 
the highest FEV I obtained from three forced expiratory manoeuvres21 , At screening, the 
postbronchodilator FEV 1 was also measured22. Thirty minutes after exercise provocation, 
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800 Ilg salhutamol was administered by MDI attached to a Volumatic spacer. Twenty minutes 
afterwards, FEV I (best of three) was measured, with reversibility expressed as: 
{(FEV,postbronchodilator - FEV ,prechallenge)IFEV, prechallenge} * 100%. 
8.3.4 Exercise challenge 
Exercise testing for measuring severity of EIB was performed using a standardized protocol23. 
Exercise challenge was performed only if preMexercise FEV! was ~ 70% of predicted and not 
under 20% of a patients' baseline FEV, at entry. A motor driven treadmill was used for 
rmilling (LE 2000, Jaeger, Germany or Tunturi J880, Finland). During the test, heart rate 
was contimuously monitored by a radiographic device (polar Sport Tester), and dry air 
(relative humidity < 10%) was inspired during miming, according to recent recommen-
dations24. Dry air was obtained by pressurized medical air, and collected in a Douglas bag 
(contents 150 liter). It was inhaled by the child through the mouth, using a face mask (Hans-
Rudolph) with an in-and expiratory port, with the nose in a separate compartment. The incline 
of the treadmill was set at 5 to 10%, depending on the physical condition of the child. During 
the first minute of the test, the children walked at slow speed to familiarize themselves with the 
procedure. The speed of the treadmill was subsequently adjusted to induce a heart rate ~ 90% 
of the predicted maximum (approx. 210Mage) by the third minute of the test. Having reached 
the target heart rate, the children were coached to run for another three minutes, unless discolll-
fOli due to dyspnoea made further running impossible. FEV I was measured in duplicate at 1, 3, 
5,7.5,10,15,20 and 30 minutes post-exercise, with the best FEV! at each time point retained 
for analysis. 
The severity of EIB was expressed as maximal %fall in FEV! from baseline (%fall), and as 
areaMunder-theMcurve (AVe) of the time-response curve (0 - 30 min). 
8.3.5 l\1ethacholine challenge 
Methacholine challenge was perfonned using a standardised dosimetric techl1ique25 • A De-
Villbiss nebulizer type 646, connected to a Rosenthal-French dosimeter, was operated by 
compressed air at 138 kPa, with the timing adjustment of the dosimeter set at 0.6 seconds. The 
dosimeter was triggered to deliver a dose of methacholine to the mouth by slow inhalation (3 -
4 sec) from functional residual capacity to total lung capacity. Doubling doses of methacholine 
bromide in 0.9% saline were inhaled, at 5 minute intervals (dose range 3M3200 mcg), each 
provocation dose given in 4 inhalations of 5 ~tliter. FEV 1 was measured as the response 30 and 
90 seconds after inhalation, the lowest, technically satisfactory FEV! used for analysis24. 
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\Vhen FEV 1 had fallen by more than 45% from baseline value, or a plateau was reached on, the 
dose response curve (defined as three subsequent responses to doubling doses of methacholine 
within a 5% range), the induced bronchoconstriction was reversed by the inhalation of 400 to 
800 mcg of salbutamol MDT connected to a Volumatic™ spacer. Bronchial responsiveness to 
methacholine was expressed as PD2omethacholine, which was determined by linear interpolati-
on between two data points on the non-cumulative log dose-response curvc25 . 
8.3.6 Measurement of sECP 
Before exercise testing, 4 ml of blood was drawn by vena pUllction, with dripping of blood 
into the glass tube (SST Becton-Dickinson). Thereafter, it was allowed to clot for 60 ±IO 
minutes at room temperature. After centrifugation, serum samples were stored by -20°C until 
further analysis by ELISA-teclmique/assay, according to the manufacturer's instructions 
(Phaflnacia Upjohn26). 
8.3. 7 Dim)' cards 
During the entire study period, absence or presence of symptoms was recorded on the diary 
cards for both nocturnal and daytime cough, wheeze, and sh0l1ness of breath, with symptoms 
related to exercise recorded for daytime only. Each item could be graded for severity using a 0 
to 3 scale, (O=none; l=mild; 2=moderate; 3=severe)27. Daytime and nighttime use of rescue 
salbutamol was noted as well. 
Peak flow measurements were made using a mini\Vright peak flow meter. Measurements 
were performed in triplicate without using a bronchodilator after rising in the morning, and in 
the evening. 
8.4 Statistical analysis 
FEV, 20 and PEFR28 values were expressed as percentage of the predicted value (%pred). 
Values ofPD2omethacholine were used after logarithmic transformation (base 2). Because the 
data of %1011, AUe and sEep were non-Gaussian (skewed to the right) distributed, log-trans-
formation (natural logarithm) was applied before using parametric tests, or, when using the raw 
data, non-parametric tests were applied. 
Dose-related effects of inhaled steroids during short- and long-term treatment were studied 
for the following outcome variables: severity of EIB (%fall and AUe), bronchial responsive-
ness to methacholine, FEV I %predicted, morning and evening PEFR, inflammatory mediators 
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(sECP) and symptoms. Daily symptom scores of cough, wheeze, shortness of breath and 
exercise-related complaints were each dichotomized as no/yes. Subsequently they were each 
averaged over a 6 week treatment period, and expressed as percentage of symptomfree days 
upon which a logit transformation was applied. 
Baseline variables were compared between treatment groups at entry into the study. Deterio-
ration of asthma while using placebo treatment was evaluated by within-group comparison of 
variables at entry and after 6 weeks of treatment using \Vilcoxon signed rank sum test. Provi-
ded baseline variables did not differ at entry and after 6 weeks of placebo treatment, the data of 
the placebo-group after re-randomization were pooled with the data of the two active treatment 
groups. In this way, the power of the study in detecting dose-related differences in protective 
effect of inhaled steroids during long-term treatment was enhanced. 
To analyse the data of the first 6 weeks of treatment, ANCOV A was used to evaluate 
treatment efficacy against placebo, with therapy as between-patient grouping factor, and the 
baseline measurement of the outcome variable as covariate. The protection index (PI) was 
expressed as: ([EIBvn placebo - EIBon act;\,etreatment]/EIBvl1 placebo). Dose-related differences in protective 
effect of inhaled steroids specifically on exercise- and methacholine-induced bronchoconstricti-
on during these first 6 weeks, were also evaluated in an alternative analysis. Based on previous 
reports in adultsl4, the reduction in %fall (d%fall in FEVl) to exercise and to a single dose of 
methacholine was compared pre~ and post-treatment, the dose of methacholine pre-treatment 
thus chosen, to match the pre-treatment %fall post-exercise to within 10% fall in FEV1. 
Thereafter, the differences in effect of inhaled steroids on both stimuli were analysed non-
parametrically, using the \Vilcoxon signed rank sum test for within-group comparisons, and the 
Mann-\Vhitney U test for between-group comparisons. 
Subsequently, 24 weeks of active treatment were evaluated for dose~response related 
differences in treatment efficacy during long-term treatment. To that end, a potential difference 
in efficacy between the two active treatment groups was explored by repeated measures 
ANOV A. Therapy was again taken as the between-patient grouping factor, and baseline 
measurement of the outcome variable as a fixed covariate, while time was added as within-
patient factor, as well as the interaction effect of time and therapy. 
To evaluate a potential role of sECP in monitoring disease severity, the level of sECP at 
each visit was related to the concomitant measurement of EIB, as well as peak How values and 
symptoms during the two following weeks, using multiple regression analysis. 
For all analyses, p-values ~ 0.05 were considered statistically significant. 
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8.5 Results 
One subject in the placebo group was withdrawn after 12 weeks of treatment because of IlOllM 
compliance. In the analysis, this subject was included up to the visit prior to withdrawal. At 
cntry, the three treatment groups were in balance with respect to age, sex, duration of asthma, 
lung fUIlction parameters, level of bronchial responsiveness, and serum inflammatory mediators 
(table I). The placebo-treated group did not change significantly with respect to any of these 
variables during the first 6 weeks of treatment (table 2). Therefore, data of the placebo group 
after Ie-allocation to active treatment were pooled with data of the active treatment groups. 
8.5.1 Treatment effects all bronchial responsiveness 
Three weeks afier starting active treatment. severity of EIB (%fall: figure I; AUC: figure 2) 
was significantly (p<0.05) improved when compared to placebo, for both 100 FI' and 250 FP 
(table 2), the geom. mean %fall being reduced from 34.1 (%) to 9.9 (%) tor 100 FI', and from 
35.9 (%) to 7.6 (%) for 250 FI' within 3 weeks. The protection index for 100 FP afier 3 weeks 
treatment was 63% for %fall, and 44% for AVe, respectively. while the protection index for 
250 FP amounted to 72% (%fall), and 53% (AUC), respectively. Reduction of FIB was sustai-
ned up to 24 weeks of treatment, with the protective effect of the two doses not significantly 
different. 
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Figure 1: Maximal %fall in FEY 1 from baseline during the study period, for active treatment and placebo 
groups (geolll. mean*e±SBI) 
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Table 2: Results of treabnent with 100 FP and 250 FP b.d. 
baseline at 3 weeks at 6 weeks at 12 weeks at 18 weeks at 24 weeks 
FEVI %predicted (%) placebo 92.1±12.5 93.0±10.0 95.4±8.8 
100 FP 96.6±6.9 100.6±7.3 100.0±9.0 101.4±11.3 97.8±7.6 97.3±6.6 
250FP 93.2±13.3 100.2±14.6+ 99.7±12.5 97.9±14.5 99.0±12.4 98.3±14.7~ 
EIB: %fall (%)i" placebo 33.2*e°.32 27.1 *e°.3S 27.3*e"O.51 
100 FP 34.1 *e°.37 9.9*e"O.66+ 1 O.3*e"O.63+ 6.2*e"J.o 9.3*e"O.78 9.7*eO.72~ 
250FP 35.9*e°.35 7.6*r!°·73+ 11.4*r!°·89+ 12.3*eo.67 11.3*eo.6s 12.3*e"o.s, 
EIB: AVeo_lo (%.min)i" placebo 764*e"O.39 599*e°.53 589*e"O.5S 
100 FP 764*e"O.34 337*e±O.34+ 353*e:l:o.39+ 280*e±O.6S 275*e:l:O.62 293*e±O.4'1 
250 FP 855*e°,49 280*e:l:O.47+ 344*e:l:O.68+ 323*e"O.5S 320*e"O.Sl 375*e±O.57~ 
PD20methacholine t placebo 26.4±1.5 nda 30.0±0.8 
(mcg)t 100 FP 26.6±1.0 nda 58.4±1.7+ 47.7±1.4 57.2±2.2 80.2±1.6~ 
250FP 20.1±1.0 nda 88.7±1.8+ 101.4±1.5 135±2.2 200±2.31 
mean±SD; t=geom. mean*e:l.SO ; t geom. mean±doubling doses; nda no data available; 
.: p<0.05 as compared to placebo;~: p<O.OOl compared to baseline; 
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Figure 2: Area under the curve (AUC)during the study period, for active treatment and placebo groups 
(geom. mean*e±SF-") 
Bronchial responsiveness to methacholine significantly improved within the first 6 weeks as 
compared to placebo (fig. 3), for both 100 FP (p~0.035), and 250 FP (p~0.0037). Although the 
effect 0[250 FP was larger than the effect of 100 FP, the difference in bronchial responsiveness 
to methacholine between the two treatment groups was not statistically significant after 6 
weeks of treatment. However, PD2omethacholine steadily increased with time in both treatment 
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Figure 3: Bronchial hyperresponsivcness to methacholine during the study period, for active treatment 
and placebo groups (geom. meau±doubling dose) 
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limbs (p=0.04), with a mean increase of 1.6 dose steps for those children using 100 FP b.d., and 
a mean increase of 3.3 dose steps for those children using 250 FP b.d. This difference in 
improvement approached significance after 24 weeks of treatment (p=0.06). 
In an alternative analysis, the change in %fall in FEV 1 to a given dose of methacholine and 
exercise was calculated in both treatment groups (figure 4a+b). In children using 100 FP twice 
daily, the median %fatl in FEV 1 to methacholine pre-treatment was 33.1 %, with the median 
%fall to exercise being 32.0%. In children using 250 FP twice daily, these values were 40.3% 
(methacholine) and 37.0% (exercise), respectively. The median change in %fall in FEV 1 in the 
100 FP group was -14% (methacholine) and -22% (exercise) respectively. Within-group 
comparison showed this difference in steroid effect to be statistically significant 
(p~0.04).Median change in the 250 FP group was -17.2% (methacholine) and -19.5% (exerci-
se), respectively, the difference in effect not being statistically significant. 
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Figure 4a: Median change in %fall in FEVI to a single dose ofmethaeholine and to exercise before 
and after 6 weeks of treatment with 100 meg flutieasone propionate twice daily 
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weeks of treatment with 100 meg fluticasone propionate twice daily 
8.5.2 Effects 011 hmgjullclioll and symptoms 
Treatment with 250 mcg FP twice daily significantly improved FEV I %predicted (fig. 5) in the 
first three weeks as compared to placebo (mean change: +7.8 %points; ]F0.0031). In the 100 
FP group the change in FEVl%predicted just failed to reach significance (mean change +4.9 
%pOillts; p=O.06) when compared to placebo. This difference in effect between the two doses 
was sustained throughout the treatment period (p=O.046), Peak flow values as recorded 011 the 
diary cards however, did not change significantly over time, neither during active nor during 
placebo treatment. 
The level of inflammatory mediators as measured by sEep in the blood, did not change 
significantly during short-term nor during long-term treatment (fig. 6). Before treatment, at 
randomisation, the level of sEep (log-transformed) correlated well with the severity of EIB for 
both the %fall in FEVI (F 0.64, p<O.OOOO), and the Aue (t= -0.63, p<O.OOOI). However, 
during treatment sEep and severity of EIB no longer correlated at any time point studied, nor 
was the change in sEep between visits related to the concurrent change in EIB. 
\Vhcn evaluating symptoms, it appeared that significantly more days and nights were 
without wheeze when using active treatment (p<O.05 compared to placebo; fig. 7). No effect of 
treatment with fluticasone propionate was found on symptoms scores of cough, shortness of 
breath and exercise-related symptoms. 
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Figure 5: Change in FEV I % of predicted frolll pre-treatmcnt Icvel for active and placebo groups 
(mean ±SEM) 
8.5.3 Adverse effects 
During the treatment period, no clinically significant abnormalities in heart ratc, systolic and 
diastolic blood pressure were observed in the treatment groups. Most repolied adverse events 
were related to respiratory infections, or contacts with allergen. No candidiasis or hoarseness of 
throat was reported during the study period. 
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Figure 6: Serum level of eosinophil cationic protein (sEep) during the study period, for active treat-
ment and placebo groups (geol1l. mean*etSEM) 
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8.6 Discussion 
In this study, we have shown that the two dose levels of fluticasone propionate 200 meg daily 
and 500 meg daily wcre equi-effective in producing fast and sustained protection against EIB 
in childhood asthma, In contrast, the reduction of bronchial hypcrrcsponsiveness to methacholi-
ne was dose-depcndent, with an ongoing timc-related improvement during the 6 month treat-
ment period, \Vithin-group comparison showed the lower dose of fiuticasone to be significantly 
better in reducing EIB as compared to a matched level of methacholinc-induced bronchocon-
strictiOll. In contrast, the higher dose was shown to be equally effective. By performing both 
direct (methacholine) and indirect (exercise) challenge tests in the same group of subjects, 
treated with either a low or a high dose of fluticasone propionate, we were able to support the 
hypothesis that steroids protect against directly and indirectly acting bronchoconstrictor stimuli 
by different mechanisms29 . The steroid-induced decrease in EIB is very likely to be due to a 
rapidly achieved reduction in cellular activity, whereas the time-related improvement in 
PD2omethacholine might predominantly be due to the relatively slow resolving of airway 
remodelling, 
128 
100 -
* * 
run-in Ot06 6to[2 12to18 
treatment period (",;~cks) 
IS \0 2·1 
• p!acdXl 
0100 FP 
Q2501'1' 
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To the best of our knowledge, our study is the first to simultaneously describe the time- and 
dose-dependency of the protective effects of inhalcd steroids against two diffcrent types of 
bronchoconstrictor stimuli within the same study population. Our results confirm and extcnd 
previous observations from shldies in asthmatic children I? and adultsl5,30 on improvements in 
bronchial rcsponsiveness to direct stimuli during long-term treatment. The fast reduction in 
EIB, followed by a sustained, time-independent protection is in agreement with a previous 
studyl8, while the absence of a steroid dose-dependency in reducing EIB is contrary to results 
obtained with budesonide during shod-term trcatrnent I6. This could be due to a difference in 
potency betwecn the two steroid fonnulations31 . 
\Vhen comparing our results to those previously described, a number of methodological 
points need to be adressed. Firstly, study populations may differ in severity of asthma. Our 
study population included children diagnosed with mild to moderate asthma, selected on the 
basis of at least 20% fall in FEV 1 after a standardized exercise. At randomisation, mean percent 
fall in FEV I from baseline was approx. 35%. The ShIdy population, for whom a dose-depen-
dent reduction in EIB was described 16, was characterized as having modcrate to severe asthma 
(the bronchial reversibility ranging from 26 to 82%), with a mean of 55% fall in FEV, from 
baseline pre-treatment. Hence, the contradictory findings regarding the (lack of) dose-response 
effects of inhaled steroids on EIB between the two studies could partly be explained by the 
difference in asthma severity of the two study populations. 
Secondly, when comparing dose-effects of inhaled steroids, the inhalation device used must 
be taken into account, becausc the effect is dependent upon the actual dose deposited in the 
lungs, and not the dose prescribed32,33. In addition, different formulae of inhaled steroids may 
exert differences in potency when used in the same dosage31 , making comparisons even more 
complicated. Finally, the time point of measurement after starting drug therapy may be impor-
tant for observing dose-related effects. No dose-response effect on EIB was found after a mean 
treatment period of three weeks, yet it may have existed during the first week of treatment. 
Thus far, little is known about the dose-response curve of inhaled steroids on lung function and 
bronchial hyperresponsiveness in asthma. The dose-response curve for fluticasone might be 
rather flat34 , the dose of200 mcg daily being near the optimum dose level. Alternatively, dose-
related effects could be masked in clinical trials, due to the heterogeneity of the response to 
inhaled steroids in individual astlunatics35. 
How can the present flndings be interpreted? It is becoming clear that corticosteroids exert 
their effects on many aspects of inflammation. They are capable of reducing the numbers of 
mast cells and eosinophils in the bronchial (sub)mucosa",27, and interfere with cellular protein 
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synthesis, leading to inhibition of pro-inflammatory cytokine and mediator sYllthesis",36. It has 
been suggested that inhaled steroids have greater efficacy in reducing eosinophil activity than 
mast cell activityll,27. Oral prednisolone significantly decreased the level of Eep in bronchial 
alveolar lavage (BAL) fluid, but not baseline eicosanoid levels in mild asthmatic patients37 . 
However, release of eicosanoids ex vivo was reduced following prednisolone treatment ill 
\'1\'0 37. Also, a significant reduction in the rise in arterialleukotrienc E" (LTE,,) during an acute 
asthma attack was described during prednisolon treatment compared to LTE4 levels in an notl-
prednisolone treated attack3S• These data would suggest that inhaled steroids are capable of 
reducing the levels of mediators thought to be important in the pathogenesis of EIB, such as 
leukotrienes8 and prostaglandiml . Thus, it can be postulated that inhaled steroids protect 
against E1B by reduced cell numbers and activity". 
Reduced cell numbers might also be an important feature in protection against 
methacholine-induced bronchoconstriction, as evidenced by the relationship between the 
severity of bronchial hyperrespollsiveness to methacholine and the numbers of mast cells and 
eosinophils in the lamina propria in steroid-treated asthmatics39. It is still unknown how 
steroid-induced reduction in the number and/or activity of cells could lead to improvement of 
BHR to methacholine. The beneficial effect is hypothesized to be the result of reductions in 
mucosal and peribronchial thickness, potentially restoring the forces of interdependence 
between airway wall and parenchyma40. These effects have a relatively short time-course" 
and could also explain the relatively acute effect seen on airway patency. In addition to tllis 
acute effect, inhaled steroids have been reported to reduce the thickening of the reticular layer 
in astlm1a during long-tenn treatment, showing the potential of reversing long-term fibrosis12. 
Indeed, recent investigations have shown that treatment with inhaled steroids, aimed at attenua-
ting bronchial hyperresponsiveness on top of improving symptoms, leads to an additional 
reduction in sub-epithelial reticular layer thickelling42. Thus, the presently observed timc-
related ongoing improvement in PD20methacholine is likely to reflect an ongoing in1provement 
of airway remodelling in asthma. However, the relative imp0l1ance of reducing cell number 
and activity, and airway remodelling in detennitling the patients' individual sensitivity to 
steroids remains to be established36. 
\Vhat is the clinical significance of our findings? These data indicate that monitoring 
exercise- and methacholine-induced bronchoconstriction implicates information on different 
aspects of the pathophysiologic mechanisms in asthma. This is sUPP0l1ed by the results from 
allergen avoidance studies in asthmatic cllildren43 • After transfering housedust mite allergic 
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children to a hypo-allergen environment, a significant reduction ill EIB was apparent after one 
month, which was not accompanied by concomitant improvements in PD2omethacholine. 
Our study has shown that in asthmatic children, in whom EIR is the dominating feature, low 
dose steroid therapy may well be sufficient for their treatment. This is a clinically relevant 
finding in view of the risk of systemic side effects ofcorticosteroids44 . Yet, when treatment is 
aimed at reversing the chronic inflammation in asthma, as reflected by improvements in 
PD2omethacholine, it can be argued that treatment should be started at high dose levels of 
steroids in order to obtain the maximal effect44• Such a view is sUPPOlied by the swift and large 
improvement in PD2omethaeholine with 500 meg fluticasone propionate daily in this study. On 
the other hand, it can not be excluded that with prolonged follow-up, the improvement in the 
low dose steroid group would have equalled the effect seen with the higher dose. Further 
studies are needed to investigate the effect of such treatment strategies, as well as studies 
evaluating the efficacy of a combination of treatment modalities to circumvent the use of high 
dose inhaled steroids. 
The usc of a biomarker in the blood to monitor airway inflammation and thereby disease 
severity was evaluated as well in this study. Fluticasone significantly increased the percentage 
of days without wheeze, yet no change was observed in the serum level of eosinophil cationic 
protein (sEep). A cross-sectional relationship between the severity ofEIB and the scnun level 
of sEep was found before starting steroid therapy, but this relationship disappeared during 
treatment lO, rendering sEep less suitable for monitoring disease severityl9. 
In conclusion, we have shown that the protection against methacholine-, but not exercise-
induced bronchocollstriction, afforded by inhaled fluticasone propionate during long term 
treatment in childhood asthma, is time- and dose-dependent. These data suppOli the hypothesis 
of different modes of action of steroids in protecting against directly and indirectly acting 
bronchoconstrictor stimuli. Reduction in EIB is very likely due to decreasing inflammatory cell 
number andlor activity, whereas improvement in PD2omethacholine might predominantly be 
due to a gradual resolving of airway remodelling. Further studies are needed to evaluate the 
best parameter to be used for clinical monitoring of treatment efficacy. 
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9. Anti-Ieukotriene therapy in EIB 
9.1 Summary 
The present study evaluated the efficacy and safety of sllOrt-term treatment with the cysteinyl 
leukoh'iene receptor antagonist zafirlukast (ZF 20 mg bd or 80 mg bd) or cromolYIl sodium 
(DSCG, 10 mg qds) all exercise-induced broncJ1Ocollslriction (EIB) in asthmatic adolescents. 
Eightteen patients, aged 12 to 17 year, with a forced expiratOlY volume in I second (FEV1) 
L 70% of predicted, and L20% filll in FEV, after a screening standardised 4-6 min treadmill 
exercise test using d,y inspired ail~ participated in a randomised, double-blim/, placebo 
controlled, cross-over trial, with one week wash-Dill between the two-week treatment periods. 
During the study, exercise testing was pe/formed 4 and 8 hours after the filial dose of each 
treatment period. EID was expressed as maximal %filll in FEV, from baseline (%fall) and as 
Area-Ullder-the-Curve (A UC) of the 30 min. time response curve. A UC and %/all were analy-
sed by ANOVA, comparing ZF and DSCG 10 placebo. The effect o/ZF was most evident during 
the recove'J' phase of EIB, the reduction in AUe being significantly differerel1t as compared to 
placebo (p<0.03) at both time points. The protection index all AUC 4 hours after dosing was 
45.5% (ZF 80 mg), and 46.3% (ZF 20 mg), respectively, while 8 hOllrs after dosing it was 
45.2% (80 mg), and 54.1% (20 mg), respectively. In contrast, treatment with DSCG did 1Iot 
attenuate EID at either time point, Dijforences il1 maximal %fall between treatments failed to 
reach statistical significance, except for ZF 20 mg 8 hours after dosing. Incidence of minor 
adverse events was 1101 dtfferent between treatment and placebo periods. These results impli-
cate leukotrielles to be mediators, involved in Ihe pathogenesis of EIB, alld show zafirlukast to 
be a safe and effective therapy ill the management of childhood asthma, affording prolonged 
protection against EIB in asthmatic adolescents. 
9.2 Introduction 
During the last decade, asthma is increasingly recognized as an inflammatory disorder of the 
airways', Recently, it has become clear that leukotrienes play an important role in the complex 
network of cells and mediators perpetuating the chronic inflanullation in asthma2,3, Predomi-
nantly generated by mast cells and eosinophils, the cysteinylleukotrienes (Cys-LT) are capable 
of producing bronchoconstriction, mucus secretion and airway oedema, as well as aggravating 
the bronchial hypenesponsiveness to histamine in asthmatic patients4, In addition, inhalation of 
Cys-LT's results in recmitment ofeosinophiis into the airway nlUcosa5. Therefore, drugs aimed 
at inhibiting the aforementioned actions, may be highly valuable in the management of asth-
ma6, 
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Exercise is a common, physiologic trigger leading to acute, usually self-limiting attacks in 
asthma7• The prevalence of this exercise-induced bronchoconstriction (EIB) among asthmatic 
patients has been found to range from around 60% to as high as 90%7,&. The precise mcclla-
nisms underlying ETB have not been fully clarified yet, the stimulus to the airways potentially 
being thermal (airway cooling and/or rewarming) or osmolar (drying of the airways), which 
activates mast cells and possibly eosinophils to release bronchoconstrictor mediators9. 
By using leukotriene receptor antagonists in adult patients, it has been well established, that 
the Cys-LT's are involved in EIB, especially in maintaining the brollchoconstriction post-
exercise lO,lJ. In atopic asthmatic children with severe EIB, an increase in urinary leukotriene 
E4 was found after exercise challenge 12• However, little is known about the efficacy and safety 
of anti-Ieukotriene therapy in childhood asthma. Cromoiyn sodium, when given shortly before 
exercise, has been shown to be beneficial in protecting against EIB in children I3. Therefore, the 
present study was aimed to evaluate the effects of short-term treatment with the eys-LTI 
receptor antagonist zafirlukast (Aecolate™) or cromolyn sodium on EIB in asthmatic adoles-
cents. To that end, we measured the protection against EIB afforded by either zafirlukast (20 
mg or 80 mg b.d.), cromolyn sodium (10 mg qid), or placebo, four and eight hours after the 
final dose of a two weeks treatment period, using a randomised, double-blind, cross-over trial. 
9.3 Materials and methods 
9.3.1 Palients 
Eightteen adolescent patients (8 female, to male) clinically diagnosed as having atopic 
asthmaI4, were recmited from the Qut-patient clinic. Mean age of the patients was 13.6 years 
(range 12 - l7 year), and their baseline forced expiratory volume in 1 second (FEV I) was L 
70% of predicted l5 . All had symptoms of episodic chest tightness and wheezing, and suffered 
from exercise-induced bronchoconstriction, as shown by a fall in FEV I of at least 20% from 
baseline after a standardized screening exercise test (table I). They were clinically stable, Le. 
no history of viral infections during the six weeks before screening, and their asthma medicati-
on had not changed in the month prior to entry into the study. Twelve patients used inhaled 
corticosteroids, the mean daily dose being 500 mcg. Long-acting Pragonists were stopped four 
weeks before screening, while p.r.n. short-acting Pragonists were lIsed as rescue medication, 
but not during the 6 hours before lung function or exercise testing. 
The study was approved by the Medical Ethics Committees of the Juliana Children's 
Hospital, and written informed consent was obtained from all participating patients. 
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Table 1: patient characteristics at the screening visit. 
Patient nr sex 
1 m 
2 III 
3 m 
4 f 
5 f 
6 III 
7 m 
8 f 
9 f 
10 m 
II m 
12 m 
13 m 
14 f 
age 
(years) 
13 
12 
12 
13 
13 
12 
13 
13 
17 
13 
14 
IS 
14 
16 
duration# 
of asthma 
12 
8 
12 
10 
13 
12 
II 
13 
17 
8 
14 
4 
10 
12 
treatmcnt§ 
flutlsalb 
salb 
flutlsalb 
terb 
flut/salb 
bud/terb 
terb 
flutlsalb 
beclo/salb 
flut/salb 
flutlsalb 
flutlsalb 
terb 
flutlsalb 
9. Anti-/ellkotriene therapy ill EIB 
dose~ 
500/pm 
-/prn 
500/pm 
-/pm 
500/pm 
400/pm 
-/pm 
1000/pm 
800/pm 
100/pm 
200/pm 
SOD/pm 
-/pm 
1000/pm 
FEVI ElB 
%predicted (%fal1) 
98.6 20.2 
103.5 39.1 
80.7 43.8 
110.6 43.6 
113.9 31.7 
107.2 37.7 
78.7 23.7 
83.1 40.1 
115.2 45.8 
101,4 25.6 
92.2 41.8 
93.9 42.2 
111.7 27.6 
118.9 36.0 
IS f 16 3 salb -/pm 117.3 28,4 
16 m 13 7 flutlsalb 100/pm 81.2 21.4 
17 f 14 6 salb -/pm 89.7 33.7 
_____ }_~ ________ ! _______ }_~ ___________ ~Q ________ }1~1!~s_".I!> _______ ~9.9!P2~~ _______ 7JJ _______ ~?,Q __ _ 
Mean 13.6 10.1 508 98.6 34.9 
SD 1.5 3.6 303 14.5 8.6 
#: duration of asthma in years; § treatment: flut-fluticasone propionate, bud- budesonide, beclo- beclomethasone 
dipropionate, salb= salbutamol, terb= terbutaline; 'it daily dose in mcg of steroids! pm= bronchodilators on 
demand; FEV I = forced expiratory volume in I second; EIB = exercise-induced bronchoconstriction expressed as 
maximal % fal in FEVI from baseline; 
9.3.2 Study design 
The study was designed as a randomised, double blind, double dummy, placebo-controlled, 
four-period cross-over trial comparing the effect of two weeks' treatment with oral zafirlukast 
(80 mg or 20 mg bd) or inhaled cromol)'n sodium (l0 mg qid) with matching oral and inhaled 
placebos. The study was powered to detect signficant differences between the active treatments 
and placebo, not to detect differences between zafirlukast and cromolyn sodium. After the 
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initial screeening exercise test, patients were randomised to one of four treatment sequences 
according to a \Villiams balanced design. At the end of each treatment period, patients perfor-
med an exercise challenge at 4 and 8 hours after their last dose of trial medication. Between 
treatments, there was a one week wash-out period. Zafirlukast was given as oral tablets, and 
cromolyn sodium was supplied in metered-dose inhalers for inhalation. 
9.3.3 Lung/unction measurements 
Short-acting Pragonists were withheld for at least 6 hours before the lung function measure-
ments or exercise challenge tests were performed. Spirometric measurements were made using 
a pneumotachograph (Masterscreen, Jaeger Germany). At each visit, baseline lung function 
was determined as the highest FEV I obtained from three forced expiratory manoeuvres l6• 
9.3.4 Exercise challenge 
Four and eight hours after the final dose of each treatment, exercise testing for measuring 
severity of EIB was performed by running on a treadmill (LE 2000, Jaeger, Germany) using a 
standardized protocol, which has been shown to produce repeatable results 17. Exercise chal-
lenge was performed only if pre-exercise FEV. was ~70% ofpredicted l5. During the test, heart 
rate was continuously monitored by a radiographic device (polar Sport Tester). Dry air (relative 
humidity <10%), obtained by pressurized medical air, and collected in a Douglas bag (contents 
150 liter), was inspired during running using a face mask with the nose clipped (Hans-Ru-
dolph). The incline of the treadmi1l was set at 5 to 10%, depending on the physical condition of 
the child. Patients were given a warming up period of one minute to get accustomed to the 
treadmill. The speed of the treadmill was then adjusted to induce a heart rate ~ 90% of the 
predicted maximum (=21O-age) by the third minute of the test, at which speed they ran for a 
maximum of three further minutes. The durations of subsequent exercise challenges were kept 
identical to the duration of the screening test for each patient. The exercise challenges were 
assessed as being reproducible if the target heart rate was reached, regardless of minor variati-
ons in speed. Post-exercise, FEV, was measured in duplicate at 1,3,5,7.5,10,15,20 and 30 
minutes, the best FEV I at each time point retained for analysis. 
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9.4 Statistical analysis 
Safety was determined at each visit by review of the patienfs state of health, physical examina-
tion, routine clinical laboratolY tests, electrocardiogram (ECG) and recording of adverse 
events. Compliance with study medication was assesed by counting the returned tablets. 
The severity of EIB was expressed as maximal %fall in FEV I from baseline (%faIl) and as 
area-under-the-curve (AUC) of the time-response cunrc (0-30 min), the latter obtained from 
plotting the percentage change in FEV 1 from baseline against time'? Recovery of ErB was 
assessed by calculating the percentage of patients with FEV I L 95% of baseline within or at 30 
minutes post-exercise. 
Analysis of variance models were fitted to the data of AUC and %falI, with effects of 
patients, treatment sequence, period and treatment included as independent variables, and 
baseline FEV, fitted as a covariate. Treatment effects were estimated separately for each dose 
of zafirlukast versus placebo and for cromolyn sodium versus placebo. The protection index, an 
estimate of the protection afforded by the active treatment over placebo 10, was expressed as: 
([least squares mean placebo-least squares mean active]lleast squares mean placebo)* I 00%. 
P-values <0.05 were considered statistically significant. 
9.5 Results 
Eightteen patients were randomized to active treatment. Patient characteristics are given in 
table 1. Two patients withdrew before the end of the trial, one withdrawal due to an asthma 
exacerbation, the other one due to a concomitant traffic accident. 
The exercise protocol was completed during treatment with zafirlukast by all but onc 
patient, who was given bronchodilator therapy because of severe bronchoconstriction (>45% 
fall in FEV,) within 10 minutes post-exercise for the 8 hour test. In contrast, intervention with 
rescue bronchodilator therapy had to be done 4 times during treatment with cromolyn sodium 
and 3 times during placcbo treatment, always following the 4 hour exercise test. In these cases, 
the AUC post-exercise could not be calculated. 
Treatment compliance with the study medication was considered good, with compliance 
over 80% of the prescribed amount of shldy dmg in 56 out of the 69 treatment periods. 
Baseline FEV 1 pre-exercise was not influenced by the four treatment regimcns at either time 
point aftcr dosing. Neither did the maximal heart rates during the last minute of the exercise 
tests vary significantly between the different exercise challenges performed (table 2). 
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final dose of each treatment period (DSCG: cromolyn sodium; ZP 20: zafirlukast 20 mg h.d.; ZF 80: 
zafirlukast 80 mg h.d.) 
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Figure Ib: Mean %fall in FEVl from baseline at various time points post-exercise, 8 hours after the 
final dose of each treatment period (DSCG: cromolyn sodium; ZF 20: zafirlukast 20 mg h,d.; ZF 80: 
zafirlukast 80 mg h.d.) 
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9.5.11!-1ficacy 
Mean %fa1l in FEV 1 from baseline post-exercise at each time point is presented in figures 1 a 
(4 hours post dose) and Ib (8 hours post dose) for the four different treatment regimens. 
Four hours after the final dose, both 20 mg and 80 mg of zafirlukast produced a statistically 
significant reduction in Aue post-exercise (p<O.Ol compared to placebo; table 2). The protec-
tion index on Aue was 45.5% for the 80 mg dose, and 46.3% for the 20 mg dose, respectively 
(figure 2). In contrast, treatment with cromolyn sodium did not result in a significant improve-
ment of the AUe (p=OAO), the protection index being 14.5%. Relatively more patients rccove-
red to greater than 95% of baseline FEV 1 within or at 30 minutes post-exercise having used 
zafirlukast than after using cromolyn or placebo. 
Similar results were obtained when the different treatment effects were evaluated eight 
hours after dosing. At this time-point, the protection index on Aue by zafirlukast was 45.2% 
for the 80 mg dose, and 54.1% for the 20 mg dose, respectively (figure 2), while the protective 
index of cromolyn sodium did not differ from zero (p=0.72). 
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Figure 2: Protection index of each treatment on AUC 4 and 8 hours after dosing 
(**:p<O.OI, *:1'<0.05 = protection significantly different from zero) 
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\Vhen evaluating the treatment effects on the maximal %fall in FEV 1 (table 2, figure 3), the 
two doses of zafirlukast produced a smaller maximal %fall in FEV I compared to placebo, 
although statistical significance was only obtained for zafirlukast 20 mg 8 hours after the final 
dose. Neither was there a significant difference in the maximal %fall in FEV 1 between treat-
ment with cromolyn sodium and placebo at both time points post-dosing (p~O.35). 
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Table 2: Exercise-induced bronchoconstriction after regular therapy with placebo. zaflrlukast and cromolyn sodium in asthmatic adolescents 
treatment number baseline FEV I maximal HR max. % fall in AVeco.)O) recovery 
(I)"f (beats/min)j· FEVI (%)t (%.min)j: (% patients) 
4 hour post dose 
zafirlukast 80 mg 15 2.79±0.50 I 86.6±7.9 2 1.0±2.4 I -257.5±49.5~ 87 
zafirlukast 20 mg 16 2.76±0.62 186.7±6.9 22.4±2.30 -253.6±46.611 81 
cromolyn sodium II 2.75±0.61 I 85.4±6.4 26.1±2.59 -404.0±61.3 57 
placebo 12 2.74±0.65 184.l±6.3 26.2±2.45 -472.3±56.9 33 
8 hour post dose 
zafirlukast 80 mg 15 2.81±0.53 I 85.8±5.5 20.7±2.05 -202.2±47.8§ 87 
zafirlukast 20 mg 14 2.75±0.64 185.0±7.0 18.7±2.02§ -169.5±50.0§ 73 
cromolyn sodium 10 2.78±0.56 I 86.9±4.5 28.2±2.39 -340.2±62.7 50 
placebo 12 2.77±0.63 186.7±5.0 25.2±2.36 -369.1±56.2 50 
1": results in mean±SD: t:results in least squares mean±SE,,: p<O.Olas compared to placebo: §: p<0.05 as compared to placebo: 
FEYl = forced expiratory volume in } second: maximal HR = maximal heart rate during the last minute of the test: max. %fall in FEYl = maximal %fall in FEY} from 
baseline post-exercise: AVe= area under the time response curve post-exercise: recovery "" percentage of patients recovered at 95% of baseline FEY} within 30 minutes 
post-exercise: 
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9.5.2 Safety 
The incidence of adverse events reported by the patients was similar across the four treatment 
periods, the most common adverse event being worsening of asthma symptoms. There were no 
treatment related differences in the laboratory parameters or safety concerns from the physical 
examination. No clinically relevant ECG abnormalities were observed. 
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Figure 3: Protection indez of eaeh treatment on %fall in FEVl 4 and 8 hours after dosing 
(*:p<O.05 = protection significantly different from zero) 
9.6 Discussion 
The present study has shown that regular treatment with the Cys-LT, receptor antagonist 
zafirlukast affords protection against exercise-induced bronchoconstriction up to eight hours 
after dosing in adolescents with mild to moderately severe asthma. The effect of zafirlukast 
was most evident during the recovery phase of EIB. the area under the curve being significantly 
less for both doses of zafirlukast as compared to placebo, with relatively more patients recove-
ring from EIB within 30 minutes. Although zafirlukast produced a smaller maximal %fall in 
FEV I than placebo, this effect failed to reach statistical significance. No protective effect on 
EIB was seen after treatment with cromolyn sodium. These data suggest that cysteinyl leuko-
trienes are important mediators ofEIB in adolescent astlullatics. 
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To our knowledge, this study is one of the first to describe the effect of regular treatment with a 
CysRLTI receptor antagonist on exerciseRinduced bronchoconstriction in childhood astImm. In 
general, our findings of a significant protection on EIB are in accordance with those obtained in 
adults astlunatics lO,II,18.20. The prolonged attenuation of EIB up to eight hours after dosing 
extend previous observations on the efficacy of single doses ofCys-LT receptor antagonists in 
protecting against EIB in asthmatic adults IO,II,18,19 and children21 ,22. Similar prolonged protecR 
tion with regular treatment was previously described for the Cys-L T 1 receptor antagonist 
cinalukast in mildly asthmatic adults2o. In keeping with our results, all but one study 19 showed 
a significant reduction in the area under the time-response curve post-exercise and a (trend 
towards) faster recovery with active treatment lO,II,18,20.22. Tlils suggests that leukotrienes are 
especially prominent in sustaining the bronchoconstrictor response. 
The protective effect by Cys-LTI antagonism in our study population appears to be somewR 
hat less than has been prescibed for adult asthmatics IO,1I,18,20, because we were only able to 
demonstrate significant, albeit weak protection against the maximal %fall in FEY 1 8 hours after 
the 20 mg dose of zafirlukast. This may be inherent to the age group studied, as preliminary 
reports of shldies in asthmatic children also suggest a slightly reduced protection on the maxiR 
mal %fall compared to adults21 ,22. Alternatively, it has been suggested from studies with a 
different Cys-LTj receptor antagonist that loss of protection occurs with regular treatment, 
especially with lower doses2o. However, this seems less likely, the effect 0[20 mg ofzafirluR 
kast in this study being equal to that of the 80 rug dose. 
No protective effect on EIB was obsented after regular therapy with cromolyn sodium in 
tlils study population. As the exercise tests were performed 4 and 8 hours after the final dose, 
the acute protective effect of cromolyn sodium on EIB was negligible, because inlilbition of 
EIB afforded by a single dose of cromolyn sodium is no longer evident 2 hours after inhala-
tionI3. The lack of effect on EIB during regular treatment with cromolyn sodium is in accor-
dance with shldies perfonned in adult asthmatics23. 
\Vhen comparing our results to those in the literahlre, a number of methodological issues 
need to be adressed. Firstly, our results give a conservative estimate of the efficacy of the 
treatment used. Nearly 25% of the patients could not complete the exercise protocol while 
using placebo due to excessive dyspneu after exercise. Because the AVC could not be calculaR 
ted in these cases, patients with the most severe EIB could not be included for the effect of 
placebo treatment. In contrast, all patients except one, were able to complete exercise testing 
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when using zat1rlukast. Thus, the effect of zafrilukast treatment was compared to the effect of 
placebo in that part of the study population with relatively less severe EIB. 
Secondly, we cannot exclude variability in timing offhe final dose of treatment, 4 or 8 hours 
before exercise challenge. In order to minimise the need for school ahsenteism in tlus study, the 
patients took their final dose at home or at school, unobserved by the investigators. However, 
we do not feel this has substantially influenced our results, as aU patients were provided with a 
watch including an alarm. In addition, compliance with dmg therapy was generally good, 
especiaUy considering this age group24, 
Thirdly, we used a standardised exercise challenge protocol, which differs slightly to some 
other studies. Previous investigators have determined the individual workload for each patient 
to induce EIB at a screening visit, and kept this workload constant during the remainder or the 
studyiO,II,18.20. In contrast, we allowed differences in speed or the treadmill and duration of the 
test to occur between exercise tests in each individual patient, provided the heart rate attained 
90% of its maximum during the last minute of the test. \Ve have shown that the response to this 
exercise protocol in inducing EIB reproduced weU 17, thus we do not feel this has affected the 
obtained results. 
How can the present findings be interpreted? The results presented in this study implicate 
leukotrienes as mediators of EIB in paediatric astluna, as suggested by increased levels of 
urinary leukotriene E4 after exercise challenge in some 12, but not all studie~5 . Their action 
appears to be most prominent in prolonging the induced brollchoconstriction. Earlier studies 
have provided evidence for a contributory role of histamine26,27 and prostaglandins in EIB28,29, 
The relative contribution of these mediators to an individual's bronchoconstrictor response 
post-exercise seems to vary from one person to another, suggesting that some asthmatics arc 
predominantly producing histamine when challenged with exercise26, whereas others preferen-
tially generate leukotrienes 11 . \Ve have previously shown that the recovery from EIB is pro-
longed with increasing age in children with asthma30, and hypothesized tIus to be due to a 
relative increase in the contribution of leukotriene synthesis, Such a hypothesis is in accordance 
with the observation that aspirin-induced astiuna, being associated with increased baseline 
levels of Cys-L T's, affects approximately 10% of asthmatic adults, but is rare in asthmatic chil-
dren31 . Hence, the seemingly reduced efficacy of zafirlukast on EIB in adolescent asthmatics as 
compared to adults lO,1l,18-20 in the present study, may be related to the age of our study popula-
tion. 
However, an equally valid explanation for the observed efficacy of zafirlukast in our study 
could be offered by the fact that 12 out of the 18 adolescents studied, were using regular 
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maintenance treatment with inhaled corticosteroids, known to attenuate the severity of EIB in 
adults23 and children32 . In addition, oral steroids are capable of reducing the rise in plasma 
levels of leukotrienes during an acute asthma attack33. On the other hand, the participating 
adolescents in our study still suffered from moderate to severe EIB, despite the use of inhaled 
steroids. Likewise, it has been shown that regular treatment with inhaled steroids did not affect 
the urinary L TE4 excretion after allergen challenge34. Hence, it is not clear to what extent the 
current usc of inhaled steroids may have interfered with leukotriene synthesis, thereby potenti-
ally influencing the efficacy of zafirlukast. 
\Vhat is the clinical relevance of these data? Firstly, our results underscore the importance of 
measuring both the maximal %fall in FEV I and the area under the time response curve when 
evaluating drug therapy for EIB 17. Secondly, zafirlukast will have clear benefits for asthmatic 
children, as its prolonged protection against EIB will reduce the need for repeated inhalation 
with bronchodilatory therapy for unplanned exercise, enabling them to engage in sport and play 
with their peers without restrictions l4. Adequate and prolonged protection against EIB may 
also be offered by inhaling long-acting Pragonists35, but a reduction in their protection has 
been described after regular (mono)therapl6. Thirdly, our results will be particularly important 
to those children in whom EIB is only partially inhibited by the lise of maintenance therapy 
with (high dose) inhaled steroids, because the addition of regular zafIrlukast, but not cromolyn 
sodium, appears to be beneficial in reducing the severity ofEIB. 
In conclusion, regular treatment with the Cys-L T 1 receptor antagonist, zafirlukast, has 
shown to be safe and elIective in the management of EIB in asthmatic adolescents, affording 
prolonged protection up to eight hours after dosing. Our results implicate that leukotrienes are 
involved in the pathogenesis of EIB, and thereby a therapeutic target in this age group of 
asthmatics. 
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10. SlImmm)" Conclusions and General discllssion 
10.1 Summary 
The main goal of this thesis was to broaden the understanding of the pathophysiologic meclla-
nisms underlying the manifestations of exercise-induced bronchoconstriction in childhood 
asthma. In addition, we set out to evaluate treatment strategies for the prevention of RIB. The 
results of the studies presented in tlus thesis are briefly summarized here. 
10.1.1 EIB: Cllrrent concepts and its relation to asthma 
The first chapter outlines the current knowledge about asthma as an inflammatory disease. The 
concept of bronchial hyperresponsiveness (BHR) and its importance in asthma is introduced. In 
chapter 2, exercise-induced bronchoconstriction in childhood asthma is reviewed, it being 
prevalent in the majority of the asthmatic children. Most prominent symptoms are wheezing, 
cough, and chest tightness during or after exercise, although chest pain on exertion and exercise 
intolerance are also suggestive of its diagnosis. The severity of EIB, as determined by standar-
dized exercise testing, reflects the severity of the underlying BHR in asthma. The precise 
mechanisms of EIB have not been fully clarified yet, the stimulus to the airways potentially 
being thermal (airway cooling andlor rewarming) or oSl11olar (drying of the airways). The 
bronchoconstrictor response itself is most likely due to the release of mediators, and possibly 
neural activity. Finally, the current knowledge on the protective effect of common asthma 
drugs on EIB are reviewed. The aims of the studies in tlus thesis are presented in chapter 3. 
10.1.2 EIB: repeatability of the response 
The first study is described in chapter 4. As data on the reproducibility of the bronchoconstricM 
tor response to dry air exercise testing in asthmatic children are lacking, the use of a standardi-
zed treadmill exercise protocol was evaluated, allowing estimation of sample sizes required for 
studies monitoring EIB in children. Twenty seven asthmatic children known to have EIB, 
performed two identical exercise challenges on separate days. The bronchoconstrictor response 
to exercise was expressed as the maximal %fall in FEV I (%fall), and as the Area-under-thc-
time-response-curve (AUC). The intra-class correlation coefficient (ICC), determined as the 
index of repeatability, was based on the log-transformed data. It was calculated to be 0.57 for 
the %fall, and 0.67 for the AUe, showing EIB to have good reproducibility. Power curves for 
sample size estimations were subsequently constmcted, indicating that if a dmg is expected to 
reduce EIB by 50%. as few as 12 patients in total suffice to demonstrate tltis effect (90% 
power) using a parallel group design. Thus. standardized exercise testing for EIB using dry 
air is adequately repeatable for use in research practice in cltildren with astluna. 
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10.1.3 EIB: the early asthmatic response 
In the second study (chapter 5), we examined the clinical expression of EIB in relation to age. 
The hypothesis for this study of a decreased recovery rate from EIB with increasing age, was 
partly based on clinical evidence, and partly on observations in the literature on adult patients. 
In fourteen asthmatic children aged 7 to 12 year, with known EIB we measured the recovery 
from bronchoconstriction induced by two different bronchoconstrictor stimuli, exercise and 
histamine, in the absence of drugs. The degree of bronchoconstriction induced by histamine 
was matched for that observed after exercise. \"e were able to show that the recovery rate from 
EIB decreased significantly with age, while no such association was found for the recovery rate 
from histamine-induced bronchoconstriction. In those children aged cleven years and older, the 
recovery rate after exercise was significantly reduced compared to the recovery rate after 
histamine challenge. In the younger age group, similar recovery rates were observed after the 
two different challenges. These data suggest that the mechanism of EIB in childhood asthma 
changes with age. 
10.1.4 EIB: the late asthmatic response 
The occurence of a late asthmatic response (LAR) after exercise was adressed in chapter 6. 
The available information is mainly derived from studies in adults, and has led to conflicting 
results. \Ve investigated the occurence of a LAR after exercise in asthmatic children with 
documented EIB, comparing lung function measurements after exercise with those on a control 
day without exercise (negative control day), as well as with lung function measurements after 
another non-specific bronchoconstrictor challenge (positive control day). Seventeen children, 
aged 7 to 14 years, randomly performed on three following study days, either a standardized 
exercise challenge, or a histamine challenge matching the bronchoconstriction after exercise, or 
measurements of lung function without any challenge. Measurements of FEV 1 at approximate-
ly the same clock hours, were repeatedly performed 011 these days during a time span of 8 
hours. All children responded to exercise with an early asthmatic reaction of different severity. 
However, between 2 and 8 hours after exercise challenge, the difference in FEV I between 
exercise and control days for each clocktime did not exceed the 99.6% confidence limits of 
nonnal diurnal variation in any of the children. These data have led liS to conclude that in 
children with mild to moderate asthma, a LAR after exercise is very unlikely to occur, implica-
ting that although exercise is capable of inducing acute bronchoconstrictor responses of diffe-
rent severity, it does not seem to lead to subsequent induction of cellular activation. 
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10.1.5 EIB: its relatiollto natural allergen exposure 
The intricate relationship between allergen exposure, airway inflammation and bronchial 
hyperresponsiveness in asthmatic children was the subject of chapter 7. Assuming the semm 
level ofECP to reflect eosinophilic ainvay inflammation, we aimed to umavel the involvement 
of the eosinophil in detennining the severity of the bronchial hypelTesponsiveness to exercise 
and to methacholine, by studying the changes induced in those variables during seasonal 
allergen exposure. A possible modifying effect of inhaled steroids was evaluated concurrently. 
To that end, measurements of sECP, and BHR to exercise and methacholine were performed in 
forty seven non-steroid or steroid treated grass pollen allergic asthmatic children and their 
controls before and during the pollen season. Results showed the sECP to be only weakly 
related to the severity of BHR to exercise, but not to methacholine, whether analyzed cross-
sectionally, or longitudinally. The season-induced rise in sECP in grass-pollen allergic non-
steroid-treated children was associated mainly with the childs' sensitization to grass pollen, 
whilst the change in BHR to exercise and metacholine was also significantly related to the 
allergen load during season. The use of inhaled steroids seemed to modify these associations, 
protecting against the allergen-induced deteriorations of asthma. These data suggest that BHR 
to indirectly acting stimuli, stich as exercise, is more related to cellular activity than BHR to 
directly acting stimuli (m.ethacholine). Measuring the scnun level of eosinophil cationic protein 
turned out to be potentially useful in monitoring disease severity in seasonal allergen exposure 
in asthmatic children. 
10.1.6 EIB: dose-re,pol/se effects of iI/haled steroids 
The effects of inhaled steroids in inhibiting EIB are being described in chapter 8. The core 
issue of this chapter was to analyse to what extent the protective effects of inhaled steroids 
would be dependent on time and dose. In addition, the hypothesis was tested that inhaled 
steroids protect against directly (methacholine) and indirectly (exercise) acting bronchocon-
strictor stimuli through different mechanisms. To verify this hypothesis, concomitant measure-
ments of exercise- (EIB) and methacholine-induced bronchoconstriction (MIB) were measured 
during long-term treatment with inhaled steroids in children with asthma. A secundary objecti-
ve of the study was to evaluate the potential role of sECP in monitoring disease activity, and 
thereby treatment efficacy. Thitty seven asthmatic children, aged 6 to 14 years, known to have 
EIB, participated in a double-blind, placebo-controlled parallel group study comparing the 
effect of f1uticasone propionate 100 or 250 mcg b.d. in reducing EIB and MIB during a 6 
months' treatment period. Results showed that both doses of fluticasone propionate were equi-
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effective in producing fast and sustained protection against EIB. In contrast, the steroid-indu-
ced reduction in bronchial hyperresponsiveness to methacholine was dose-dependent, with an 
ongoing time-related improvement throughout the treatment period. \Vithin the same individu-
als, the higher dose of fluticasone propionate proved to be equally effective in reducing 
matched levels of exercise- and methacholine-induced bronchoconstriction. The lower dose 
reduced the BHR to exercise to a significantly greater extent than the BHR to methacholine. 
These data support the hypothesis that inhaled steroids protect by different mechanisms against 
directly (methacholine) and indirectly acting (exercise) stimuli in childhood astluna. Before 
treatment, the severity of EIB, as a reflection of disease severity, was related to the level of 
ECP in the blood. However, during treatment, an association between (changes in) EIB and 
sECP was no longer apparent, rendering sEep less helpful in monitoring treatment efficacy. 
10.1.7 EIB: fhe role ojleukafrielles 
In chapter 9, the relative involvement of leukotrienes in EIB in children was studied by using 
pre-treatment with a cysteinyl leukotriene (Cys-L T) receptor antagonist. Based pal11y on the 
results described in chapter 5, the hypothesis that leukotrienes are especially involved in 
prolonging the bronchoconstrictor phase post-exercise, was tested in eightteen asthmatic 
adolescents aged 12 to 17 years. Using a randomised, double-blind, cross-over trial, we measu-
red the protection against EIB afforded by either the Cys-L T I receptor antagonist zafirlukast, or 
by cromolyn sodium, and compared tius to placebo treatment. Measurements of EIB were 
perfonned four and eight hours after the final dose of a two weeks treatment period. At four 
hours post-dose, the effect of zafirlukast was most evident during the recovery phase of EIB, 
the area-under-the-time-response curve post-exercise being significantly less than during 
placebo. No significant protective effect was observed for cromolyn sodium at this time point. 
Differences in maximal %fall between treatments failed to reach statistical sigluficance. 
Similar results were obtained when analysing the treatment effects at 8 hours post-dose. These 
data implicate that leukotrienes are important mediators of EIB in childhood asthma, their 
activity especially manifested in prolonging the bronchoconstrictor response after exercise. 
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10.2 Conclusions 
* The bronchoconstrictor response to dry air exercise challenge in astlunatic children is 
adequately reproducible to allow the set-up of research studies in a limited number of 
subjects while retaining sufficient statistical power. 
* The recovery rate from exercise-induced bronchoconstriction decreases with increasing age, 
suggesting a change in the pathophyisology ofElB when children grow older. 
* In children with mild to moderate asthma, exercise challenge, as compared to allergen 
challenge, does not result in equivalent late astlmlatic responses 2 to 8 hours after challenge. 
This suggests that exercise, unlike allergen exposure, is a symptomatic trigger of asthma, 
reflecting the severity of the underlying bronchial hyperresponsiveness. 
* The extent of change in the bronchial responsiveness to exercise or methacholine during 
natural allergen exposure, is determined by the patients' degree of sensitization as well as 
the total allergen load. Treatment with inhaled corticosteroids protects against allergen-
induced inflammatory changes. Bronchial responsiveness to exercise, but not methacholine, 
is related to cellular activity as reflected by the level of serum eosinophil cationic protein. 
* Fast and sustained protection against EIB in asthmatic children is afforded by the use of 
inhaled steroids, the effect of treatment with 200 mcg fluticasone propionate daily not 
significantly different from treatment with 500 mcg daily. In contrast, the reduction in 
bronchial hypelTesponsiveness to methacholine is dose-dependent, with an ongoing time-
related improvement during a 24 week treatment period. Thus, inhaled steroids protect 
differently against directly and indirectly acting bronchoconstrictor stimuli. 
* Pre-treatment with the cysteinyl leukotriene receptor antagonist, zafirlukast, significantly 
attenhmtes the severity of EIB in astlunatic adolescents, most notably during the recovery 
phase, implicating the cysteillyl lcukotrienes to be imp0l1ant mediators of EIB, particularly 
in prolonging the bronchoconstriction post-exercise. 
157 
10.3 Gcncral discussion 
10.3.1 Exercise-induced bronc/wcons/riction 
The results of the studies presented in this thesis confirm and extend previous observations on 
the pathophysiologic mechanisms of exercise-induced bronchoconstriction in childhood 
asthma. Putting EIB in the perspective of the overall clinical picture of asthma will help in 
determining its clinical relevance and thus the choice of therapeutic intervention. The most 
relevant in the discussion is the issue whether EIB is merely a reflection of BHR and airway 
inflammation or whether EIB itself contributes to these asthma characteristics. 
In trying to understand the mechanisms of EIB, comparisons have often been made with 
allergen challenge i ,2, Provocation with either of these two stimuli initiate an acute asthma 
attack, with release of a similar mediator profile shortly after the challenge3,4. It is now well 
established that allergen challenge will induce a late asthmatic response (LAR) in about 50% of 
asthmatic patients. The occurrence of tills LAR is accompanied by inflammatory changes 
within the airways, mainly an infiltration of eosinophils, and increased BHR, such as seen in 
chronic asthmas. \Vhen a LAR is absent however, such changes in inflammation and BHR do 
not occur. Therefore, the LAR has provided unique opportunities to study the pathophysiology 
of chronic astma. 
\Ve failcd to observe equivalent late asthmatic responses after exercise, in agreement with 
previous studies6-s, despite our attempts towards improved study methodology and advanced 
statistical analysis. Moreover, it was shown by othcrs that the percentage of sputum cosinopWls 
did not change significantly 6 to 9 hours after exercise compared to the pre-exercise values, in 
contrast to the percentage of sputum eosinophils in the same time period after antigen 
challenge9. In addition, exercise challenge has not been fOllnd to increase the bronchial hyper-
responsiveness, as determined by the sensitivity to methacholine 1o or histamin€ . These 
findings suggest that EIB is a consequence rather than a cause of airway inflammation, its 
severity merely a reflection of airway hyperresponsiveness. 
10.3.2 Allergen-exposure 
The above view is supported by the results of the study descibed in chapter 7, investigating 
the association between allergen exposure, ainvay inflammation and the bronchial hyperres-
ponsiveness to exercise as well as methacholine. Before discussing the relevance of these 
results, some remarks need to be made on the study methodology. At the time of initiation of 
this particular study, natural allergen exposure instead of laboratory allergen challenge was 
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chosen for ethical reasons. Firstly, advantage of this approach is that the natural behaviour of 
asthma and bronchial responsiveness is studied. The obvious drawback is inability to mani-
pulate the level of exposure. Secondly, as invasive techniques such as bronchial biopsies or 
bronchial lavages are considered ethically unacceptable in childhood asthma except for dia-
gnostic or theapeutic interventions, we had to rely on measurements of eosinophil cationic 
protein in serum (sEep) for information on ainvay inflanunation ll . Despite these limitations, 
we feel that the results obtained confirm and extend previous observations under natural 12,13 as 
well as laboratory conditions l4, linking allergen exposure to subsequent changes in bronchial 
hyperresponsiveness. It seems valid to assume that the link between allergen exposure and 
increasing BHR is the development of airway inflammation l5 . In our study, it was obscnred 
that during natural allergen exposure, BHR to methacholine as well as the severity of EIB, 
increase in similar fashion. In this respect, the observed relationship between the change in the 
level of sEep and the subsequent change in EIB underlines the relevance of inflammatory cell 
activity in the mechanism ofEIB3• 
10.3.3 "Direct" or "indirect" bronchial challenge? 
Hence, the results thus far, strengthen the conviction that EIB is reflecting airway inflammation 
and the severity of the underlying bronchial hyperresponsiveness. One could then question 
whether determining the severity of EIB adds to information obtained by measuring the BHR 
to methacholine. Arguments against this view are forwarded by the results described in chapter 
8. The difference in time- and dose-dependency of the protective effects of inhaled cOliicoste-
roids on exercise- and methacholine-induced bronchoconstriction, as was observed in our 
study, suggests that different information is to be gained from measuring the response to 
directly (methacholine) and indirectly (exercise) acting stimuli. This is in accordance with 
studies in adult asthmatics, implicating that BHR to methacholine is more likely to provide 
information on the chronic aspects of inflammation, possibly related to the remodelling proces-
ses in astiul1a I6,17, while exercise responsiveness responds more acutely to changes ih allergen 
exposurel8• Hence, our results support the view that although exercise (a physiologic stimulus). 
and methacholine (a pharmacological stimulus). both reflect BHR, they measure different 
components of the airways dysfunction l9• 
11.3.4 Mediators ofastllllUi and age 
Moreover, it was shown that the expression ofEIB changes with age (chapter 5). \Ve postula-
ted that the prolonged recovery time of EIB would be due to an increased involvement of 
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leukotrienes with age. Such a hypothesis is supported by the observation that the protective 
effect of the cysteinyl-receptor antagonist, zafirlukast, is especially prominent in the recovery 
phase (chapter 9). 
The significance of a changing mediator profile in EIB is not clear, however, it is tempting 
to speculate that this may reflect a development in the underlying airway inflammation. Such a 
view is supported by the data of chapter 7, in which the influence of allergen exposure on EIB 
was especially evident in an increased area-under-the-curve, not in the maximal %fa11 in FEV 1. 
Secondly, the role of the eosinophil in EIB in asthmatic children seems to be less prominent, as 
evidenced by the weak association between sECP and severity of EIB in childhood as compa-
red to adult asthma2o. A preliminary report on biopsy results in atopic astluuatic children 
compared to atopic asthmatic adults has suggested age-related difference in the immunopatho-
logy of asthma21 . \V11ether these observations support or refute the suggestion that childhood 
asthma is more mast cell dependent22 , while progression of the disease and disease severity is 
more likely T-cell driven23,24, remains to be elucidated. Clearly, there is a need for studies on 
the airway pathology in childhood asthma linking EIB to airway inflammation. 
Regardless of these speculations of development of airway inflammation over time howe-
ver, the involvement of leukotrienes in the pathogenesis of EIB may give rise to some con-
cerns. Leukotrienes are known to be pro-inflammatory mcdiators25 , capable of producing 
bronchoconstriction, mucus secretion and airway oedema, aggravating the bronchial hyperres-
ponsiveness26, recmiting eosinophils into the ainvay mucos;7 , as well as resulting in seconda-
ry release ofneuropeptides28• These actions of the Cys-LT's might explain some of the adverse 
effects observed in response to exercise challenge in asthmatic patients, such as an increase in 
the maximal ainvay narrowing to methacholine post-exercise29, or an aggravated reaction to 
allergen provocation after EIB30,31. Therefore, one could speculate whether exercise in asthma 
may be more than a trivial bronchoconstrictor stimulus, and that through the release of Cys-
LT's, exercise may play some role in maintaining airway inflammation. 
10.4 Directions for future research 
Standardized dry air exercise testing is a valuable tool in the management of childhood asthma, 
the severity of exercise-induced bronchoconstriction reflecting the degree of the underlying 
bronchial hyperresponsiveness. Fuhlfe studies should be aimed at unraveling the relative 
contribution of the different mediators in EIB in relation to age, as well as antigen exposure. In 
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doing so, the diagnostic value of exercise testing will be strengthened, and new therapeutic 
strategies explored. 
\Vhen compared to the model of allergen challenge, exercise most likely does not lead to the 
induction of airway inflammation. However, as summarized above, exercise may playa role in 
maintaining the airway inflammation in asthma through the release of leukotrienes. Clearly, 
there is a need to further ShIdy the expression of EIB in relation to inflammatory changes in the 
airways. As invasive techniques, such as broncial biopsies and lavage studies, are presently not 
allowed for research purposes in paediatric asthma, the use of alternative techniques, such as 
induced sputum, should be considered. 
According to recent guidelines, inhaled corticosteroids are currently the drug of choice when 
treating children with moderate to severe asthma. Yet part of these asthmatic children stilll 
experience EIB despite the use of maintenance treatment with inhaled steroids. Fm1her studies 
should evaluate treatment strategies aimed at inhibiting exercise-related symptoms in this 
group of children, such as combinations of steroids with long-acting P2agonists, or with 
antileukotriene therapy. For those children well controlled on inhaled steroids, the prognostic 
value of exercise testing when tapering down maintenance treatment should be investigated, as 
tItis may be potentially helpful in monitoring disease activity. 
In summary, EIB is a frequently occuring event in the daily life of many asthmatic c1tildren. 
The expression of EIB reflects the underlying bronchial hypelTesponsiveness, and may be 
related to the underlying airway inflammation. The relative importance of EIB in maintaining 
inflammation should further be explored. However, as participation in spotis without limitation 
is one of the aims of therapeutic intervention and has proved to be beneficial physically as well 
as psychologically, exercising should be encouraged in all asthmatic children. 
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Samenvalling 
SamcnYaUillg 
Veel kinderen met astma krijgen bij inspanning in meer of mind ere mate van luchtwegvemau-
wing. Dit wordt inspanningsgeYnduceerde bronchusobstmctic (exercise-induced bronchocon-
stricti on: EIB) gcnoemd. Het hoofddoel van dit proefschrift was om het inzicht te verdiepen in 
het pathofysiologisch mechanisme dat ten grondslag ligt aan EIB bij kinderen met astma. Dc 
resultaten van de studies uit dit proefschrift worden hieronder verkort weergegeven. 
In hoofdstuk 1 wordt kart de huidige kennis over astma samengevat. Astma is de meest 
voorkomende longziekte bij kinderell, en wordt gekeruuerkt door wisselende periodes van 
luchtwegvernauwillg, al dan niet met klachten van kortademigheid, piepen op de borst, en/of 
hoesten. De klachten ontstaan na blootstelling aan luchtwegvernauwende prikkels (allergenen, 
vimsinfecties, rook, mist ell koude). Bij astma is de gevoeligheid van de luchtwegen voor dit 
soort prikkels verhoogd. Dit wordt "bronchiale hyperreactiviteit" genoemd. Hieraan ten grond-
slag ligt een specifiek ontstekingsproces in de luchtwegen, ontstaan via immunologische weg. 
In hoofdstuk 2 wordt een overzicht gegeven van de literatuur over EIB, oak weI inspannings-
astma genoemd. Belangrijke klachtell zijn piepen op de borst, hoesten en kortademigheid 
tijdens of na een flinke inspanning. Ook pijn op de borst, en inspanningsintolerantie kunnen 
duiden op EIB. De ernst van EIB kan gemetell worden met behulp van longfunctie onderzoek 
voor en na een gestandaardiseerde inspanningsproef, en is cen afspiegeling van de mate van 
bronchiale hypeneactiviteit bij astma. Het precieze mechanisme waardoor EIB ontstaat is niet 
geheel bekend, echter afkoeling en uitdroging van de luchtwegen door de snelle ademhaling 
tijdens inspanning spelen een belangrijke roI. De llichtwegvemallwing zelf is waarschijnlijk het 
gevolg van de uitstoot van broncho-actieve stoffen uit pulmonale cellen. alsook prikkeling van 
zenuwuiteinden in de luchtwegen. EIB kan worden voork6men door het gebruik van medicij-
nen, die of gedurende korte tijd de reactie blokkeren, of op lange tennijn het ontstekingsproccs 
in de luchtwegen venninderen. 
Dc doelstellingen van de studies in dit proefschrift worden in hoofdstuk 3 uitgewerkt. 
In hoofdstuk 4 wordt de eerste shIdie beschrcven. Omdat gegevens over de reproducecrbaar-
heid van EIB bij kinderen met astma ontbreken, werd de reproduceerbaarhcid van de luchtweg-
respons op een gestandaardiseerde inspamlingsproef onderzocht. Tijdens deze inspalmingsproef 
werd droge lucht ingeademd. Zevenentwintig kinderen, bekend lllet BIB. verrichtten twee 
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identieke inspanningstesten op verschillende dagen. De luchtwegvernauwing na inspanning 
werd enerzijds beschreven als het maximale percentage daling in de FEV I (%daling) en 
anderzijds als de oppervlakte onder de tijd-response curve (AUC). De reproduceerbaarheid 
werd bepaald met behulp van de intra-class correlatie coefficient, welke een waarde liet zien 
van 0.57 voor de %daling, en 0.67 voor de AUC. Aan de hand van de gegevens konden tevens 
berekeningen worden gemaakt over de benodigde hoeveelheid deelnemers (=steekproefgrootte) 
in studies die het effect van medicijnen op EIB onderzoeken. Geconcludeerd werd dat de 
reproduceerbaarheid van EIB dusdanig goed is, dat de gestandaardiseerde inspallningsproef 
met gebruik van droge lucht zeer bruikbaar is voor studies naar EIB bij kinderen. 
In hoofdstuk 5 werd de klinische uitingsvonn van EIB in relatie tot de leeftijd onderzocht. De 
hypothese, dat het herstel van de luchtwegvernauwing na inspanning trager verIoopt wanneer 
kinderen ouder worden, was voor een deel gebaseerd op klinische observatie, en dcels op 
literatuur gegevens bij volwassenen. Bij veertien kinderen in de leeftijd van 7 tot en met 12 
jaar, allen bekend met EIB, onderzochten we de snclheid van herstcl van luchtwcgvernauwing 
vcroorzaakt door twee verschillende prikkels, te weten histamine en inspanning. De mate van 
luchtwegvernauwing veroorzaakt door histamine was vergelijkbaar met dc luchtwegobstructie 
in aansluiting aan inspanning. \Ve konden laten zien dat de herstelsnelheid na inspanningsge-
induceerde luchtwegvernauwing significant aiham met de leefiijd, terwijl een dergelijk verband 
niet kon worden waargenomen na histamine geYnduceerde luchtwegvernauwing. Verdere 
analyse liet zien dat in de groep van killderen ouder dan elf jaar, de snelheid van herstel van 
EIB significant verlaagd was ten opzichte van histamine veroorzaakte luchtwegvemauwing. In 
de groep jongere kinderen evenwel verliep het herstel van de obstructie door de twee vcrschil-
lende prikkels even sne!. Deze gcgevcns suggereren dat het mechanisme van EIB verandert met 
de leeftijd bij kinderen met astma. 
Het optreden van een late astmatische respolls (LAR) na inspanning was het onderwerp in 
hoofdstuk 6. De huidige informatie is vooral afkomstig van studies in volwassen astma 
patienten, en de resultaten zijn niet eenduidig. \Ve onderzochten het v66rkomen van een LAR 
na inspalming bij kinderen met astma, door longfunctie gegevens enkele uren na inspannillg 
gemeten te vergelijken met metingen verricht op een controle dag zonder inspanning. Ook 
werden deze metingen vergeleken met longfunctie gegevens verkregen na provoeatie met ccn 
ander soort luchlwegvernauwende prikkel, namelijk histamine. Zeventien kindcren in de 
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lceftijd van 7 tot en met 14 jaar, verrichtten, in willckeurige volgorde op 3 verschillende dagen, 
een gestandaardiseerde insparmingsproef, of een histamine provocatietest waarbij eenzelfde 
mate van luchtwegvernauwing als na inspalll1ing werd gei'nduceerd, of longfunctie metingen 
zonder voorafgaarlde provocatie. Het meten van de longfunctie (FEV I) werd elk half um 
herhaald gedurende cen periode van acht um op deze studie dagen. AIle kinderen vertoonden in 
aansluiting aan de inspanning cen acute luchtwegvemauwing van wisselcnde ernst. Echter de 
longfunctie in de periode 2 tot 8 uur na inspanning verschilde niet van de nonnale variatic in 
FEV 1 op de controle studie dagen. Hieruit werd geconeludeerd dat het voorkomen van cen late 
astmatische respons na inspanning bij kinderen met mild tot matig astma niet erg waarschijn~ 
lijk is. Dit zou kunnen betekenen dat hoewel inspanning kan leiden tot acute luchtwegvernau~ 
wing, er waarschijnlijk geen activatie van ontstekingscellen ontstaat. 
In hoofdstuk 7 werd de complexc relatie tussen allergeen expositie, luchtwcgontsteking en 
bronchiale hyperreactiviteit onderzocht. Doel van het onderzoek was de bijdrage van de 
eosinofiele eel aan de bronchiale hyperreactiviteit voor inspanning (EIB) en methacholine (een 
farmacologischc prikkel) te bepalen, door veranderingen in bronchiale hyperreactiviteit ten 
gevolge van blootstelling aan graspollcn te correleren aan verallderingen in de ontsteking van 
de luchtweg. Aangenomen werd, dat het gehalte van het serum eosinofiel cationic protein 
(sECP) in het bloed een afspiegeling was van de eosinofiel gemedieerde luchtwegontsteking. 
Tevcns werd onderzocht of hct gebruik van inhalatiesteroi"den een modificcrcnd effect kon 
hebben. Voor en tijdens het graspollen seizoen werdcn daarom metingen van sECP, EIB en 
bronchiale hyperreactiviteil voor methacholine verricht bij kindercn met een graspoHenallergie, 
al dan niet behandeld met inhalatiesteroIden. Ais controle groepen werden kinderen zonder 
graspollenallergie ingesloten in de studie. De resultaten Heten zien dat de hoogtc van het sECP 
slechts in geringe mate correleerde aan de ernst van het EIB, en niet aan de methacholine 
reactiviteit. De toename van het sECP in graspollen allergische kinderen leek voornamelijk 
bepaald te worden door de sensibilisatiegraad van het kind, terwijl de verandering in EIB en 
hyperreactiviteit voor methacholine mede bepaatd werden door de hoevcclhcid allergeen 
(graspollcn) waaman het kind had blootgestaan. Het gebruik van inhalatiesteroIden leek te 
beschermen tegen de allergeen~ge"(nduceerde verergering van astma. Deze gegevens suggereren 
dat de bronchiale hyperrcactiviteit voor indirect aangrijpende luchtwegvernauwende prikkels 
(inspanIllng) meer zijn gerelateerd aan cellulaire activiteit dan direct aangrijpende stimuli 
(methacholine). Het bepalen van de hoogte van sECP in het bloed zou van waarde kunnen zijn 
bij kinderen met astma, w3lmeer er sprake is van seizoensgebonden allergeen expositie. 
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In hoofdstuk 8 worden de effeden van inhalatiesteroi'den (lCS) aangaande de bescherming 
tegen EIB beschreven. De belangrijkste doelstelling van dit onderzoek was am te analyseren in 
hoeverre deze effecten afhankelijk zijn van dosis en tijdsduur van de behandeling. Tevens werd 
onderzocht of de bescherming van lCS tegen direct-werkcnde (methacholine) en indirect-
werkende luchtwegvernauwcnde prikkels (inspanning) teweeg wordt gebracht via verschillende 
mcchanismen. am deze hypothese te kunnen toetsen, werden gelijktijdig metingen verricht van 
EIB en methacholine reactiviteit, tijdens lange termijn behandeling met ICS bij kindcren met 
matig astma. Door tevens de hoogte van het sECP te bepalen, kon de potentie hiervan voor het 
beoordelen van ontstekingsactiviteit (en dus bchandelingseffectiviteit) worden onderzocht. 37 
kinderen in de leeftijd van 6 tot en met 14 janr, participeerden in deze dubbelblilldc, placebo-
gecontroleerde paraUelgroep shIdie. Gedurende 6 maanden werden zij behandeld met fluticaso-
ne propionaat, in een doserillg van 200 mcg of 500 mcg per dag. De rcsuItaten Helen zien dat 
beide doseringen een snelle en bIijvende verbetering in EIB bewerkstelligen. De verbetering in 
de bronchiale reactiviteit voor methacholine was daarentegen wei afhankelijk van dosering en 
tijdsduur van behandeling. Daarnaast bleek dat voor behandeling lllet ICS de hoogte van het 
sECP in het bloed cOlTeleerde aan de ernst van EIB, echter tijdens behandeling kon een derge-
lijk verband niet worden waargenomen. Deze gegevens ondersteunen de hypothese dat het 
beschermend effect van ICS op direct en indirect aangrijpende luchtwegvernauwende prikkels 
wordt gecffectueerd via veschillende mechanism en. 
In hoofdsfuk 9 tenslotte, is het aandeel van de cysteinyl leukotricncn (Cys-LT) in het mccha-
nisme van het EIB bij kinderen met astma het onderwerp van shIdie. De hypothese van dit 
onderzoek, dat de Cys-LT vooral belangrijk zijn in het onderhouden van de luchtwegvernau-
wing na inspanning, was deels gebaseerd 01' de resuItaten uit hoofdstuk 5, en werd getoetst 
door een groep adolescenten met astma te behandelen met een Cys-LTI receptor antagonist, 
zafirlukast. In een dubbelblinde, placebo-gecontroleerde, gekmiste studie-opzet werd de mate 
van bescherming tegen EIB gemeten na een twee weken durende behandeling met zat1rlukast 
(20 mg of 80 mg 2xdaags), of cromoglycaat (10 mg 4xdaags), of placebo. Gestandaardiseerdc 
inspanningsprovocatietesten werden "erricht 4 en 8 uur na inname van de laatste dosis van de 
behandeling. Analyse van de metingen 4 uur ua inname van de laatste dosis lieten zien dat een 
beschermend effect van zafirlukast vooral tot uiting kwam in een significant sneller hersteI van 
de luchtwegvernauwing na inspannning, in vcrgelijking met de placebo behandeling, terwijl 
geen effect werd gevonden op de maximale daling in longfunctie. Cromogiycaat daarentegen 
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Samellvatting 
Iiet geheel geen beschermend effect zien. De resultaten 8 uur na inname van de laatste dosis 
van een bchandelingsperiode lieten eenzelfde beeld zien. Dcze gegevens impliceren dat cystei w 
nyl leukotrienen belangrijke mediatoren zijn in de pathofysiologie van EIB bij kinderen met 
astma, vooral actief in het onderhouden van de luchtwegvernauwing na inspanning. 
COllclusics 
* De Iuchtwegvemauwende reactie op een inspanningsprovocatietest met inademing van 
droge lucht bij kinderen met astma is voldoende reproduceerbaar. De opzet van studies naar 
EIB is daardoor mogelijk in een beperkt aantal proefpersonen met behoud van voldoene 
statistische power. 
* De snelheid van herstel van inspanningsgei"nduceerde bronchusobstructie neemt af met de 
leeftijd, mogelijk duidend op cen verandering in de pathofysiologie van EIB. 
* Vergeleken met een allergeen provQcatie, leidt een inspmmingsprovacatietest bij kinderen 
met mild tot matig astma, niet tot eenzelfde latc astmatische reactie. Dit suggereert dat EIB 
slechts een afspiegeling is van bronchiale hypeneactiviteit, en niet een aorzaak, in tegenstel w 
ling tot allergeen expositie. 
* De mate van verandering in bronchial reactiviteit voor insparuling of methacholine tijdens 
natuurlijke allergeen expositie, is afhankelijk van de sensibilisatiegraad alsmede de hoeveel w 
heid allergeell. Bronchiale hypelTeactiviteit voor inspanning, maar niet methacholine, is 
gerelateerd aan cellulaire activiteit, zoals afgemeten aan het sECP. Behandeling met inhala-
tiesterai"den beschermd tegen allergeen-gernduceerde verergering van luchtwegontsteking. 
* Behandeling met inhalatiestero"idell bij kinderen met astma lcidt tot een snelle en blijvende 
verbetering van EIB, waarbij het effect van 200 mcg fluticasone propionaate niet verschilt 
van dat van 500 mcg per dag. De verbetering in bronchial reactiviteit voor methacholine 
daarentegen, is niet aIleen afhallkelijk van de dosering, maar oak van de tijdsduur van 
behandeling. Het beschermend effect van inhalatiesteroi"den tegell direct en indirect aangrij-
pende luchtwegvernauwende prikkels wordt waarschijnlijk teweeg gebracht via verschil-
lende mechanismen. 
* Behandeling met de cysteinylleukotrieen (Cys-LT) receptor antagonist zafirlukast, geeft een 
significante verbetering van het EIB in adalescenten met astma, vooral tijdens de herstelfa w 
se. Dit impliceert dat de Cys-LT's belangrijke mediatoren zijn in EIB, m.n. in het onderhou-
den van de luchtwegvernauwing na inspanlling. 
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